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ABSTRACT 
 
Oncolytic viruses are designed to be novel cancer treatments that not only specifically 
target cancer cells, but can act as vectors to express proteins of interest within the tumor bed.  
Myxoma virus (MYXV), a rabbit-specific poxvirus, was evaluated as an oncolytic viral 
treatment for cancer in immunocompetent mouse models of cancer.  In addition, a recombinant 
MYXV that expresses the murine gene for interleukin 15 (IL-15) was also used, in order to 
determine if increased expression of IL-15 within the tumor bed could improve MYXV 
treatment by recruiting additional anti-tumor immune cells to the tumor.  In vitro experiments 
evaluated MYXV infectivity in murine melanoma, glioma, and lymphoma cells using a 
recombinant MYXV that expresses the fluorescent protein tdTomato (MYXV:Tomato).  These 
studies indicated that B16-F10 melanoma cells were fully-permissive to MYXV infection, while 
GL261 glioma cells were partially permissive, and EL4 cells were non-permissive.  All stages of 
virus morphology were observed in the permissive cells and there was evidence of cell-to-cell 
spread of MYXV.  Other studies have shown that the susceptibility of human cancer cell lines to 
MYXV infection depends on the presence of phosphorylated Akt, which was present in the B16-
F10 melanoma and GL261 glioma cell lines.  Cancer cell death occurred following infection 
with MYXV and was likely due to cell lysis and necrosis as apoptosis was not evident at 48 
hours post infection.  Initial in vivo studies using immunocompetent mice bearing intracranial 
melanoma or lymphoma tumors demonstrated that a single inoculation of intratumoral (IT) 
MYXV:Tomato was safe but did not produce any significant increase in survival, while studies 
using intracranial GL261 were inconclusive.  However, other studies have shown that MYXV 
treatment of melanoma not located in the brain can increase survival if multiple injections are 
given.  Therefore, weekly IT injections of MYXV or MYXV expressing the gene for murine IL-
15 (MYXV:IL15) were administered in an immunocompetent mouse model of subcutaneous 
melanoma.  The injections were safe and MYXV:IL15 did not cause any detectable adverse 
clinical signs or any significant increase in viral clearance.   A statistically significant increase in 
survival time was obtained in mice given repeated IT injections of MYXV or MYXV:IL15 as 
compared to controls.  The survival time in tumor-bearing mice treated with MYXV expressing 
IL-15 was not significantly different than mice treated with MYXV.  In addition, MYXV-driven 
expression of IL-15 was evaluated to determine if it would recruit natural killer (NK) cells and 
cytotoxic T lymphocytes (CTLs) to the tumor.  An extensive pathologic study of the mouse 
model including histopathology and immunohistochemistry (IHC) was performed at various time 
points to determine the levels of immune cell infiltration in the tumor and the effects of 
intratumoral virus inoculation.  The number of lymphocytes and neutrophils observed 
histologically to be infiltrating into the tumors as well as into the tissue surrounding the tumors 
was significantly increased in mice treated with live MYXV or MYXV:IL15 versus PBS treated 
control mice.  However, IHC revealed that a statistically significant increase in the number of 
infiltrating cytotoxic lymphocytes (NK cells or CTLs) was not present in MYXV:IL15 treated 
mice versus control mice, although increased levels of IL-15 were detected within the tumors.  
Serum neutralization assay revealed that some of the mice treated with MYXV, MYXV:IL15, or 
UV-MYXV, developed an antibody response to MYXV.  The presence of an antibody response 
did not correlate with survival time or the amount of leukocyte response observed by histology 
or IHC.   In conclusion, treatment with weekly IT injections of MYXV or MYXV:IL15 
significantly prolonged survival in mice bearing B16-F10 tumors, which correlated with an 
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increase in the number of neutrophils and lymphocytes infiltrating in and around the tumors, but 
MYXV:IL15 did not increase survival over MYXV alone.   
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CHAPTER 1 
INTRODUCTION 
 
 There is a need for novel treatments of cancer that are targeted, effective, and do not 
cause immunosuppression.  We believe that treatments that activate the immune system and 
recruit it to the tumor can result in an antitumor immune response, increasing survival.  To 
accomplish this, we used myxoma virus and a myxoma virus that expressed murine interleukin-
15 as a treatment for murine tumors in immunocompetent mice and monitored survival time as 
well as the immune response at various time points.  This introductory chapter discusses the 
many considerations that need to be taken into account when using a virus to treat cancer 
including current cancer treatment results, safety of virus treatment, pathogenesis, anti-tumor 
mechanism, and tumor biology and immunology. 
Current cancer treatment modalities 
 For the past several decades, treatment of cancer has centered on surgical tumor removal, 
chemotherapy, and radiation, with few other treatments utilized.  Of those treatments, surgery 
and radiation are targeted to the tumor by the attending physician based on macroscopic visual 
clues such as gross visualization of the tumor and medical imaging which cannot detect small 
metastases.  Both surgery and radiation purposefully require involving the adjacent normal tissue 
in order to make sure that the entire tumor is targeted.  Chemotherapy targets rapidly growing 
cells, which can affect metastases, but also kills rapidly proliferating normal tissues such as the 
gut epithelium, hair follicles, and the bone marrow, resulting in side effects such as mucositis 
(nausea, vomiting, diarrhea), hair loss, and immunosuppression, respectively.  
Immunosuppression can lead to life-threatening secondary infections and is a significant cause of 
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post cancer treatment complications.  In addition, some cancers such as malignant melanoma are 
not amenable to surgical removal (depending on location), are considered radioresistant, and/or 
do not respond well to chemotherapy.    
 Chemotherapy and radiation treatment also predispose the treated patients to increased 
development of additional cancers due to their mechanism of damaging deoxyribonucleic acid 
(DNA).  A study of over 1500 Hodgkin’s lymphoma cancer survivors found that the risk of 
developing a second cancer was over 5 times that expected for the normal population (Tucker et 
al. 1988).  Some secondary cancers occur at even higher rates, such as breast cancer (20% 
incidence by 45 years of age) and thyroid carcinoma (36-fold increased rate) (Neglia et al. 2001).  
Cardiac disease is second to neoplastic disease as a cause of post-treatment death for Hodgkin’s 
disease (Hancock, Donaldson, and Hoppe 1993), and a study of over 14,000 patients found a 2-5 
increased risk of heart disease in patients treated with 250mg/m2 of anthracyclines (Mulrooney et 
al. 2009).  Certain chemotherapeutics are also known to cause specific complications, such as 
irreversible ototoxicity (Einar-Jon et al. 2011).   
 Long-term risks from radiation exposure are dependent upon the area irradiated, the 
dosage of radiation received, and the age of the patient.  They include: 1) a two- to six-fold 
increased risk of developing congestive heart failure, myocardial infarction, pericardial disease, 
and valvular abnormalities if the heart has received 15 gray (Gy) or more (typical treatment 
doses range from 20-80 Gy) (Mulrooney et al. 2009), and a 45-fold excess mortality risk of acute 
myocardial infarction in patients treated with more than 30 Gy of mediastinal radiation before 
the age of 20 (Hancock, Donaldson, and Hoppe 1993), 2) a severely increased risk of 
hypothyroidism;  up to 51% in patients treated with 35-45 Gy to the neck (von der Weid 2008),  
3) a 1.8 fold increased risk of developing diabetes mellitus, with even higher odds in patients 
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who received whole body, abdominal, or cranial irradiation (Meacham et al. 2009), 4) an 
increased risk of ocular problems such as cataracts, double vision, legal blindness, and dry eye if 
the ocular area has been irradiated (Whelan et al. 2010) significantly increased rates of stillbirths 
and neonatal deaths in women who have received 10 Gy or more, and in young girls who 
received 1 Gy or more, of radiation to the uterus or ovaries (Signorello et al. 2010).   
 The 2010 annual report on the status of cancer in the United States (an annual 
collaboration of the American Cancer Society, the Centers for Disease Control and Prevention 
(CDC), the National Cancer Institute, and the North American Association of Central Cancer 
Registries) concluded that overall cancer rates are declining by approximately 1% per year due to 
a combination of prevention, early detection, and treatment (Kohler et al. 2011).  However, low 
survival continues to be a problem for some cancers, such as glioblastoma, in which the 5 year 
survival rate has only recently exceeded 20% (Kohler et al. 2011).  In addition, some cancers 
were found to have a statistically significant increase in death rates, including melanoma and 
liver cancer in men, and liver and pancreatic cancer in women (Kohler et al. 2011).  Novel 
treatments are needed to treat these cancers that do not respond well to traditional therapies. 
Cancer resolution secondary to infection 
 The first documented indication that viruses could treat cancer occurred just over a 
century ago.  In 1910, Dr. De Pace reported a case at the International Cancer Congress of a 
woman with a large vegetating cervical carcinoma who experienced complete remission of her 
tumor after being bitten by a rabid dog and undergoing treatment with the Pasteur-Roux live 
attenuated rabies vaccine (De Pace 1912).  This sparked several studies with intentional 
treatment of cancer patients with the rabies vaccine, in which partial remissions were observed 
(Pack 1950).  Another case report described remission of untreated chronic lymphocytic 
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leukemia following revaccination for smallpox (Hansen and Libnoch 1978).  Other cases of 
cancer remission following viral infection have also been reported throughout the last century, 
including complete remission of lymphocytic lymphosarcoma following viral hepatitis 
(Weintraub 1969), 5 cases of complete remission of Hodgkin’s disease following measles (Taqi 
et al. 1981), and 4 cases of partial remission of leukemia in children after contracting chickenpox 
(Bierman et al. 1953)  Intentional treatment of various cancers with several different viruses was 
attempted sporadically, primarily in the early to mid 20th century, with partial remissions 
typically obtained (Bierman et al. 1953; Okuno et al. 1978; Nemunaitis 1999; Moore 1957; 
Southam and Moore 1952).  Due to the lack of complete remissions, the use of viruses as a 
treatment of cancer was largely abandoned until recently.  Modern day advances in the ability to 
manipulate the viral genome to attenuate viruses or to add genes of interest, has resulted in the 
possibility of engineering oncolytic viruses with increased efficacy and safety.   
Viral cancer therapy 
 Viruses have shown promise as a way to preferentially kill neoplastic cells by selectively 
replicating within and lysing them (oncolytic virotherapy) as well recruiting the immune system 
to the tumor bed.  Due to initial concerns about the safety of using viruses in humans, 
particularly in immunocompromised cancer patients, several engineered viruses were 
manipulated to make them replication-incompetent mutants.  However, the lack of viral 
replication resulted in minimal effects in vivo.  Studies now typically use viruses that replicate 
normally, or use conditionally-replicative viruses.  Conditionally replicative viruses are 
engineered so that they are only able to replicate in neoplastic cells, and not in normal, non-
transformed cells.  Recently, viral engineering has centered on methods to make the viruses more 
effective for cancer treatment, often by attempting to recruit the immune system.  Recombinant 
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viruses can be used for targeted delivery of tumor-associated antigens (vaccine virotherapy), 
cytokines/chemokines (viral immunotherapy), or cancer modulating chemicals (drug 
virotherapy) to the tumor bed.  Viruses can even deliver chemotherapeutics that can increase 
permissiveness of the neoplastic cells to viral infection, or can decrease clearance of the virus.  
For example, rapamycin is a drug that can increase the levels of phosphorylated Akt in cells, 
which preferentially allows some viruses to replicate in those cells, and it is an 
immunosuppressive drug that decreases the immune response and thus decreases the immune 
system clearance of the virus (Thomas et al. 2011; Lun et al. 2009).  The reason that viruses are 
useful to specifically target neoplastic cells is because viruses are able to exploit the activated or 
suppressed cellular mechanisms that also support tumor growth (Parato et al. 2005).  Many 
tumor cells already have acquired mutations in key components of the intracellular signaling 
pathways, disrupting or involving proteins such as Myc, Ras, Akt, PI3K, and p53.  These 
mutations make them susceptible to viral infection by blocking apoptosis, promoting 
proliferation, and subverting the host’s immune response.    
Recent and current oncolytic virus clinical trials   
 There are many viruses that are currently being studied that either naturally target 
neoplastic cells or have been engineered to selectively target and replicate in neoplastic cells.  
None of the viruses currently being researched are able to treat every type of cancer, and it is 
unlikely that there will ever be a single virus that will be able to treat every cancer or be 100% 
effective and safe.  Similar to current chemotherapy protocols, oncolytic virotherapy will likely 
be tailored to treat the specific cancers for which each virus is most effective.  However, there 
are certain properties that are desirable overall for an oncolytic virus (Table 1.1).  They include 
safety for the patient (even if immunosuppressed) and the patient’s contacts, lack of 
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pathogenicity for livestock (or any other animals), lack of the ability to integrate into the patients 
DNA, low mutation rate (so the virus cannot mutate into a more virulent form), the ability to 
enter, replicate within, and kill the cancer cells without harming normal cells, the ability to be 
given systemically (to reach metastases), and the ability to recruit an immune response (which 
can also target the cancer cells).   
 China approved the world’s first oncolytic virus, H101, in 2005 for the treatment of head 
and neck squamous cell carcinoma (HNSCC) (Yu and Fang 2007).  The virus is a conditionally-
replicative adenovirus (CRAd) which has the gene for E1B-55kD deleted, so that it can only 
replicate in cells lacking functional p53, a tumor suppressor gene (Yu and Fang 2007).  
Meanwhile, there are many human clinical trials ongoing in the United States and Europe using 
different oncolytic viruses to treat various cancers (Appendix B).  An overview of recent clinical 
trials with oncoviruses is given in the following paragraphs.   
Adenovirus:  Adenoviruses are non-enveloped, linear, double-stranded DNA viruses 
with genomes approximately 38 kilobases (kb).  They are one of the most extensively studied 
viruses that have been genetically engineered for oncolysis.  Adenoviruses (Ad) are endemic in 
the human population and are typically associated with mild respiratory infection so many 
people already have antibodies to them.  In order to limit viral replication to cancer cells 
(conditionally replicative), adenovirus genes that function to neutralize normal cell defense (e.g. 
E1A, E1B) are deleted or replaced.  H101, the replication-selective oncolytic adenovirus that was 
approved for cancer treatment in China, has a deletion of the gene encoding the E1B-55-kD 
protein.  E1B-55-kD is a protein that is responsible for inactivating p53 in the host cell after 
infection, preventing apoptosis (Barker and Berk 1987).  Therefore, the deletion mutant should 
only be able to replicate in tumor cells that are defective in p53, and not in normal cells.   
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Several other adenoviral treatments for various cancers are in human clinical trials.  An 
adenovirus that expresses interferon gamma (TG1042)  just finished a phase II trial for treatment 
of cutaneous T and B cell lymphomas (Dummer et al. 2010), and was found to cause regression 
of some distant tumors as well as the injected tumors.  A phase 1 trial using a single IT injection 
of adenovirus that is driven by a telomerase reverse transcriptase (TERT) promoter 
(Telomelysin) was found safe and resulted in a tumor response (Nemunaitis 1999).  The wide use 
of adenovirus is mainly due to its extensive use in gene therapy; however, the attributes that 
make it ideal for gene therapy (maintaining the transduced cell, evading the immune system, and 
preventing viral replication) do not make it ideal for oncolytic virotherapy (Thorne, Bartlett, and 
Kirn 2005) where increased viral replication and cell death are desired.  
Herpesvirus:  Herpesviruses are enveloped, double-stranded DNA viruses with a 
genome approximately 152 kb, and are generally neurotropic.  Herpes simplex 1 virus is 
typically used for oncolytic virotherapy, and it is endemic in the human population.  It usually 
causes mucosal ulceration but can rarely cause severe medical illness in immunocompetent 
adults.  OncoVEXGM-CSF (herpes simplex virus 1 JS1/34.5-/47-/granulocyte-macrophage colony 
stimulating factor) is an oncolytic herpes simplex type 1 virus that caused local and distant tumor 
regression and increased survival in patients with metastatic melanoma in a Phase II trial, with a 
26% response rate (Senzer et al. 2009; Kaufman et al. 2010).  The same virus has also had 
success in Phase I/II trials for squamous cell carcinoma of the head and neck (SCCHN), with a 
response rate of 82% (Harrington et al. 2010a).  NV1020 (a replication-competent highly 
attenuated herpes simplex virus) demonstrated 50% stabilization of disease in a phase I/II 
clinical trial for refractory colorectal cancer metastatic to the liver (Geevarghese et al. 2010).  
HF101 (a naturally mutated herpesvirus with a high replication rate) just finished a phase I 
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clinical trial to treat unresectable pancreatic cancer, where it demonstrated a 17% partial 
response rate and 50% stabilization of disease (Nakao et al. 2011).  Treatments using 
herpesviruses have generally been safe with most toxicities limited to grade 1 or 2, rare dose 
limiting toxicities (DLT), and seroconversion in most patients.   
Reovirus:  Reovirus is a non-enveloped double-stranded segmented ribonucleic acid 
(RNA) virus.  Most humans have antireovirus antibodies, suggesting a high incidence of 
subclinical infection (Tai et al. 2005).   Reovirus type 3 Dearing (RT3D, Reolysin) is a naturally 
occurring reovirus isolated from the human respiratory and gastrointestinal tracts (Rosen, Evans, 
and Spickard 1963).  Reolysin naturally targets cancer cells with an activated Ras pathway, 
whether due to a Ras mutation or due to upregulation of epidermal growth factor receptor 
signaling.  Reolysin therefore, has benefits in that it does not require any additional manipulation 
to enhance its specificity or to modify it to a less virulent form.  A phase 1 study evaluating IT 
treatment with Reolysin combined with radiation therapy for treatment of advanced solid cancers 
found only mild toxicity, no DLT, and no viral shedding (Harrington et al. 2010b).  In addition, 
100% of patients had either a partial response or stable disease, depending on the dose of 
radiotherapy they received (Harrington et al. 2010b).  
Parvovirus:  Parvoviruses are small nonenveloped single-stranded DNA viruses that are 
only able to replicate in cells in S phase (actively replicating cells).  The first clinical trial using 
parvovirus to treate glioblastoma multiforme (GBM) is currently underway and is scheduled to 
be given intratumorally (IT) as well as systemically (IV) (Rommelaere et al. 2010). 
 Picornavirus:  Picornaviruses are non-enveloped viruses with single-stranded positive-
sense RNA viruses.  Picornaviruses include coxsackievirus, poliovirus, and Seneca Valley virus 
(SVV).  A recent phase I trial using IV SVV to treat solid tumors with neuroendocrine features 
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revealed that the virus is safe with no dose-limiting toxicites (DLT) (Rudin et al. 2011).   
Intratumoral viral replication occurred and antiviral antibodies were detected and correlated with 
clearance of the virus (Rudin et al. 2011).  However, only 3% (1/30) of patients developed stable 
disease and there were no tumor regressions (Rudin et al. 2011).  
Paramyxovirus:  These are negative-strand RNA viruses that result in syncytia 
formation in the cells they infect.  The viruses most commonly used for oncolytic virotherapy are 
Newcastle disease virus (NDV) and measles virus (MV).  NDV is an avian virus, and is selective 
for tumors cells that have defective interferon (IFN) production.  PV701, a replication-competent 
strain of NDV, has been found to cause objective responses in humans but can also cause 
toxicity.  A phase 1 trial of PV701 given IV at various doses and times to patients with advanced 
solid cancers, resulted in 1.6% CR (1/62), and 1.6% PR (1/62), and 22.6% SD (14/62) (Pecora et 
al. 2002).  The most common side effect was flu-like symptoms observed after treatment that 
decreased in severity with subsequent treatments.  However, toxicity was not uncommon, and 
included grade 3 (pain, tremors, dehydration, hypoxia, hypoglycemia, fever, fatigue, nausea, 
vomiting) and grade 4 toxicities (dyspnea, diarrhea) (Pecora et al. 2002).  One patient with pre-
existing pulmonary compromise died after treatment due to respiratory failure.  In addition, virus 
was shed in the sputum and urine at low levels (Pecora et al. 2002).  MV is a human pathogen 
that can cause serious disease, but most people have been vaccinated against it.  MV 
predominantly enters cells by the CD46 receptor, which is overexpressed in some tumor cells.  A 
phase I trial that administered MV IP every 4 weeks for up to 6 doses found that MV is safe, 
with no DLT, immunosuppression, or virus shedding (Galanis et al. 2010).  There was no 
significant change in anti-MV antibodies after treatment, despite multiple doses (Galanis et al. 
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2010).   There were no objective clinical responses (regressions) but there was dose-dependent 
disease stabilization in 67% (14/21) patients (Galanis et al. 2010).    
 Poxvirus:  Poxviruses have many attributes that are desirable for oncolytic virotherapy 
that have been extensively reviewed by Thorne (Thorne, Bartlett, and Kirn 2005).  Poxviruses 
are unique in that they can enter a wide variety of cell types (McFadden 2005), as opposed to 
most other viruses, which can only enter cells that express a specific cell marker.  They also 
naturally tend to target neoplasms, where new leaky vessels are being formed.  Poxviruses have a 
large genome that allows for the insertion of as much as 25 kb of contiguous DNA, enabling the 
expression of large eukaryotic genes (Kaufman et al. 2002),.  This allows poxviruses to be 
engineered to express therapeutic genes such as tumor antigens and cytokines that could 
potentially enhance their therapeutic efficacy.  In addition, poxviruses have their own replication 
machinery and therefore remain in the cytoplasm, so recombination of viral DNA into the host 
DNA has not been reported as it has with other viral vectors (Thorne, Bartlett, and Kirn 2005).  
Having their own replication machinery enables poxviruses to start transcription immediately 
upon entering the host cell, resulting in fast and efficient cell-to-cell spread (Thorne, Bartlett, and 
Kirn 2005).  Additionally poxviruses can release infectious virions from the infected cell before 
it has lysed the cell (CEVs and EEVs), resulting in the detection of free infectious virions as soon 
as 6 hours post-infection (HPI), versus adenovirus which remains intracellular until the cell is 
lysed and free virus is not available to infect adjacent cells for 48-72 HPI (Thorne, Bartlett, and 
Kirn 2005; Shenk 1996).   
 Poxviruses are large stable, enveloped, double-stranded DNA viruses with genomes that 
range from 130-300 kb that replicate with high fidelity.  Vaccinia virus (VACV) is the poxvirus 
that is most often used in oncolytic virotherapy, due to its large genome (200 kb) that allows the 
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insertion of large genes, and its history of use as a vaccine to eliminate smallpox, which has 
resulted in extensive characterization of its toxicity.  JX-594 is a replication-competent 
thymidine kinase deletion mutant VACV that expresses human granulocyte macrophage colony-
stimulating factor (GM-CSF) and lac-Z and is currently in a phase III clinical trial for treatment 
of unresectable primary hepatocellular carcinoma (Merrick, Ilett, and Melcher 2009).  Trovax 
(MVA-5T4) is an attenuated VACV expressing the tumor antigen 5T4, which is expressed by 
most solid tumors (Harrop et al. 2010) and has been studied in 2 phase I/II clinical trials and 7 
phase II clinical trials.  Increased survival has been associated with high antibody levels to 5T4 
(Harrop et al. 2010).  Due to the many benefits of poxviruses, we are also studying poxviruses, 
specifically myxoma virus, as novel oncolytic viral therapeutics. 
Poxvirus biology 
 The Poxviridae family is composed of many viruses (Table 1.2) which infect numerous 
animal species.  It has two subfamilies, one which infects vertebrates (Chordopoxvirinae) and 
one which infects insects (Entomopoxvirinae).  Chordopoxvirinae has many virus genera, 
including Orthopoxvirus, with members including vaccinia virus (the vaccine used to eradicate 
smallpox) and variola virus (the cause of smallpox), among others, and Leporipoxvirus, whose 
member myxoma virus (MYXV) is the virus used in this study. 
 Poxviruses infect cells through an unknown mechanism, as a specific cell surface 
receptor that the virus binds before cell entry has not been identified.  Since they are able to enter 
many cells it has been suggested that poxviruses can either:  1) use many different types of cell 
receptors, or 2) use a cell receptor that is ubiquitous (such as surface gylcosaminoglycans), or 3) 
fuse with the plasma membrane itself (Townsley et al. 2006; Carter et al. 2005).   Fusion of 
VACV to the plasma membrane can occur at neutral pH and is mediated by a multi-protein 
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poxviral entry fusion complex carried by the virion (Moss 2006).  Poxviruses are believed to be 
restricted to infecting certain cell types in specific animal species through mechanisms that affect 
their replication after they enter the cell.  This is different from most other viruses, which can 
only infect cells that express their virus-specific cell receptor. 
 Poxviruses produce three forms of infectious particles (virions): intracellular mature virus 
(IMV or MV), cell-associated enveloped virus (CEV) and extracellular enveloped virus (EEV).  
IMV particles are the most abundant form of the virus, and are retained within the cell cytoplasm 
until cell-lysis.  IMVs are more numerous and robust and are therefore believed by some to be 
important in the spread of poxviruses between individuals (Smith, Vanderplasschen, and Law 
2002).  They are brick-shaped with a lipoprotein shell (core membrane) surrounding a complex 
core structure that contains the linear double-stranded DNA genome and several virus-encoded 
proteins (Figure 1.1).  The core is surrounded by lateral bodies and an outer membrane.  CEVs 
and EEVs are similar to IMVs but have an additional lipoprotein envelope.  They are believed to 
be responsible for viral spread throughout the body of an individual, and are important for early 
virus dissemination.  Efficient cell-to-cell spread can occur when actin tails are induced to form 
underneath the cell surface below CEVs, facilitating virus penetration of the surrounding cells 
(Hiller et al. 1979).  Long-range spread of the virus is accomplished by release of the EEVs, 
although they only represent a fraction of a percent of the total infectious particles.  This is due 
to their being covered by a membrane that provides resistance to destruction by complement and 
decreased susceptibility to neutralization by antibodies (Smith, Vanderplasschen, and Law 
2002). 
 The virus-encoded proteins within the core of the infectious virions include RNA 
polymerase, enzymes for RNA capping, methylation, and polyadenylation, and a transcription 
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factor.  These proteins are packaged within the virus core so as to enable early viral protein 
synthesis after cell entry, allowing rapid replication.  Without these proteins, the poxvirus DNA 
is itself, noninfectious.  Poxviruses are able to remain within the host cell cytoplasm because 
they provide their own replication machinery.  The entire poxvirus life cycle takes place within 
the cytoplasm of the host, and does not enter the nucleus.  This feature distinguishes poxviruses 
from other DNA viruses, which must enter the nucleus to replicate, and makes viral integration 
into the host DNA highly unlikely.  
Smallpox 
 The most notorious poxvirus is the causative agent of smallpox, the orthopoxvirus variola 
virus (VARV).  Smallpox is a highly contagious disease that was previously endemic in every 
country.  It was unmistakably described as far back as the fourth century A.D, although 
mummified remains suggest that the disease was prevalent as far back as 3000 B.C. (Fenner et 
al. 1988).  Smallpox changed the course of human history, and at times decimated the human 
population, possibly accounting for up to 10% of all deaths in the world (Barquet and Domingo 
1997).  Mortality rates vary among types, but the most common type, variola major, has a 
mortality rate of approximately 20-30% in adults with an even higher rate in young children 
(Fenner et al. 1988).  Death, when it occurs, is believed to be secondary to toxemia and shock 
(Martin 2002).  Early attempts to decrease the mortality rate and severity of disease were 
initiated as early as 1000 A.D. in China, thru a process known as variolation.  In this process, 
individuals were intentionally exposed to smallpox material (pus or scabs) either by nasal 
inhalation or through skin abrasions.  Variolation typically resulted in a milder form of the 
disease.  Edward Jenner introduced the concept of vaccination in 1796, when he noticed that 
milkmaids who developed cowpox lesions were resistant to smallpox.  He took material from a 
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cowpox lesion on a milkmaid and inoculated a young boy, who was subsequently exposed to 
smallpox and found to be resistant.  Jenner repeated this experiment on other children with the 
same outcome.  Initially, vaccination against smallpox was performed with cowpox virus, but 
over time switched to vaccinia virus (VACV), the origin of which is unknown.  By the end of the 
19th century, the vaccine was produced by harvesting lymph from infected live animals (typically 
calves).   
 Since humans are the only known reservoir of VARV, the potential to eliminate the virus 
was proposed in 1953 and a worldwide global eradication program against smallpox was begun 
in 1959.  The program involved vaccinating a large portion of the human population.  The 
campaign intensified in 1965 and was eventually successful, with the last naturally occurring 
case of smallpox reported in Somalia in 1977, and with the WHO declaring in 1980 that 
smallpox had been eradicated (Wehrle 1980).     
Vaccinia virus 
 The most studied poxvirus is VACV, and it is the poxvirus most often used in oncolytic 
virotherapy.  The actual origin of VACV is unknown, as it is distinct from VARV, cowpox virus, 
and all other poxviruses.  It emerged sometime in the 19th century, and soon became the 
smallpox vaccine of choice due to its ability to be cultivated in many different animals and its 
ability to provide cross-protective immunity against other Orthopoxviruses (Jacobs et al. 2009).  
There were many different VACV strains; however, the New York City Board of Health 
(NYCBH) strain, a 1st generation VACV, was the strain used in the eradication program in the 
Americas and West Africa (Jacobs et al. 2009).  Other strains used include:  the EM-63 strain 
(Russia and India), the Lister strain (United Kingdom), the Paris strain (France), the Copenhagen 
strain (Denmark), the Bern strain (Switzerland), the Ankara strain (Turkey), the Temple of 
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Heaven and the Vaccinia Tian Tan strains (China), and the Dairen strain (Japan) (Rosenthal et al. 
2001).  The strains vary in their safety, with fewer side effects noted in the NYCBH strain, and 
higher rates of complications noted in the Lister and Copenhagen strain, with the highest rates in 
the Bern strain (Kretzschmar et al. 2006). 
 While the adverse events are minimal as compared to smallpox, vaccination with VACV 
can still cause some serious side effects.  The most common adverse event after vaccination is 
mild pain at the inoculation site (47%), with 2-3% reporting the pain as severe.  Fever above 
100ºF (37.7ºC) occurs in 5-9% of vaccinees, and fever above 103ºF (38.8ºC) occurs in 3% 
(Kretzschmar et al. 2006).  Mild systemic complications, including headache, myalgia, chills, 
nausea, fatigue, and difficulty sleeping, occur in over 25% of vaccinees.  Serious complications 
reported after vaccination with VACV include erythema multiforme (164.6/million vaccinees), 
inadvertent inoculation (25.4-529/million vaccinees), and generalized vaccinia (23.4-241/million 
vaccinees).  Inadvertent inoculation includes autoinoculation, where the virus is spread to sites 
other than the vaccination site by touching the inoculation area and then another site, the most 
serious site generally being the eyes (Figure 1.2A).  Similarly, the virus can also be spread to 
people in contact with the vaccinated person.  Generalized vaccinia (Figure 1.2B) typically 
occurs in the young or in immunocompromised vaccinees.  Vaccinia virus can also cause very 
uncommon but severe side effects after vaccination such as vaccinia necrosum (a.k.a. 
progressive vaccinia, 1.5cases/million people vaccinated, Figure 1.2C), eczema vaccinatum 
(38.5/million, Figure 1.2D), and postvaccinal encephalitis (12.3/million), which result in a rate of 
1 death/million primary vaccinations (Rotz et al. 2001).  Eczema vaccinatum occurs in people 
who have eczema or other skin conditions that result in skin compromise, allowing the virus to 
spread all over the body.  Postvaccinal encephalitis is the most lethal complication, causing 
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inflammation of the brain that is believed to be due to an immune response to viral infection, 
rather than to spread of the virus to the brain.  Vaccinia necrosum tends to occur in people who 
lack effective cellular immune responses, while generalized vaccinia is believed to be due to 
immaturity of the immune system.  Therefore, there is already evidence that VACV can be a risk 
in immunocompromised individuals.  Recently, vaccination with VACV has been found to cause 
myopericarditis at a rate of approximately 100/million vaccinees, with rare cases of myocardial 
infarction and dilated cardiomyopathy (Mora, Khan, and Sperling 2009).  Also, VACV has been 
shown to commonly infect ovarian tissue in addition to neoplastic cells, in vivo (Moss 1996; 
Whitman et al. 1994).  Even in modified, less virulent strains, VACV can often be found in the 
ovaries of mice whether they are inoculated by intraperitoneal or intravenous injection (Suter et 
al. 2009; Puhlmann et al. 2000).  
 Due to the widespread vaccination of people up until the 1970’s with VACV, many older 
individuals have previously been vaccinated with VACV, and it unknown how this will affect 
the ability of the virus to replicate within the tumor bed, or to spread to other tumors in the body.  
The presence of a pre-existing antibody response to VACV would theoretically result in rapid 
clearance of the virus by the immune system, limiting the ability of the virus to infect the 
neoplastic cells and spread to adjacent cancer cells.  Despite this, use of vaccinia virus as an 
oncolytic virus in clinical trials has not been limited by the presence of pre-existing VACV 
antibodies, similar to studies using measles, reovirus, or adenovirus.   
 Importantly, VACV is able to infect cattle, and could therefore get into the livestock 
population, such as has already occurred in Brazil.  In Brazil, VACV primarily infects milking 
cows and dairy workers, but can also be found in nursing calves and in horses.  Infection of dairy 
cattle has resulted in economic losses as cattle can develop secondary mastitis (Leite et al. 2005).  
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Milk obtained from infected cows has also been shown to contain virus particles which remain 
infectious after heat treatment at 65ºC for 30 minutes, suggesting that virus particles would be 
present in solid curds and cheese whey (de Oliveira et al. 2010).  The introduction of such 
infection into the U.S. dairy population would be economically devastating to the cattle industry, 
in addition to becoming a source of infection to the human population.     
Myxoma virus 
 To avoid complications with VACV, myxoma virus was evaluated as a cancer treatment 
in this study.  MYXV is a rabbit-specific poxvirus that causes a lethal infection, termed 
myxomatosis, in European rabbits (Oryctolagus cuniculus) and a benign infection characterized 
by a cutaneous fibroma in the North American brush rabbit (Sylvilagus bruneii) and the South 
American tapeti (Sylvilagus brasilensis) (Fenner 2000; Fenner 1983).  Myxomatosis was first 
reported in 1896 in South America (as reviewed in Stanford, Werden, and McFadden 2007) as a 
rapid systemic and lethal infection of European rabbits, and was subsequently found to be 
endemic in the natural rabbit population.  It is mechanically (passively) transmitted by arthropod 
vectors, resulting in an initial primary skin lesion in wild and European rabbits.  In European 
rabbits, the disease progresses with swelling of the muzzle and anogenital region, 
blepharoconjunctivitis, and formation of secondary edematous (myxomatous) skin lesions 
(Fenner and Ratcliffe 1965; Fields, Knipe, and Howley 1996).  Death typically occurs in 8-15 
days and is believed to be due to multi-organ dysfunction and secondary lung infections (Fenner 
and Ratcliffe 1965; Fields, Knipe, and Howley 1996).  Myxoma virus causes even higher rates of 
lethal infection in European rabbits (near 100%) than VARV caused in humans.   
 Due to the high mortality rate, the Lausanne strain of MYXV was released in Australia in 
1952 in an attempt to control the millions of rabbits that were devastating the country.  The 
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European rabbit had been intentionally released in Australia in 1859 for hunting and, due to the 
mild winters and lack of predators, rapidly increased their numbers and spread across the 
country.  Myxoma virus infection resulted in a mortality rate of over 99% of the infected rabbits.  
However, not all rabbits were infected, and in those that were, co-evolution of the virus and the 
surviving rabbits resulted in a decreased mortality rate (Best, Collins, and Kerr 2000; Kerr and 
McFadden 2002; Marshall and Fenner 1958; Marshall and Douglas 1961).  
 Lack of pathogenicity is a requirement for a successful oncolytic virus therapeutic and 
makes MYXV (a Leporipoxvirus) an attractive alternative to VACV.  Shortly after the release of 
MYXV in Australia, the public raised concerns about the safety of MYXV to the human 
population.  In order to prove that MYXV was safe, 3 scientists injected themselves with live 
MYXV virus, and suffered no ill effects.  While this small population may not prove that MYXV 
is safe in all people, MYXV has been found to be non-pathogenic for all non-rabbit vertebrate 
species tested (Fenner and Ross 1994; Burnet 1968; Pignolet et al. 2008), and despite its 
widespread infection in Australia, no ill effects to the human population have ever been shown.  
Due to its restricted host range, MYXV has some advantages when compared to VACV for use 
as an oncolytic virotherapeutic.  Since it does not infect people, treatment with MYXV should 
not result in any adverse events, should not infect ovarian tissue, and there should not be any pre-
existing immunity to MYXV in those treated.  It also should not raise any concerns about a 
potential threat to livestock population, with the exception of rabbitries that use European 
rabbits.  However, even this potential threat can be alleviated by manipulation of the virus, as 
MYXV:IL15 (Liu et al. 2009) and MYXV that expresses the gene for Interleukin 12 (IL-12) 
(Stanford et al. 2007a) have both been shown to be non-pathogenic in European rabbits.  Despite 
its strict host range, MYXV has been shown to productively infect cultured cancer cells from 
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several species in vitro, including human (Sypula et al. 2004; Woo et al. 2008; Lun et al. 2007), 
murine (Thomas et al. 2011; Stanford et al. 2008), racine (Lun et al. 2010), canine (Urbasic et al, 
accepted AJVR 2011) and feline (Macneill et al. 2011).  .   
Myxoma virus infection of human cells 
 Myxoma virus was shown to productively infect the majority (15/21) of human tumor 
cell lines in one study (Sypula et al. 2004).   The cell lines tested included melanoma, 
osteosarcoma, prostate, renal, lung, colon, breast, and ovarian cancer cells.  Additional studies 
have demonstrated that 87.5% (7/8) of human malignant glioma cell lines tested were fully 
permissive to MYXV infection in vitro (Lun et al. 2005) and 83.3% (5/6) of human 
medulloblastoma cell lines tested were fully permissive in vitro (Lun et al. 2007).  Infection of 
human acute myelogenous leukemia (AML) CD34+ cells in vitro demonstrated a 65% rate of 
MYXV:GFP infection, while normal CD34+ human hematopoietic stem and progenitor cells 
(HSPCs) did not have any evidence of MYXV:GFP infection (Kim et al. 2009). 
 Susceptibility of human tumor cell lines to infection with MYXV has been found to 
correlate with the level of endogenous phosphorylated Akt (also known as protein kinase B), 
within the cell (Werden and McFadden 2008).  Akt is a serine/threonine kinase that plays a role 
in the regulation of proliferation, apoptosis, angiogenesis, and metabolism (Datta et al. 1997; 
Cardone et al. 1998; Pap and Cooper 1998).  Tumor cells with high levels of phosphorylated Akt 
are fully permissive to MYXV infection, while cells that do not express any phosphorylated Akt 
are resistant to MYXV infection (Wang et al. 2006).  Studies have shown that treatment of some 
tumors with rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), can 
increase levels of phosphorylated Akt, enhancing the oncolytic potential of MYXV (Stanford et 
al. 2007b). 
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 Conversely, cells that are not permissive to infection with MYXV have been shown to 
induce anti-viral cytokines upon MYXV infection.  Human macrophages that were infected with 
MYXV rapidly co-induced tumor necrosis factor (TNF) and type 1 interferon (IFN), which then 
aborted MYXV infection in normal human cells in a paracrine-like manner (Wang et al. 2008).  
The addition of TNF and IFN-β cytokines to primary human fibroblast cell lines has been shown 
to make them resistant to MYXV infection (Bartee et al. 2009b).  These two cytokines induce a 
synergistic antiviral state, and it has also been demonstrated that the ability to induce this 
synergistic antiviral state has been lost in most human cancer cells (Bartee and McFadden 
2009a). 
Myxoma virus infection of murine cells 
 The presence of phosphorylated Akt may be important for MYXV permissiveness in 
mouse cells as it is in human cells.  The murine melanoma B16F10LacZ cell line has been found 
to have a high endogenous level of phosphorylated Akt and inhibition of Akt kinase activation 
drastically inhibited the ability of the MYXV to replicate in the cell line in vitro (Stanford et al. 
2008).   
 The ability of MYXV to replicate in mouse cells has also been found to depend on 
disruption of the Erk-interferon-STAT1 signaling pathway (Wang et al. 2004).  Interferons 
(IFNs) are a family of inducible cytokines that are important in innate antiviral defense and 
trigger the transcription of hundreds of IFN-stimulated genes (ISG) that have antiviral, as well as 
antiproliferative/antitumor, and immunomodulatory effects (Fensterl and Sen 2009; Samuel 
2001).  Type I and III IFNs can be induced in virtually all cell types by the recognition of viral 
pathogen associated molecular antigens (PAMPs), which are conserved molecular patterns 
present in pathogens, whereas type II IFNs are only induced in certain immune cells (T cells and 
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NK cells) upon stimulation by specific cytokines, such as IL-12 (as reviewed by Fensterl and Sen 
2009).  Type I IFNs (IFN-α and IFN-β) are often induced in normal cells (primarily plasmacytic 
dendritic cells) during viral infections by activation of Erk 1/2 (extracellular signal-regulated 
kinase) signaling which operates upstream of IFN regulatory factor 3 (IRF3).  STAT1 is a 
transcription factor that is downstream of IFNs and is essential to mediate antiviral effects.  
Disruption or deficiency of any of the molecules in this pathway renders normally nonpermissive 
mouse primary fibroblast cells susceptible to infection with MYXV (Wang et al. 2004).  This 
pathway is often disrupted in cancer cells, presumably because cancer cell growth would be 
limited by the antiproliferative/antitumor actions of the ISGs. 
Myxoma virus cancer treatment in vivo 
 Myxoma virus has shown oncolytic effects against many different tumor models in mice.  
When two malignant humanglioma cell lines (U87 and U251) were implanted orthotopically in 
nude (immunodeficient) mice, a single intratumoral (IT) injection of MYXV “cured” the 
majority (87.5% and 100%, respectively) of the treated mice (Lun et al. 2005).  Intracerebral 
administration of MYXV to the immunodeficient mice was safe, resulting in minimal 
inflammation and slight weight loss that was not statistically significant (Lun et al. 2005).  The 
“cured” mice had either no detectable tumor (75%) or had residual tumor cells (25%) detectable 
by microscopic examination of the tissues (histology).   Similar findings occurred with a mouse 
model of human medulloblastoma, in which 60% (3/5) of mice treated with a single IT injection 
of MYXV were “cured”, with 2 of those having no tumor cells remaining and 1 having a very 
small residual tumor (Lun et al. 2007).  However, initial studies using MYXV in 
immunodeficient mouse models did not examine the immune response to MYXV treatment.  
 In a study using MYXV in an immunocompetent mouse model of metastatic (lung) 
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melanoma (Stanford et al. 2008) it was shown that a single intravenous (IV) injection of MYXV 
did not significantly reduce the number of lung metastases.  The addition of rapamycin or the use 
of multiple MYXV injections did reduce the size or number (respectively) of lung metastases.  
The same study showed that multiple (daily) injections of MYXV could significantly decrease 
the size of subcutaneous melanoma tumors in an immunocompetent mouse model (Stanford et al. 
2008).  Similarly, a study using an immunocompetent racine model of intracranial glioma 
demonstrated that a single injection either did not statistically improve survival (RG2 tumors) or 
only slightly prolonged survival (F98 tumors), but survival was significantly increased when 
rapamycin (an immunosuppressive drug) was given in combination with MYXV (Lun et al. 
2010).  In order to improve the efficacy of MYXV treatment without having to resort to 
immunosuppressants, additional factors can be inserted into the MYXV genome such that they 
are expressed locally within the tumor as the virus replicates.  These can range from 
antiangiogenic factors to factors that stimulate the immune system, or factors that breakdown the 
connective tissue of the tumor to enhance spread of the virus.   
Tumor biology and immunology 
 When considering designing a recombinant oncolytic virus to treat a tumor, there are 
many factors to consider, including the tumor microenvironment and the immune system.  The 
tumor microenvironment is composed of tumor cells, immune cells, stromal cells, vessels, and 
extracellular matrix (ECM), as well as soluble factors (secreted by the normal and neoplastic 
cells), and areas of edema and necrosis.  In this sense, the tumor can almost be regarded as an 
organ, with its own particular requirements for growth and survival. The tumor environment is a 
place that must foster tumor cell survival, proliferation, and migration, as well as drive the 
proliferation of new vessels (angiogenesis) to provide nutrition to the cancer cells.  The tumor 
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microenvironment has increased osmotic pressure due to the presence of these new vessels, 
which are usually abnormal and leaky, as well as due to pressure produced by overgrowth of the 
tumor cells.  This leads to inefficient perfusion, with subsequent heterogeneous areas of hypoxia 
and acidosis, both of which contribute to resistance to radiotherapy and many chemotherapeutics.  
Decreased blood flow has also been found to occur after treatment with oncolytic viruses, and 
can result in tumor cell necrosis, restricting the ability of the virus to spread (Breitbach et al. 
2007).  
 Another contributor to treatment resistance is the ECM, which is composed of complex 
secretions of proteins and proteoglycans produced by both the neoplastic cells and the tumor 
stromal cells.  The secretion of ECM is increased in many tumors, contributing to the increased 
interstitial fluid pressure.  In addition, the interwoven meshwork of secreted proteins forms a 
physical barrier that significantly limits the dispersal of therapeutics within the solid tumor.  This 
has also been a problem with viral oncolytics, with virus observed to be restricted to small focal 
areas within the tumor in several studies (Sauthoff et al. 2003; Markert et al. 2009; McKee et al. 
2006; Cheng et al. 2007).  This localization can be decreased by pre- or co-treatment with 
collagenase, hyaluronidase, metalloproteinases, or other proteins that digest the ECM (McKee et 
al. 2006; Cheng et al. 2007; Kuriyama et al. 2000; Ganesh et al. 2008; Kim et al. 2006).    
 An equally important aspect of cancer biology is the ability of the tumor cells to evade 
the immune system.  Leukocyte infiltration into tumors was first observed as far back as 1863 by 
Rudolf Virchow, the father of pathology, who postulated a possible relationship between 
inflammatory infiltrates and tumor growth (as reviewed in Zou 2005).  In 1957, Burnet and 
Thomas theorized about the existence of host immunological resistance to the development of 
cancer (tumor immunosurveillance; as reviewed in Zou 2005).  However, these theories were not 
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given much credence until recently due to the lack of documented spontaneous tumor 
eradication.  Failure of the immune system to recognize and eradicate tumors has been thought to 
be due to one or more deficiencies:  1) antigen-presenting cells (APCs) are not stimulated 
enough, 2) there are not enough local effector T or NK cells, 3) there are not enough cytokines, 
or 4) the tumors do not present enough antigen.  Indeed, anti-tumor immunity is believed to 
cause selective pressures that favor the outgrowth of tumor cells with reduced immunogenicity, a 
process called immunoediting.  For example, a recent study (Thomas et al. 2011) using adoptive 
transfer of T cells targeted to recognize an antigen on tumor cells found that tumors that recurred 
in the treated animals had low or absent expression of the antigen recognized by those T cells 
(termed antigen loss variants).  Alternatively there could be tolerizing conditions (cytokines 
and/or cells) present that limit the immune response.  For instance, some human tumors have 
been found to have increased levels of  vascular endothelial growth factor (VEGF), IL-6, M-
CSF, transforming growth factor-β (TGF-β), IL-10, cyclooxygenase-2 (COX-2), and 
prostaglandin E2 (PGE2), while having decreased levels of GM-CSF, IL-12 and IFNγ (as 
reviewed in (Zou 2005).  This aberrant cytokine pattern in the tumor microenvironment blocks 
dendritic cell (DC) differentiation and maturation, thereby affecting the ability to prime an 
antitumor immune response to tumor-associated antigens (TAAs).  Additionally, there are cells 
that decrease the immune response, such as regulatory T cells (CD4+CD25+Foxp3+ T cells), 
which are involved in maintaining peripheral tolerance, and myeloid-derived suppressor cells 
(MDSC), which are a heterogenous group of myeloid-derived cells that are often found in 
increased numbers in neoplastic conditions.  
 Improving the immune response to a tumor can theoretically be achieved by replacing the 
decreased levels of immune system effector cells and cytokines, or by decreasing inhibitors of 
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the immune system.  In those tumors where the immune response does not appear to be 
suppressed, the presence of infiltrating leukocytes has been shown to correlate with an improved 
prognosis.  The number of tumor infiltrating NK cells has been found to correlate with survival 
prognosis in colorectal cancer (CRC), gastric carcinoma, and squamous cell lung cancer (Coca et 
al. 1997; Villegas et al. 2002; Ishigami et al. 2000).  High densities of infiltrating lymphocytes 
have been found to correlate with a good prognosis in many types of human cancer.  High IT 
memory T-cell density in CRCs has been shown to correlate with decreased metastases to lymph 
nodes and distal organs (Pagès et al. 2005).  In a review of 602 CRCs, the patients with the 
highest densities of CTLs and memory T cells had an 86.2% survival rate 5 years after diagnosis, 
versus patients with the lowest densities of these cells, which has a survival rate of 27.5% (Pagès 
et al. 2009).  Staging the tumors according to immune cell infiltration was found to be superior to 
the traditional staging method, and was one of the few independent prognostic factors (whereas 
tumor stage was not) (Bindea et al. 2011).  Tumors with high density of T cell infiltration in the 
center and at the infiltrating margin, as well as tumors with low helper T cell infiltration, were 
found to have a better prognosis than tumors with a heterogeneous distribution of T cells 
between the center and margin, or in tumors with low numbers of infiltrating T cells or higher 
proportions of helper T cells (Bindea et al. 2011).     
 Cytokines within the local tumor environment are modified in such a way as to allow 
tumor cells to overgrow and avoid detection by the immune system.  Such modulations typically 
include decreased or absent IFN production by the tumor cells, which allow viruses to infect and 
replicate within the tumor, but not in the healthy tissue outside of the tumor.  Since 
tumorigenesis is a slow process that can resemble a chronic infection, the immune response to a 
persistent tumor shifts from an acute TH1 dominant response to a TH2 dominant response, 
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drastically altering T cell responses and cytokine expression (Tsung et al. 1997, and as reviewed 
in Zou 2005).  Since the local expression of cytokines can have a profound effect on the local 
immune cell response, oncolytic viruses have been engineered to express cytokines that can shift 
the immune response to one that may recognize the tumor, as a form of immunotherapy.  
Interleukin 2 
 Interleukin 2 (IL-2) was the first approved immunotherapy that was based entirely on 
immunomodulation (as reviewed in Dillman 2011).  IL-2 was also approved for the treatment of 
metastatic renal carcinoma in 1992, for the treatment of melanoma in 1997, and for the treatment 
of metastatic carcinoma in 1998 (Dillman 2011; Eklund and Kuzel 2004).  IL-2 does not directly 
target cancer cells, but exerts its antitumor effects by stimulating cytotoxic T lymphocytes and 
NK cells.  Immunotherapy with high-doses of adjuvant IL-2 is the current standard of care in 
high-risk stage II and stage III melanoma.  It has been found to increase overall survival from 2.8 
to 3.8 years, and result in durable complete remission in 4% of patients (Atkins et al. 1999; 
Algazi, Soon, and Daud 2010).  Localized immune therapy has also been used to treat cutaneous 
melanoma metastases and has been found to induce high rates of complete and partial 
regressions in the injected tumors, however, visceral metastases were either not affected or 
subsequently developed (Weide et al. 2010; Radny et al. 2003).   
         Unfortunately, IL-2 is toxic at high levels, causing grade 3 and 4 toxicities, including 
hypotension and vascular leakage reminiscent of septic shock (Eklund and Kuzel 2004).  In 
addition, high-dose IL-2 therapy has been documented to cause myocarditis in approximately 
3.5% of treated patients (Eisner, Husain, and Clark 2004). 
Interleukin 15  
 Interleukin-2 and IL-15 are cytokines with similar biological properties, despite being 
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different genetically and antigenically.  This is likely due to their shared receptor signaling 
components (IL-2/15Rβγc).  Specificity of function is provided by their unique α-chain receptors 
that complete the heterotrimeric receptor complexes (IL-2Rαβγ and IL-15Rαβγ).  It is the 
distribution of the distinct IL-15Rα and IL-2Rα chains in vivo that determines where each 
cytokine will bind and activate a signaling pathway via the common βγc receptor.  In addition, 
IL-15 and its α-chain receptor have a much broader tissue distribution than IL-2 or its α-chain 
receptor.  Recently, it has been found that IL-15Rα has high-affinity (Ka ≥ 1011 M-1) for IL-15, 
even in the absence of other receptor components, but only transduces signals if it binds to IL-
2/15Rβγc.    Interleukin 15 may bind the IL-2/15Rβγc with intermediate affinity (Ka ≥ 1011 M-1) 
without binding IL-15 Rα (Giri et al. 1995; Giri et al. 1994). 
 Interleukin-15 is a cytokine produced by multiple tissues, including monocytes, 
macrophages, kidney, heart, lung, skeletal muscle, placenta, bone marrow stroma, and thymic 
epithelium (Grabstein et al. 1994; Leclercq et al. 1996).  Interleukin-15 has multiple immune 
functions (Figure 1.3), including T cell proliferation, activation of cytotoxic effector cells, and 
activation of monocytes (Perera, Goldman, and Waldmann 2001), as well as costimulatory 
proliferation of activated B cells (Armitage et al. 1995).  Additionally, IL-15 has critical 
influence on the differentiation, proliferation, maturation, and survival of NK and CD8+ cells 
which are the cells involved in detecting virally-infected cells and tumor cells (Perera, Goldman, 
and Waldmann 2001).     
 Interleukin-15 cancer therapy is more experimental than IL-2 therapy.  Nonetheless, IL-
15 treatment has had positive effects in several cancer models.  Intratumoral administration of 
syngeneic DCs transduced with IL-15 (using a simian virus 40 viral vector) was associated with 
a strong antitumor response in colon carcinoma tumors in mice, with 73% complete tumor 
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remission, and correlated with in vivo priming of tumor-specific CD8+ T lymphocytes and NK 
cells (Vera et al. 2005).  The cured mice developed immune memory, with resistance to 
rechallenge of tumor cells (Vera et al. 2005).  Similarly, immunotherapy using a recombinant 
adenovirus expressing IL-15 was found to significantly inhibit growth of human cervical cancer 
and human breast cancer in murine models (Yu et al. 2010; Yiang et al. 2009).  Mice that 
overexpress IL-15 are significantly more resistant to tumor growth when challenged with B16-
F10 melanoma cells than B6 control mice, while mice that do not express IL-15 have increased 
susceptibility (Davies et al. 2010).  Interleukin-15 has also been demonstrated to have anti-tumor 
properties independent of NK cell and CTL functions, which is thought to be due to stimulation 
of macrophages to produce IL-12 and nitric oxide (NO) (Davies et al. 2010).  Interleukin-15 (and 
IL-12) can activate macrophages through the induction of IFNγ and TNFα (Carson et al. 1994; 
Fehniger, Carson, and Caligiuri 1999a).  In addition, IL-15 is a potent stimulus for GM-CSF 
production by human and murine NK cells (Carson et al. 1994; Fehniger et al. 1999b; Fehniger 
et al. 2000), which can activate DCs.  We hypothesized that the therapeutic efficacy of MYXV 
could be enhanced using a recombinant MYXV that delivers murine IL-15 directly into the 
tumor microenvironment.  We further theorized that a recombinant MYXV designed to express 
an immunostimulatory cytokine (IL-15) would be a potent oncolytic therapeutic and would not 
require combination therapy with a chemotherapeutic drug.   
Natural killer cells 
 Natural killer cells are large granular lymphocytes that are a component of the innate 
immune system response against both tumor cells and virally-infected cells, making them a very 
important player in oncolytic viral therapy.  Natural killer cells develop from the common 
lymphoid progenitor cells in the bone marrow and circulate to the secondary lymphoid organs 
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and many other tissues.  Natural killer cell precursors respond to IL-15 by maturing into 
functional NK cells and becoming activated (Leclercq et al. 1996; Yu et al. 1998).  Mice that do 
not have any IL-15 or do not have the IL-15 receptor alpha (IL-15 -/- and IL-15 Rα -/- mice) lack 
NK cells, suggesting that IL-15 is necessary for the differentiation of mature NK cells (Kennedy 
et al. 2000).  In addition, other cytokines (Figure 1.4) including IL-2, IL-12, IL-21, and IFN-α/β 
play a role in NK cell maturation or activation (Biron et al. 1999; Smyth et al. 2002; Nutt et al. 
2004). 
 Natural killer cells are predominantly found in the peripheral blood, at sites of 
inflammation, and in the lymph nodes in humans (Ferlazzo et al. 2004; Freud et al. 2006) and in 
the spleen of mice.  Natural killer cells have abundant cytoplasm that contains granules filled 
with granzymes and perforin.  Upon activation, NK cells exocytose these granules which 
perforate the targeted cell and cause apoptotic cell death.  Natural killer cells also produce a 
variety of chemokines and cytokines (Figure 1-4), including IFN-γ, TNF, GM-CSF, the C-C 
chemokines macrophage inflammatory protein (MIP)-1α and MIP-1β, and regulated upon 
activation, normal T cell-expressed and secreted (RANTES) (Biron et al. 1999; Dorner et al. 
2004).  Natural killer cells produce MIP-1α and MIP-1β after stimulation with IL-15, which is 
enhanced by IL-12 (Fehniger, Carson, and Caligiuri 1999a; Bluman et al. 1996).  Interferon 
gamma production is restricted to NK cells and activated T cells, and occurs in response to 
stimulation by IL-12 and IL-18, not to viral PAMPs (Fensterl and Sen 2009).  Interferon gamma 
produced by NK cells activates macrophages, which produce cytokines, including IL-15, which 
activates NK cells, and is just one component of the cross-talk that occurs between NK cells and 
macrophages, as shown in Figure 1-4.   
 Natural killer cells express a large number of activating and inhibitory receptors that 
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function to ensure activity against virally-infected cells and tumor cells, while maintaining self-
tolerance to non-infected, non-transformed cells.  Natural killer cells are able to detect self 
molecules that are induced in conditions of cell stress, which increases the likelihood that they 
will be activated during an infection.  As part of the innate immune system, once activated, NK 
cells are able to kill target cells in the absence of antibody (as reviewed in Lanier 2005).   
Immune response to oncolytic viruses 
 The ability of the virus to replicate within cancer cells is a key attribute of a successful 
oncolytic virus; however the primary goal of oncolytic virus therapy is destruction of the 
neoplastic cells.  This can be accomplished by direct cell lysis secondary to viral replication, or 
by directing the immune response against infected cancer cells.  The benefit to involvement of 
the immune system is the potential to develop immunologic memory against the neoplastic cells.  
It has been theorized that a vigorous local immune response against virally-infected tumor cells 
may activate the immune system to recognize tumor cell antigens as well as viral antigens, 
resulting in tumor clearance locally and systemically (Thorne, Bartlett, and Kirn 2005).  CD8+ 
cytotoxic T lymphocytes (CTLs) have the ability to specifically recognize and kill tumor and 
virus-infected cells.  Therefore, development of an immune response to virally-infected tumor 
cells would ideally generate a CD8+ CTL response.  Poxviruses such as VACV can induce a 
CTL response against virally-infected cells (Fujiwara et al. 1984), and some animals cleared of 
tumor by recombinant VACVs are resistant to rechallenge with cells of the same tumor type 
(Kirn et al. 2007).  In one study using VACV expressing GM-CSF delivered intratumorally, 
patients demonstrated regression of distant metastases, as well as the injected tumor.  The 
uninoculated masses (metastases) did not have any sign of VACV infection, but did have T-
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lymphocyte infiltration, suggesting that the immune system had been primed to recognize the 
neoplastic cells (Mastrangelo et al. 1999).   
 We hypothesized that MYXV expressing the gene for IL-15 could induce a cell-mediated 
antitumor immune response and increase survival in immunocompetent mice with tumors.  The 
virus was injected intratumorally, in order to achieve the maximum concentration of virus in the 
tumor bed.  Chapter 3 describes the effects of MYXV and MYXV:IL15 treatment in cancer cell 
cultures.  Chapter 4 reviews the outcome of a single intratumoral injection of MYXV in three 
murine models of brain cancer.  And lastly, in chapter 5 we monitored the response of murine 
subcutaneous melanomas to treatment by evaluating the tumors histologically at various time 
points after injection, as well as comparing survival times in virus treated and control animals to 
multiple injections.  We found that multiple injections MYXV and MYXV:IL15 have beneficial 
effects on survival compared to controls, and recommend further experiments designed to 
increase the beneficial treatment effects.       
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Chapter 1 Tables and Figures 
 
Ideal oncolytic virus Myxoma virus 
 
Not a human pathogen but will infect human cancer cells 
• Avoids pre-existing immunity  
Yes 
Not able to infect livestock Yes 
Limited side-effects or toxicity to normal tissues Yes 
Large genome capable of transgene insertion 
• Allows virus to be armed with therapeutic genes 
Yes 
Virus is able to rapidly replicate and cause cytolysis  Yes 
Does not combine with the host genome 
• Ideally does not ever enter the host nucleus 
• Minimizes the risk of virus-host genetic recombination events 
Yes 
Can be given systemically Yes, in mice 
Raises a potent inflammatory response 
• May aid in the establishment of an antitumor immune response 
Yes 
 
Selectively replicates in tumor cells without infecting normal cells Yes 
Can be combined with other cancer treatments Likely 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1.  Properties of an ideal oncolytic virus.   
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Subfamily Genus Species 
Chordopoxvirinae Avipoxvirus canarypox, crowpox, fowlpox, juncopos, 
mynahpox, pigeonpox, psittacinepox, quailpox, 
peacockpox, penguinpox, sparrowpox, 
starlingpox, turkeypox 
Capripoxvirus goatpox, lumpy skin disease, sheeppox 
Leporipoxvirus myxoma, hare fibroma, rabbit fibroma, squirrel 
fibroma 
Molluscipoxvirus molluscum contagiosum 
Orthopoxvirus camelpox, cowpox, ectromelia, monkeypox, 
raccoonpox, skunkpox, Uasin Gishu, vaccinia, 
variola, volepox 
Parapoxvirus Auzduk disease, bovine popular stomatitis, 
chamois contagious ecthyma, orf, 
pseudocowpox, parapox of red deer, sealpox, 
squirrelparapox 
Suipoxvirus Swinepox 
Yatapoxvirus tanapox, yaba monkey tumor 
Entomopoxvirinae Alphaentomopoxvirus Melontha melontha 
Betaentomopoxvirus Amsacta morrei, Melanoplus sanguinipes 
Gammaentomopoxvirus Chrionimus luridus 
 
 
 
 
 
Table 1.2.  The poxvirus family.   
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Figure 1.1.  Poxvirus structure.  Poxvirus intracellular mature viruses (IMVs) are brick-shaped 
with a lipoprotein core wall (membrane) surrounding a complex core that contains the linear 
double-stranded DNA genome and several virus-encoded proteins.  The core is surrounded by 
lateral bodies and an outer membrane that contains surface proteins.  Cell-associated enveloped 
viruses (CEVs) and extracellular enveloped viruses (EEVs) are similar to IMVs but have an 
additional lipoprotein envelope important for early virus dissemination.  *Figure source: 
ViralZone www.expasy.ch/viralzone, Swiss Institute of Bioinformatics 
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Figure 1.2.  Vaccinia vaccination complications.  One of the most common complications 
is autoinoculation (A) the most severe of which can be the eye.  Eczema vaccinatum (D) 
is the next most common complication, while vaccinia necrosum (C) and generalized 
vaccinia (B) are uncommon.  *Pictures are from the CDC and Dr. Weyland (A) and from 
Dr. Moses Grossman of the California Emergency Preparedness Office – Immunization 
Branch (B-D), www.gorydetails.net/demo_sites/SmallpoxSite/smpx_vaccine09.html 
A C 
D B 
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Figure 1.3.  IL-15 functions. IL-15 is a pleiotropic cytokine that functions in NK cell 
development, lymphocyte homeostasis, and peripheral immune functions. Multiple cell types 
elaborate IL-15, including activated (eg, virus- or bacteria-infected) monocytes/ 
macrophages, dendritic cells, and epithelium, as well as constitutive production by 
BM stromal cells. IL-15 has a critical role in the development of the NK lineage, as 
well as in its survival, expansion, and function. Other innate lymphocytes (NK-T, 
CD8aa i-IEL, TCRgd DETCs) and memory-phenotype CD81 T cells depend upon 
IL-15 for survival or expansion. IL-15 also plays multiple roles in peripheral innate and 
adaptive immune cell function. *Used with permission of American Society of Hematology, 
from Interleukin-15:  Biology and relevance to human disease, Fehniger and Caliguiri, 97, 1, 
2001. 
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Figure 1.4.  NK cell and macrophage interaction. IL-15 participates in innate immune cross-talk 
between activated monocytes/macrophages and NK cells. After an infectious insult (1), 
macrophages produce cytokines (2), including IL-15, that bind to constitutively expressed 
cytokine receptors on NK cells. Stimulated NK cells in turn produce cytokines that activate the 
macrophage (3), including IFN-γ, allowing the macrophage to clear the offending pathogen and 
stimulating further cytokine production.  *Used with permission of American Society of 
Hematology, from Interleukin-15:  Biology and relevance to human disease, Fehniger and 
Caliguiri, 97, 1, 2001. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
Cell lines 
 A murine melanoma cell line, B16-F10, a murine glioma cell line, GL261, and a murine 
lymphoma cell line, EL4, were obtained from Dr. Ed Roy (University of Illinois, Champaign-
Urbana).  We also used B16-F10, GL261, and EL4 cells that express the SIY peptide (H-2Kb-
restricted SIYRYYGL peptide, an exogenous 8 amino acid peptide target for 2C TCR T cells) 
and a green fluorescent (GFP) marker by retroviral transduction with the pLEGFPSIY vector as 
previously described (Blank et al. 2004; Spiotto et al. 2002), that are designated B16.SIY, 
GLSIY, and DP1, respectively.  B16.SIY was a gift from Dr. Thomas Gajewski (University of 
Chicago, IL), while GLSIY and DP1 were obtained from Dr. Ed Roy.  An immortalized rabbit 
kidney epithelial cell line, RK13, (obtained from Dr. Richard Moyer, University of Florida, 
Gainesville, FL) was used as a positive control cell line for viral infection and titers.  Cell lines 
were maintained using standard cell culture techniques in Eagle’s minimum essential medium 
(MEM; Mediatech, Inc, Manassas, VA) supplemented with 1mM sodium pyruvate, 1× non-
essential amino acids, 292 µg/mL L-glutamine, 100 units/mL penicillin,100 µg/mL streptomycin 
(supplemented MEM) and 10% fetal bovine serum (FBS; Hyclone Laboratories, Inc), except for 
DP1, which was maintained in Roswell Park Memorial Institute (RPMI) media.  All cell lines 
were incubated at 5% CO2 and 37ºC. 
Viruses 
 The Lausanne strain of MYXV and recombinant MYXV expressing red tomato 
fluorescent protein (MYXV:Tomato) with or without expression of IL-15 (MYXV:IL15) were 
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used to infect the tumor cells.  In addition, recombinant MYXV expressing red (MYXV:RFP) or 
green (MYXV:GFP) fluorescent protein were also used in some of the in vitro experiments.   
The recombinant viruses were created in Dr. McFadden’s lab by intergenic insertion of a 
fluorescent protein cassette driven by a synthetic vaccinia virus early/late promoter between 
M135R and M136R of the MYXV genome as previously described (Johnston et al. 2003).  
MYXV:Tomato was originally designated vMyx-tdTr (Liu et al. 2009).  MYXV:Tomato is the 
MYXV that was used in most of our in vitro experiments and all of the in vivo experiments, and 
is often simply referred to as MYXV in this paper.  MYXV:IL15 virus (originally designated 
vMyx-IL-15-tdTr) was created by adding an IL-15-expressing cassette containing murine IL-15 
driven by a poxvirus p11 late promoter at an intergenic site between M135R and M136R to wild-
type myxoma virus, and then adding the tomato red fluorescent cassette downstream as described 
(Liu et al. 2009).  Production of IL-15 from RK13 cells infected with MYXV:IL15 was 
confirmed by Liu et al. 2009, while no detectable levels of IL-15 were observed in the 
supernatants of cells infected with MYXV:Tomato.  Biological activity of the virus-expressed 
IL-15 was shown by survival and decreased lesions in all rabbits treated with MYXV:IL15, 
while all rabbits treated with MYXV:Tomato died (Liu et al 2009).  UV-inactivated virus (UV-
MYXV) was prepared by exposing MYXV:Tomato to a G30T8 germicidal UV light that 
produced irradiation at 254 nm for 24 h.  Viral inactivity was confirmed by the lack of cytopathic 
effect, viral plaques, and fluorescence when cultured on RK13 cells.  Viruses injected into mice 
underwent sucrose-pad purification.  Briefly, sucrose-pad purified viruses were grown in RK13 
monolayers in 150 cm2 dishes until the majority of the cells appeared infected and then cells 
were scraped into the medium with a sterile rubber policeman.  Next, cell-associated virus was 
isolated by repeatedly lysing pelleted cells in TM buffer (100 mM Tris-HCl pH 8.1 and 100 mM 
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MgCl2) and physically disrupting cells using a sterile dounce.  Cellular debris were pelleted at 
400 ×g for 15 min and supernatants were collected.  Pooled supernatants were centrifuged at 
1000 ×g for 10 min to remove nuclear debris, overlaid onto a 36% sucrose pad, and then ultra-
centrifuged at 18,000 rpm for 80 min in order to pellet the purified virus.  Virus was resuspended 
in a small amount of PBS (less than 1 mL per dish of cells collected) and the virus was retitered 
on RK13 cells.   
 Titering consisted of placing 10-fold serial dilutions of virus in supplemented MEM 
without serum on confluent RK13 cells in 6-well plates.  The inoculated cells were incubated for 
1 hour at 37ºC and 5% CO2, the inoculum was removed, and the RK13 cells were overlaid with 
1:1 agarose (Amresco, Ohio):2× MEM (supplemented) with 20% FBS.  Plaques were visualized 
as small white foci (red foci under fluorescent light) and counted at day 7 post-infection (PI). 
Viral infections and mock infections 
 Cells were seeded into 6-well plates and allowed to grow in supplemented media until 
they reached approximately 90-95% confluency.  Viral infections were performed with the 
appropriate multiplicity of infection (MOI, the ratio of infectious virus particles per cell target) 
of MYXV or recombinant MYXV, which was diluted in supplemented media without serum for 
a total volume of 400 μl per well.  Mock infections consisted of adding 400 μl of supplemented 
media without serum per well, without the addition of any virus.  The cells covered with 
inoculum (virus diluted in media or media only) were incubated at 37ºC and 5% CO2 for 1 hour, 
rocking every 15 min.  After 1 hour, the inoculum was removed and the cells were overlaid with 
1.5 ml of supplemented media with 10% FBS per well.   
Viral growth curves 
 Cells were infected as previously described with a MOI of 5 pfu/cell for the single step 
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growth curves (SSGC) and at a MOI of 0.1 pfu/cell for the multistep growth curves (MSGC).  
Cells were scraped into the media and collected 0,4,8,12,24,48 HPI for the SSGC and at 
0,12,24,48,72,96 HPI for the MSGC.  The cells were pelleted at 500 ×g for 5 min, supernatant 
was removed, and the cells were resuspended in 0.5 ml of phosphate-buffered saline (PBS) and 
stored at -80ºC.  Collected cells were disrupted by 3 freeze/thaw cycles and sonication in order to 
release virus from the cells.  The collected cellular contents underwent titering in duplicate (as 
previously described).  Virus infections of each cell line were performed in triplicate in order to 
calculate an average pfu/mL. 
Cytopathic effect    
 Photomicrographs were taken of the MYXV:Tomato-infected and mock-infected cell 
lines at 0, 4, 8, 12, 24, 48, 72, and 96 HPI using phase microscopy to evaluate cytopathic effects 
(CPE) caused by MYXV.  Images were acquired using a Leica DMI 4000 B microscope with 
ImagePro Express software (Media Cybernectics, Bethesda, MD).  Cells infected with 
MYXV:Tomato were imaged using a 560/40 nm bandpass excitation filter and an exposure time 
of 200 ms, in order to visualize expression of fluorescence by the virus.     
Western immunoblots  
 The levels of Akt and phosphorylated Akt in each cell line were determined by 
performing Western immunoblots.  Cells were inoculated with MYXV:Tomato (MOI=5) and 
collected at 0 and 4 HPI for detection of Akt and phosphorylated Akt.  Cells were scraped into 
media and centrifuged at 500 ×g for 5 min.  The supernatant was discarded, the cell pellet 
washed in PBS, and the pelleting repeated.  The cell pellet was resuspended in 50 µl of cell lysis 
buffer with 2× Halt protease and phosphatase inhibitor (ThermoScientific, Inc).  The solution 
was placed on ice for 20 min, and then nuclei and other insoluble material were pelleted at 5000 
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×g for 15 min.  The cell extract was saved and frozen at -80ºC.  The total protein concentration 
was measured by Bradford analysis.  Then 50 µg of cell extract was used for the immunoblot, 
which was run on PAGEgel dual run and blot vertical mini-gel system (PAGEgel, Inc) using 
10% sodium dodecyl sulfate polyacrylamide gel electrophoresis.  Proteins were transferred to a 
nitrocellulose membrane.  Then, the nitrocellulose membrane was blocked in a solution of milk 
blocking solution for 1 hour at room temperature (RT).  Akt rabbit polyclonal primary antibody 
and Phospho-Akt (Ser 473) rabbit polyclonal antibody were obtained from Cell Signaling 
Technology, Inc (Danvers, MA).  The primary antibody was diluted 1:100 in antibody dilution 
solution according to manufacturer’s (Cell Signaling Technology, Inc) instructions and was 
placed on the membrane overnight at 4 ºC.  Secondary antibody conjugated to horseradish 
peroxidase (Goat anti-rabbit IgG Poly-HRP) was obtained from Chemicon (Temecula, CA).  
After washing the nitrocellulose membrane 3 times in TBS/T (1× Tris Buffered Saline with 0.1% 
Tween-20), the secondary antibody was diluted 1:200 in milk blocking solution for 1 hour at RT.  
After incubation, the membrane was washed 3 times in TBS/T. Immunoreactive bands were 
detected by using Amersham ECL Streptavidin HRP conjugate solution (GE Healthcare) 
according to manufacturer’s instructions and exposed to radiographic film, which was processed.     
Enzyme-linked immunosorbent assays 
 The concentrations of type 1 IFN (IFNα and IFNβ), tumor necrosis factor (TNFα), and 
IL-15 in cell cultures and tissue lysates were determined using commercially available enzyme-
linked immunosorbent assays (ELISAs).  Samples were prepared by infecting cells with live or 
UV-inactivated virus (MOI=5 for IFNα, IFNβ, TNFα, and MOI=1 for IL-15), or mock-infecting 
them, as previously described.  Infected cell culture supernatants were collected at 24 and 48 
HPI, as well as at 72, 96, and 168 HPI for IL-15.  In addition, tumors from mice treated with 
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MYXV:IL15 were collected and homogenized for detection of IL-15 within the treated tumors.  
All samples were concentrated using Amicon Ultra-4 centrifugal filter devices (Millipore), from 
initial sample volumes of 1.5-4 ml, to a final volume of approximately 450 µl, by centrifuging at 
3220 ×g at RT for 5-10 min as needed.  IFNα and IFNβ ELISAs (PBL Biomedical Laboratories 
mouse interferon ELISA kits), TNFα ELISA (eBioscience mouse TNF alpha ELISA Ready-
SET-Go), and the IL-15 ELISA (eBioscience mouse interleukin-15 ELISA Ready-SET-Go) were 
performed according to the manufactures instructions.  Each kit included a purified protein 
standard which was used to establish a standard curve.  Positive controls for each ELISA were 
obtained by adding known quantities of standard from the ELISA kits to additional cell lysates 
from the cell lines, while negative controls were obtained from wells that contained media but 
did not contain any cells.  Negative controls were subtracted from the test samples in order to 
compensate for background.  A Molecular Devices (Sunnyvale, CA) SPECTRAmax Plus384 
Microplate Spectrophotometer was used to detect absorbance at 450 nm. 
Electron microscopy 
 All cell lines were infected at a MOI of 10 pfu/cell as previously described.  Cells were 
collected at 24 HPI by scraping into the media, centrifuged at 500 ×g for 5 min, and the pellet 
was placed in Karnovsky’s fixative and shipped on ice to the University of Florida 
Interdisciplinary Center for Biotechnology Research for processing and imaging using a Hitachi 
H-7000 with Olympus Soft-Imaging Systems Megaview III digital camera for transmission 
electron microscopy.   
Trypan blue assay 
 Cells were infected with MYXV:RFP (MOI=10) or mock-infected as previously 
described and collected at 0, 24, and 48 HPI.  Cells were stained by combining cells suspended 
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in media with 0.4% trypan blue solution at a 1:10 ratio.  Trypan blue dye is permeable to dead 
cells but not to intact cells.  Clear cells and blue cells were counted on a hemocytometer to 
quantify the percentage of dead (blue) cells.  Data was analyzed with a t-test for independent 
samples using Statistica software (StatSoft; Tulsa, OK).  Any nonparametric data was compared 
using a Mann-Whitney U test.  Significance was given to P-values ≤ 0.05.    
Cell viability assay 
 A Promega CellTiter-Blue Cell Viability Assay (Promega, Madison, WI) was performed 
for each cell line.  Viable cells convert resazurin, a redox dye, into a fluorescent product 
resorufin, that is detectable a 590 nm.  5 × 104 cells were added to each well of a 96-well plate, 
centrifuged at 200 ×g for 5 min, and incubated for 4 h in media with 10% FBS to allow the cells 
to adhere to the plate.  Media was then removed and cells were mock-infected or infected with 
MYXV (MOI=10) in 50 µl of media without serum as previously described.  Infections were 
done in triplicate.  Wild-type MYXV was used so as to avoid interference of viral fluorescence 
(if MYXV:Tomato, MYXV:RFP, or MYXV:GFP were used)  with the fluorescence produced by 
resorufin.  Virus inocula were removed, 100 µl of media with 10% FBS was added, and cells 
were incubated for 24-48 h.  Twenty microliters of cell titer blue reagent was added 3 h before 
analysis.  Analysis was performed using Molecular Devices (Sunnyvale, CA) SpectraMAX 
GEMINI EM Microplate Spectrofluorometer with excitation at 544 nm and emission at 590 nm.  
Data was analyzed with a t-test for independent samples using Graph Pad Prism 5 (GraphPad 
software: La Jolla, CA).  Significance was given to P-values ≤ 0.05.         
Annexin V assay 
 Flow cytometry assays were performed to detect cells undergoing the early events 
associated with apoptosis.  Confluent cells were mock-infected or infected with MYXV 
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(MOI=5) as previously described and collected at 48 HPI.   Cell concentration was determined 
with a hemocytometer and aliquots of 105 cells were incubated with FITC-conjugated annexin V 
(BD Pharminogen FITC Annexin V Apoptosis Detection Kit 1) and 7-aminoactinomycin D (7-
AAD) (BD Pharminogen) according to the instructions provided by BD Biosciences.  A positive 
control was obtained by exposing some cells to staurosporine, an agent that induces apoptosis.  
The BD Biociences LSR II flow cytometer located in the Roy J. Carver Biotechnology Center at 
the University of Illinois was utilized to collect the data.  Data were analyzed using De Novo 
FCS Express version 3 software (De Novo Software, Los Angeles, CA).  Compensation control 
samples were evaluated for each cell line.  Data was statistically analyzed with a t-test for 
independent samples using Graph Pad Prism 5 (GraphPad software: La Jolla, CA).  Any 
nonparametric data was compared using a Mann-Whitney U test.  Significance was given to P-
values ≤ 0.05.         
Mice 
 C57BL/6 mice, an inbred strain obtained from Jackson Laboratory (Bar Harbor, ME), 
were used as they are the most frequently used mouse models in immunological studies, and are 
regarded as a TH1-dominant mouse strain (Rivera and Tessarollo 2008; Watanabe et al. 2004).  
Mice were 6 weeks old when obtained and were allowed to acclimate for 7 days before tumor 
inoculation.  All mice were female in order to monitor for viral infection of the ovaries.  Mice 
were housed at the University of Illinois at Champaign-Urbana and all procedures were approved 
by the Institutional Animal Care and Use Committee.  Mice were housed up to 5 mice per cage 
in microisolator cages in a model MD75JU140MVSP 140-position Double-Sided Individually 
Ventilated Cage Rack (70-bins per side), with a top exhaust pak model EP5000E (Allentown Inc:  
Allentown, NJ), and set at 60 air changes per hour.  The mice were kept in 11” x 6” x 5” clear 
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plastic bins with stainless steel wire caging (Allentown Inc:  Allentown, NJ) that contained corn 
cob bedding.  Mice were allowed free access to Harlan 8604 food pellets (24% protein, 4% fat) 
and tap water accessed by water bottles.  All procedures involving the mice took place in a 
NuAire biosafety level 2 hood:  NU-602-400 series 20 BSC class II type A/B3 (NuAire 
Laboratory equipment supply; Plymouth MN).  Mice were kept in a room set at 72 °F  with 
humidity that varied from 30-70%, 10-15 air changes per hour, with a 12:12 light:dark cycle, and 
with negative pressure to the hallway (biosafety level-2 ).   
Brain tumor model injection protocol 
 Mice were stereotactically injected on one or both sides of the brain in the ventral 
striatum of the cerebrum (AP 0.5 mm, Lat 2.5 mm, DV 4mm) with 5 × 104 tumor cells in 0.3 μl 
PBS (as described in Thomas et al 2011).  5 × 104  to 1.5 × 106 pfu’s of virus in 0.3-0.6 μl PBS 
was stereotactically injected into the tumor between days 3 and 14 post tumor inoculation (PTI) 
depending on the rate of tumor cell growth (Table 2.1), in order to give the tumor cells time to 
establish.  Mice were monitored and weighed daily until a criterion of euthanasia was met. 
Euthanasia criteria consisted of:  lethargy, significant neurological disease signs (e.g.circling, 
head tilt), or loss of 25% of baseline body weight.  Mice were euthanized and tissues were 
collected for histopathology and IHC as described previously. Survival data was measured from 
the time of the initial viral injection and plotted using a Kaplan-Meier curve.  Survival treatment 
groups were compared with a Log-rank (Mantel-Cox) test.  Significance was given to P-values ≤ 
0.05.    
Subcutaneous tumor model injection protocol  
 Mice were anesthetized with isoflurane gas prior to injection of cells.  B16-F10 cells (5 x 
104 in 100 μl PBS) were injected subcutaneously into the left flank of C57BL/6 mice and tumors 
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were allowed to establish.  Once tumors reached a minimum of 5 mm in diameter, the tumors 
were directly injected with 1 × 106 pfu MYXV-IL15:Tomato or MYXV:Tomato in 100 μl PBS.  
Controls were established by injecting tumors with 100 μl PBS or UV-inactivated 
MYXV:Tomato.  In order to overcome clearance of the virus by the immune system, injections 
were repeated on a weekly basis for survival mice and the inoculum was injected into several 
sites in the larger tumors in order to spread the virus.  Six mice from each treatment group were 
collected at 24 h, 48 h, 96 h, and 1 week after virus treatment, and 12 mice from each treatment 
group were allowed to reach a criterion of euthanasia.  Mice were observed and weighed every 
three days until tumors established, and then weighed daily.  Tumors were measured with a 
micrometer until a criterion of euthanasia was met.  The criteria (designated in the University of 
Illinois Institutional Animal Care and Use Committee, approved protocol # 10074) consisted of:  
tumors ≥ 3 cm in diameter, lethargy, significant dermal ulceration over the tumor site, or 25% 
baseline body weight loss.  Survival data was measured from the time of the initial viral injection 
and plotted using a Kaplan-Meier curve.  Survival treatment groups were compared with a Log-
rank (Mantel-Cox) test or a Gehan-Breslow-Wilcoxon (GBW) test using Graph Pad Prism 5 
(GraphPad Software; La Jolla, CA).  Significance was given to P-values ≤ 0.05.      
Tissue collection 
 Mice were anesthetized with isoflurane gas prior to euthanasia with an intraperitoneal 
injection of 0.5 ml pentobarbital.  All major internal organs were grossly examined on all mice in 
order to check for metastases, evidence of viral infection, or other pathology.  All major organs 
and the tumors were collected and placed in 10% buffered formalin for examination by light 
microscopy (histopathology).  A section of tumor from most mice and a section of the major 
internal organs (brain, eye, salivary gland, lung, thymus, heart, liver, kidney, spleen, 
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gastrointestinal tract, genital tract, bladder) from at least one mouse per treatment group were 
also frozen and stored in a liquid nitrogen tank (approximately -170ºC) for viral titers.  A section 
of the tumor from most mice was also placed in OTC (optimal cutting temperature, Ted Pella, 
Inc) compound, flash frozen, and then stored a liquid nitrogen tank (approximately -170ºC) for 
immunohistochemistry (IHC).   
Histopathology 
 Tumors and major organs (brain, eye, heart, lung, liver, kidney, spleen, uterus, and ovary) 
were trimmed into cassettes, processed, paraffinized, and evaluated by light microscopy.  
Tumors were rated on percent necrosis, neutrophil infiltration, and lymphocyte infiltration (Table 
2.2).  Representative photomicrographs of each grade were taken (Figure 2.1).  For the 
inflammatory cell infiltrates, all fields were looked at and the 400× field with the highest number 
of inflammatory cells was used for grading.  Since the presence of virus within the tumor was 
likely highly localized due to the focal nature of the injection, evaluation of the most severely 
affected area is a more appropriate method to gauge the immune response to the virus, as 
averaging multiple fields (where virus may not be present) would underestimate the immune 
response.  The site of cellular infiltration (surrounding the mass, within the mass, within areas of 
necrosis, perivascular) was also noted.  Organs were examined for evidence of metastases or 
inflammation.   
Immunohistochemistry 
 Tissues flash-frozen in OTC compound were trimmed to 6 μm sections on a cryostat, 
placed on a slide, rinsed with PBS, and blocked with 10 % goat serum for 1 hour at room 
temperature.  Serial sections were analyzed for infiltrating leukocytes.  Tissues were incubated 
with either rabbit anti-mouse granzyme B polyclonal antibody (Abcam Inc) to detect NK and 
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CTL cells, rat anti-mouse MHC Class II 1A + 1E monoclonal antibody (Abcam Inc) to detect 
APCs including macrophages, rat anti-mouse CD3 monoclonal antibody (Abcam Inc) to detect T 
cells, rat anti-mouse CD4 monoclonal antibody (BD Biosciences) to detect helper T cells, rat 
anti-mouse CD8a monoclonal antibody (BD Biosciences) to detect cytotoxic lymphocytes, or rat 
anti-mouse Ly-6G (Gr-1) monoclonal antibodies (eBioscience) to detect neutrophils.  The 
antibodies were diluted in PBS and placed on the tissues for 1 h at RT.  All tissues were washed 
with PBS and amplified with a secondary antibody that had a fluorescent (fluorescein 
isothiocyanate, FITC) marker:  goat polyclonal antibody to rat IgG-H&L FITC (Abcam Inc); 
except for the rabbit anti-mouse granzyme B polyclonal antibody treated tissues, which were 
amplified with a goat anti-rabbit FITC (Jackson Lab) secondary antibody.  Slides were rinsed 
with PBS, covered with Vectashield mounting medium with fluorescence with DAPI (Vector 
Labortatory, Inc), and coverslipped.  IHC was performed on at least 3 tumors per treatment 
group.  The entire tumor was reviewed and the 400× field with the highest number of positive 
cells was used for evaluation of the immune response.  The number of positive cells per 400× 
field was recorded, and representative photomicrographs were taken.   
MYXV red fluorescence 
 Evidence of MYXV expressing red fluorescence protein was examined in all tumors on 
frozen (IHC) sections that had not been covered with Vectashield mounting medium.  The 
presence of red fluorescence was recorded as a 0 or 1, indicating absence or presence of the 
virus, respectively.  Localization with any foci of inflammation observed on similar IHC tissues 
was noted and photomicrographs were taken.  Treatment groups were analyzed by a Fisher’s 
exact test.  Significance was given to P-values ≤ 0.05.    
Antibody production 
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 Plaque reduction neutralization tests (PRNTs) were performed to quantify anti-MYXV 
antibody production in mice after treatment with UV-MYXV, MYXV:Tomato, and 
MYXV:IL15.  PRNT50 values represent the reciprocal of the serum dilution that reduced the 
viral titer by 50%.  The 50% endpoint titer was defined as ½ of the average titer recovered from 
virus inoculum incubated with serum from PBS-treated mice.   
 To collect serum, blood was removed from mice by cardiac puncture at the time of 
euthanasia, placed into red-topped tubes, and centrifuged.  Murine serum was added to an equal 
volume of diluted MYXV:GFP (1:1) in order to make a 1:2 dilution of the serum and inoculate 
RK13 cells with a known number of viral particles (100 pfu/well).  In addition, serum from 
virally treated survival mice was also serially diluted (1:4, 1:8, 1:16, 1:32) with supplemented 
MEM without serum.  Serum did not have complement proteins heat-inactivated prior to use 
because it has been found that complement is essential for in vitro neutralization of (and in vivo 
protection against) the extracellular enveloped virion produced by poxviruses (Benhnia et al. 
2009). 
 PRNTs were performed by incubating RK13 cells in 24-well plates (TPP Techno Plastic 
Products AG, Trasadingen, Switzerland) with serum and virus for 1 h.  Cells were then overlaid 
with 50:50 2× supplemented MEM with 20% FBS:1% agarose and evaluated by fluorescent 
microscopy for viral plaques at 7 days PI.  Virus titers (pfu/mL of diluted sample) were plotted 
versus the reciprocal of the sample dilution of serum from UV-MYXV, MYXV:Tomato, and 
MYXV:IL15-treated mice.  Using Microsoft Excel 2010, the sample dilution of the 50% 
endpoint was determined by linear interpolation of the dilutions above and below the 50% 
endpoint titer.  Samples were compared for statistical significance using unpaired t-tests with 
GraphPad Prism software. 
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Viral detection in vivo 
 Tumors and organs were individually weighed and homogenized in 400 µl of 
supplemented MEM without serum.  All tumors from MYXV:IL15, MYXV:Tomato, UV-
MYXV, and PBS treated mice were homogenized and those of mice treated with live virus were 
serially diluted.  The tissue homogenates were placed on 6-well plates of RK13 cells for 1 h at 
37ºC, at which time they were washed with PBS and the cells overlaid with 50:50 2× 
supplemented MEM complete with 20% FBS:1% agarose.  Six-well culture plates were 
examined by fluorescent microscopy for red fluorescent foci at 1 week and the number of foci 
was recorded in order to determine the amount of virus per gram of tissue.   
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Chapter 2 Tables and Figures 
 
 
Tumor cells Cell # and volume Virus PFU’s and volume Days PTI 
B16.SIY 5 × 104 in 0.3μ l MYXV:RFP 5 × 104 in 0.3μ l 5 
B16.SIY 5 × 104 in 0.3μ l MYXV:Tomato 5 × 104 in 0.3μ l 3 
B16.SIY 5 × 104 in 0.3μ l MYXV:Tomato 5 × 104 in 0.3μ l 3 
DP1 5 × 104 in 0.3μ l MYXV:Tomato 7.5 × 105 in 0.6μ l 5 
GL261 5 × 104 in 0.3μ l MYXV:Tomato 1.5 × 106 in 0.5μ l 11 
GL261 5 × 104 in 0.3μ l MYXV:Tomato 1.5 × 106 in 0.5μ l 11 
GL261 5 × 104 in 0.3μ l MYXV:Tomato 1.5 × 106 in 0.5μ l 14 
 
 
 
 
 
 
 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Percent Necrosis 0% 1-15% 16-49% 50-74% 75-100% 
Neutrophil Infiltration 0-10 11-25 26-49 >50 TNTC 
Lymphocyte Infiltration 0-5 6-15 16-30 >30 TNTC 
 
 
 
 
 
 
 
 
 
Table 2.2.  Histopathology grading of tumors.  
 
Table 2.1.  Intracranial murine tumor experiments.  
 
PFU = plaque-forming units.  PTI = post-tumor inoculation. 
TNTC = too numerous to count, and had >150 cells per 400× field. 
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Grade 1 
Grade 2 
Grade 3 
Grade 4 
Necrosis Neutrophils Lymphocytes 
Figure 2.1.  Histopathology grading of tumors.  Images are representative examples 
of Grade 1-4 for degree of tumor necrosis, neutrophil infiltration, and lymphocyte 
infiltration.  Necrosis images at are 4× magnification, while neutrophil and 
lymphocyte images are at 400× magnification. 
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CHAPTER 3 
IN VITRO MYXOMA VIRUS INFECTION OF MURINE TUMOR CELL LINES 
 
 In order to determine if our murine cancer cell lines were susceptible to infection with 
MYXV, we tested several cell lines for evidence of viral replication and cell death.  We also 
evaluated cellular production of phosphorylated Akt and IFNs, two mechanisms known to affect 
MYXV replication.  We hypothesized that MYXV would infect, replicate within, and cause cell 
death in murine tumor cells lines that contained activated Akt and failed to produce antiviral 
Type 1 IFNs.  .  
Cytopathic effects were observed in all murine tumor cell lines in vitro 
 In order to characterize the ability of MYXV to infect B16-F10, B16.SIY, GL261, 
GLSIY, EL4, and DP1 cell lines in vitro, the cells were inoculated with a high (MOI=5) or low 
(MOI=0.1) multiplicity of infection.  Then the cells were observed at various time points post-
inoculation and compared to mock-infected cells.  RK13 cells were also inoculated as a positive 
control for viral growth.  Inoculation resulted in significant cytopathic effects (CPE) in the rabbit 
control cell line (RK13) the melanoma cell lines (B16-F10, B16.SIY) and the glioma cell lines 
(GL261, GLSIY), and mild CPE in the lymphoma lines (EL4, DP1) as demonstrated in Figure 
3.1.  CPE caused by MYXV:Tomato inoculation included rounding up and hyalinization of the 
cells, with eventual detachment from the culture plate of the adherent cell lines, while the 
nonadherent lymphoma cell lines (EL4, DP1) showed hyalinization and granulation.  Red 
fluorescence was observed in the virus-inoculated cell lines using fluorescence microscopy 
(Figure 3.1).  Since the tomato red protein is expressed by an early-late poxviral promoter, red 
fluorescence by the cells confirms early translation of the MYXV genome.  CPE were first 
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evident in B16-F10, B16.SIY, GL261, and GLSIY cells between 8 and 12 HPI at high MOI (5).  
CPE were first evident in B16-F10 and B16.SIY cells between 12 and 48 HPI, while they were 
not evident in GL261 and GLSIY cells until 24 to 48 HPI at low MOI (0.1).  CPE were 
significantly more severe after inoculation with MYXV:Tomato at MOI=5 as compared to 
MOI=0.1 and were more evident in melanoma (B16-F10, B16.SIY) cells than in glioma (GL261, 
GLSIY) cells.  CPE was mild in the lymphoma cell lines and red fluorescence of the cells was 
not evident.  In summary, while CPE was evident in all of our cell lines treated with MYXV, the 
degree of CPE present varied according to cell type and virus concentration used, with more 
severe CPE in the melanoma cell line and in cell lines treated with a higher MOI         
The B16-F10 melanoma and GL261 glioma cell lines contain phosphorylated Akt 
 Previous studies have demonstrated that MYXV infects human and murine cells with 
phosphorylated Akt (Werden and McFadden 2008; Stanford et al. 2008).  Western immunoblot 
analysis confirmed that the B16-F10 and GL261 murine cell lines and those transformed with the 
SIYGFP peptide have phosphorylated Akt at the time of inoculation of the virus, as well as 
during the early stages of infection (Figure 3.2).  As expected, given the lack of severe CPE in 
the lymphoma cell lines, EL4 and DP1 were not found to have any significant amount of 
phosphorylated Akt before or after infection (data not shown).   
The B16-F10 melanoma and GL261 glioma cell lines do not produce IFNα and TNFα in 
response to infection with MYXV, but GL261 produced IFNβ after infection with MYXV 
or UV-MYXV 
 Previous studies have demonstrated that MYXV is able to infect murine cell lines that do 
not produce Type I IFNs in response to infection (Wang et al. 2004).  We assessed the murine 
melanoma and glioma cell lines for production of Type I IFNs and TNFα.  None of the cell lines 
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produced significant concentrations of IFNα (data not shown) or TNFα (Figure 3.3A), whether 
mock-infected or infected with live or UV-inactivated MYXV, at early (4 h) or late (24 h) time 
points after inoculation.  Most cell lines also failed to produce IFNβ in response to infection; 
however, the GL261 parental cell line produced IFNβ in response to infection with UV-
inactivated and live virus at 24 HPI, and was highest in the cells infected with UV-inactivated 
MYX (Figure 3.3B).  Positive controls for each ELISA were obtained by adding known 
quantities of standard to additional cell lysates from the cell lines, while negative controls 
consisted of wells that contained media but did not contain any cells.    
Myxoma virus productively infects RK13, B16-F10, and GL261 cell lines 
 We next performed SSGC and MSGC of all cell lines to demonstrate the ability of 
MYXV:Tomato to replicate in the tumor cell lines (SSGC) as well as its ability to spread to 
adjacent cells (MSGC).  Viral titers were high in the B16-F10 and B16.SIY melanoma cell lines, 
similar to the positive control (RK13) cells in both SSGC and MSGC (Figure 3.4).  Viral titers 
were also robust but slightly lower in the GL261 and GLSIY glioma cell lines tested (Figure 
3.4).  Viral titers mildly increased in the EL4 and DP1 lymphoma cell lines in the SSGC but the 
titer did not logarithmically increase in the EL4 cell line in the MSGC, and the DP1 titer was 
very low and was undetectable by the 96 h time point in the MSGC (Figure 3.4B).  Logarithmic 
increases in viral titers suggest virus replication and production of infectious viral progeny 
occurs in the melanoma and glioma cells.  Growth curves were repeated using MYXV:IL15 and 
showed similar logarithmic viral growth (Figure 3.5). 
Melanoma and glioma cell lines supported all stages of viral morphogenesis  
 To confirm that orderly and complete maturation of MYXV occurs within murine tumor 
cells, electron microscope (EM) analysis of all cell lines was performed and images were 
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compared to previous studies of poxvirus morphology (Resch, Weisberg, and Moss 2009; Bisht 
et al. 2009; Roberts and Smith 2008; Chichon et al. 2009; Duteyrat, Gelfi, and Bertagnoli 2006).  
No previous studies have examined MYXV morphology in tumor cells to our knowledge.  Since 
a complete cycle of MYXV replication has been estimated to occur within 16 HPI (Duteyrat, 
Gelfi, and Bertagnoli 2006), permissive cell lines should contain all stages of viral morphology 
by 24 HPI.  All stages (crescent, immature virions, immature virions with a nucleoid, 
intracellular mature virions, wrapped virions, cell-associated virions, and enveloped virions) of 
MYXV virus maturation were observed in B16-F10, B16.SIY, GL261, and GLSIY as well as in 
the positive control RK13 cells at 24 HPI (Figure 3.6).  Subjectively, virions were more abundant 
within the B16-F10 and B16.SIY melanoma cell lines than in the GL261 and GLSIY glioma cell 
lines.  No immature or mature virions were observed within the EL4 or DP1 lymphoma cell lines 
at 24 HPI, and most of these cells were lysed (data not shown).  This data confirms the virus 
growth curve data findings.   
Myxoma virus infection causes significant cell death of murine neoplastic cells 
 One of the main goals of viral therapy of cancer is to induce significant cell death of 
tumor cells (oncolysis).  We evaluated the ability of MYXV to cause cell death of murine tumor 
cell lines in vitro.  Cell death was analyzed utilizing trypan blue exclusion of cells infected with 
MYXV:RFP (MOI=10) versus mock-infected cells.  Significant cell death was observed in all 
cell lines infected with MYXV:RFP, and was calculated as a percentage of dead cells (trypan 
blue positive cells) compared to mock-infected controls (Figure 3.7A-C).  When infected cells 
were compared to mock-infected cells, significant cell death was observed by 0 HPI in the RK13 
control cell line and continued at 24 and 48 HPI (Table 3.1; Figure 3.7A-C).  Significant cell 
death was observed in the B16-F10 and B16.SIY melanoma cells at 24 and 48 HPI but not at 0 
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HPI (Table 3.1; Figure 3.7A-C).  Significant cell death was observed in the GL261 glioma cells 
at 48 HPI, but was not significant at 0 or 24 HPI (Table 3.1; Figure 3.7A-C).  Significant cell 
death was observed in the GLSIY glioma cells at 0 HPI, 24 HPI, and 48 HPI (Table 3.1, Figure 
3.7A-C), similar to the RK13 cells (Figure 3.7A-C).  Significant cell death was observed in the 
EL4 and DP1 lymphoma cells at 0 and 24 HPI, but the degree of cell death of the inoculated cells 
versus the mock-infected cells was not significant at 48 HPI (Table 3.1; Figure 3.7A-C) because 
most of the remaining cells were trypan blue positive (dead) at 48 HPI, regardless of whether 
they were infected with virus or were mock-infected.  Due to the questionable infectivity of the 
lymphoma (EL4 and DP1) cell lines as evidenced by CPE, growth curves, and ultrastructural 
examination, and evidence from trypan blue assay that the cells do not survive past 48 hours (in 
vitro) to support MYXV infection, further in vitro studies utilizing the lymphoma cell lines were 
discontinued.   
 Due to the fact that many of the cells killed by MYXV infection are lysed and would not 
be detectable by the trypan blue assay, the effect of viral infection on cell viability and 
proliferation was also examined using a CellTiter blue cell viability assay.  A statistically 
significant decrease in the number of live cells was observed in all of the cell lines (RK13 
p<0.0001, B16-F10 p<0.0001, B16.SIY p=0.0026, GL261 p=0.0099, GLSIY p<0.0001) infected 
with live MYXV, versus mock-infected cells (Figure 3.7D).  However, viable cells were still 
present at 24 and 48 HPI with MYXV despite using a high MOI of 10. 
 To evaluate whether cell death caused by MYXV infection was driven by apoptotic cell 
pathways, B16-F10 and GL261 cells were mock-infected or infected with MYXV:Tomato 
(MOI=5) and labeled with annexin V and 7-amino-actinomycin D (7-AAD) at 48 HPI, then 
detected using flow cytometry.  Annexin V is a protein that is able to detect the presence of 
 59 
apoptotic cells by binding to the negatively-charged phospholipid, phosphatidylserine, which is 
expressed on the surface of apoptotic cells but not on live cells.  7-AAD is a fluorescent protein 
that has a high affinity for DNA, but does not readily pass through intact cell membranes, and is 
therefore useful for detecting necrotic cells.  The percent of apoptotic cells was not significantly 
different between infected and mock-infected cells (Figure 3.7E), suggesting that infected cells 
were dying by necrosis.   
Discussion 
 In vitro experiments showed that both of the murine melanoma (B16-F10 and B16.SIY) 
cell lines are highly permissive to infection with MYXV, with evidence of cytopathic effect, 
production of phosphoryated Akt, lack of production of Type 1 IFNs, complete intracellular viral 
morphogenesis, significant cell death, and production of high virus titers.  The permissiveness of 
B16-F10 cells to a recombinant MYXV (vMYXlac) was previously reported by McFadden 
(Stanford et al. 2008).  That study revealed similar viral growth curves and classified B16-F10 
cells as highly permissive to infection with vMYXVlac.   
 Murine glioma (GL261 and GLSIY) cells were also shown to be permissive to infection 
with MYXV in our in vitro experiments, but not to the degree that the melanoma cells were.  
McFadden’s group also looked at the permissiveness of GL261 to infection with MYXV, but did 
not consider the cells to be permissive, with a minimal decrease in GL261 cell viability at 72 HPI 
with 1 MOI, and just over a 20% decrease in cell viability at 72 HPI when infected with 10 MOI 
of MYXV (Lun et al. 2009).  While our lab also found that the number of GL261 cells do not 
decrease much after MYXV infection (the least of all the cell lines studied in our lab), the 
difference was still found to be statistically significant.  Combined with the presence of virions in 
the cell by EM, the positive CPE observed when cells were infected, and the increase in the 
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number of trypan blue positive cells after infection, we classified the GL261 cells as semi-
permissive to MYXV infection.  While the difference between our findings and those of the 
McFadden group are possibly due to differences in the criteria used to classify the cells as 
permissive or nonpermissive, there are a number of other reasons why our findings may differ 
from theirs.  For one, the McFadden lab titers their virus on BGMK (baby green monkey kidney) 
cells, while our MYXV is titered on RK13 cells.  Since RK13 cells originate from the naturally 
affected host, they may support a different level of viral growth than the BGMK cells at different 
time points after viral inoculation.  Alternatively, it may be that the passage number of our 
GL261 cells was likely different than the passage number of McFadden’s GL261 cells. This may 
indicate that one of the cell lines changed to have different properties than the original cell line.  
For example, studies have shown that that IFN levels may increase (Johnston et al. 2005, 235-
248) or decrease (Wang et al. 2009) as cells undergo progressive passaging.  We did find that 
infection of the GL261 cell line resulted in the production of IFNβ.  While this cytokine was not 
produced when the cells were infected with live virus, all poxviruses employ at least 1 
mechanism to disrupt interferon responses (Seet et al. 2003), and MYXV is predicted to encode 
2 proteins that disrupt interferon responses (Barrett et al. 2001).  We think that UV-inactivation 
of MXV prevented expression of the proteins that would have suppressed interferon production 
in the GL261 cells, while the mere presence of the inactivated virus particle was enough to 
trigger production of IFNβ in these cells.   
 The murine lymphoma cells (EL4 and DP1) did not appear to support viral growth in our 
in vitro experiments, although the virus did cause a significant increase in cell death.  This may 
be due to the fact that in rabbits, apoptosis of lymphocytes within the lymph nodes is a major 
feature of MYXV infection (Best, Collins, and Kerr 2000).  Detectable viral antigen is not found 
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within these apoptotic lymphocytes, but the apoptotic lymphocytes are often adjacent to infected 
cells (Best, Collins, and Kerr 2000).  This is similar to our in vitro findings, in which murine 
lymphocytes had evidence of cell death but viral growth curves and EM did not indicate that the 
cells were able to support MYXV infection.  Myxoma virus encodes at least 4 
immunomodulatory proteins (M-T2, M-T4, M-T5, and M11L) that act as intracellular apoptosis 
inhibitors in rabbit lymphocytes.  Myxoma virus mutants in which one or more of these 
immunomodulatory genes have been deleted have been shown to induce rapid apoptosis in 
infected rabbit lymphocytes that aborts the viral infection, while infection occurs normally in 
rabbit fibroblasts (Barry et al. 1997; Macen et al. 1996).  It may be that these viral proteins do 
not function effectively in EL4 or DP1 murine lymphocytes, and therefore any MYXV may 
result in lymphocyte apoptosis and nonproductive infection in these cells.   
 While all of the cell lines had statistically significant cell death rates after infection with 
MYXV:RFP as compared to controls (mock-infected) by trypan blue assay, the degree of cell 
death measured was not as significant as what was visually observed by CPE.  This was believed 
to be due to the large amount of cell death by cell lysis, which would not be measurable as blue 
cells by trypan blue assay.  Therefore we compared the number of viable cells remaining after 
infection with MYXV versus controls by CellTiter blue viability assay.  Comparing the number 
of live cells per well in MYXV-infected wells versus the number in mock-infected wells would 
ideally represent the impact of viral infection on the cell population.  While we observed a 
statistically significant decrease in the number of cells in the infected wells, there were still 
neoplastic cells remaining, even after infection with 10 MOI.  One confounding factor is that 
while the virus is infecting and lysing cells, the remaining uninfected cells are able to continue to 
grow and proliferate, increasing their numbers.  Proliferation of the remaining cells may occur at 
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an even higher rate after viral infection than mock infection, as there is less cell overgrowth 
present to restrict the ability of the cells to replicate, and there would be more nutrients 
remaining in the media.  However, this likely represents what will occur in vivo, where 
uninfected cells will continue to proliferate and replace the cells killed by the virus.  The 
turnover rate of the neoplastic cells versus the replicative capacity of the oncolytic virus used is, 
therefore, an important thing to consider, as it is critical that the wave-front of viral replication be 
able to overtake that of the neoplastic cells.  In order for this to occur, the virus used for 
treatment will need to be able to replicate rapidly and produce large numbers of infectious 
virions that are released rapidly.  This need is why poxviruses are possibly superior to other 
oncolytic viruses, since they replicate quickly, produce many infectious progeny, and CEV’s can 
infect neighboring cells before the cell is lysed.  The infectious virions will then be able to infect 
adjacent cells, ideally before those cells are able to replicate.  The rate of virus spread has been 
found to be a critical factor in the success of tumor virotherapy using mathematical modeling, as 
has treating smaller tumors (small starting number of neoplastic cells) (Wein, Wu, and Kirn 
2003).   
 All of the in vitro results indicated that MYXV productively infects the murine 
melanoma (B16.F10) and the murine glioma (GL261) cell lines, with evidence of cytopathic 
effect, complete viral replication, and increased cell death, allowing us to procede with in vivo 
experiments.  
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Chapter 3 Tables and Figures 
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Figure 3.1. Cytopathic effect. Cell lines were mock-infected or infected with MYXV:Tomato.  
Rabbit control (RK13), murine melanoma (B16-F10, B16.SIY) and murine glioma (GL261, 
GLSIY) cell lines show significant CPE by 24 HPI when infected with 5 MOI of virus, and by 
48 HPI when infected with 0.1 MOI. Lymphoma cell lines (EL4, DP1) had only mild CPE.  
Phase microscopy photomicrographs were obtained using an exposure time of 5 ms.  
Fluorescent photomicrographs were obtained with a 560/40 nm bandpass excitation filter and 
an exposure time of 200 ms and depict fluorescent virus present in cells in the third column. 
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Figure 3.2.  Detection of phosphorylated Akt.  Melanoma and glioma cell lines were 
infected with MYXV:Tomato or mock–infected with supplemented MEM without serum 
and allowed to incubate for 1 hour.  The inoculum was removed and cells were either 
collected immediatedly (0 HPI), or overlaid with supplemented MEM with serum and 
collected 4 hours later (4 HPI).  Cell lysates were evaluated for the presence of activated 
Akt (Akt-phos) and total Akt by western immunoblot.   
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Figure 3.3.  Cytokine ELISAs.  Cells were infected with MYXV:Tomato (MOI=5).  
Supernatants were collected at 4 or 24 HPI, concentrated, and TNFα (A) and IFNβ (B) 
levels were detected as described in materials and methods.  Error bars represent standard 
error of the mean of results from three experiments.  The positive control in A consisted of 
standard mixed with cell lysates. 
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Figure 3.4. MYXV:Tomato viral growth kinetics.  Cell lines were infected with 
MYXV:Tomato at a MOI=5 (A) or MOI=0.1 (B).  Cells were collected at various time 
points, frozen and thawed 3 times, sonicated to release virus, and then titered on RK13 
cells.  Foci were counted after 7 days.  The rabbit control (RK13), murine melanoma 
(B16-F10, B16.SIY) and murine glioma (GL261, GLSIY) cell lines demonstrated a 
logarithmic increase in viral titer.   
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Figure 3.5. MYXV:IL15 viral growth kinetics.  Cell lines were infected with 
MYXV:IL15 at a MOI=5 (A) or MOI=0.1 (B).  Cells were collected at various 
time points, frozen and thawed 3 times, sonicated to release virus, and then 
titered on RK13 cells.  Foci were counted after 7 days.  The rabbit control 
(RK13), murine melanoma (B16-F10, B16.SIY) and murine glioma (GL261, 
GLSIY) cell lines demonstrated a logarithmic increase in viral titer 
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Figure 3.6.  Electron microscopy.  RK13 (A), B16-F10 (B top row), B16.SIY (B 
bottom row), GL261 (C top row), and GLSIY (C bottom row) cells 24 HPI with 
MYXV (MOI=5).  Magnification at 17,000-30,000x (left column), 40,000-60,000x 
(middle column), and 80,000-100,000x (right column).  Crescents (CR), Immature 
virions (IV), Immature virions with nucleoid (Nu), Intracellular mature virions (IMV), 
Wrapped virions (WV), Cell-associated enveloped virions (CEV), and Enveloped 
virions (EV) are all present. 
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Figure 3.6.  Electron microscopy continued. 
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Figure 3.7. Cell viability assays.  Trypan blue assays were performed using cells infected 
with recombinant MYXV:RFP (MOI=10) or mock-infected.  At 0h (A), 24h (B), and 48h 
(C) PI, cells were stained 1:10 in trypan blue solution and counted on a hemocytometer.  
Data was calculated as the percent of dead cells versus total remaining intact cells for both 
infected cells (striped bar), and mock-infected cells (solid bar).    
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Figure 3.7. Cell viability assays continued.  CellTiter-Blue Assays were performed 
at 24 h (D light bar) and 48 h (D dark bar) PI.  Data was calculated as a percent of 
fluorescence produced in MYXV-infected cells (MOI=10) versus that produced in 
mock-infected cells.  Apoptotic cells (E) were detected 48 HPI with an Annexin 
V/7-ADD flow cytometry assay.   * Indicates statistical significance (p<0.05). 
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 RK13 B16-F10 B16.SIY GL261 GLSIY EL4 DP1 
0 HPI  0.0078 0.0037 0.2699 0.9037 0.0009 <0.0001 <0.0001 
24 HPI 0.0183 0.0007 0.0024 0.4258 0.0016 <0.0001 <0.0001 
48 HPI 0.0004 0.0091 0.0013 0.0068 0.0060 0.0725 0.00 
Table 3.1.  P values from statistical comparison of cell death.  Different 
hours post-inoculation (HPI) in MYXV-infected (multiplicity of infection = 
10) and mock-infected cell lines as measured by Trypan blue exclusion 
assays.  
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CHAPTER 4 
TREATMENT OF MURINE BRAIN TUMORS WITH RECOMBINANT MYXOMA 
VIRUSES 
 
 The purpose of these experiments was to create murine models of primary and secondary 
brain cancer in order to test a novel cancer treatment using an oncolytic virus, MYXV.  We 
hypothesized that treating murine brain tumors with live IT MYXV would be safe and would 
result in increased survival compared to controls (PBS or dead MYXV). 
Introduction  
 Metastatic brain tumors are the most common intracranial neoplasms in adults and their 
incidence is rising, possibly secondary to increased survival time after cancer diagnosis.  
Metastasis to the brain is considered one of the worst sequela to most cancers, typically resulting 
in the cancer stage being upgraded to stage IV, which has a worse prognosis.  The incidence of 
aggressive primary brain tumors, such as glioblastoma, anaplastic astrocytoma, and lymphoma 
are also increasing, particularly in the elderly and in certain areas of the world.  The increased 
incidence of these aggressive tumors is histology specific, and not simply due to improved 
diagnostic techniques (Werner, Phuphanich, and Lyman 1995; Surawicz et al. 1999; Kohler et al. 
2011).  Brain tumors can be very difficult to treat depending on their location and degree of 
invasiveness due to the critical structures present, the limited space in the cranial vault, the 
presence of the blood brain barrier, and the possibility of neurotoxicity.  New highly effective 
treatment modalities that can specifically target tumors while sparing the normal vital brain 
tissue are needed.  To determine the safety and efficacy of using MYXV to treat brain tumors, 
we performed preliminary studies using MYXV in immunocompetent mice to treat three types of 
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tumors that have potential to affect the brain; melanoma, lymphoma, and glioma.  
 Malignant melanoma was chosen as a model because it is the second most common cause 
of brain metastasis (behind lung cancer) with an incidence proportion of 6.9% (Sloan, Nock, and 
Einstein 2009).  Melanoma has a high propensity in adults to metastasize to the brain, with 
nearly 37% of patients with stage IV melanoma eventually developing clinically apparent brain 
metastasis.  However, autopsy results indicate that this rate may actually be much higher, with 
55-75% of patients dying of melanoma found to have brain metastasis (as reviewed in Sloan, 
Nock, and Einstein 2009).  Of those patients with known melanoma metastases to the brain, 
approximately 95% of these patients die of due to their brain tumors, with a median survival of 
less than 1 year despite treatment (Sampson et al. 1998).  While patients may be treated with 
surgery if the tumor is resectable, systemic treatment is rarely beneficial since most 
chemotherapeutic agents do not penetrate well into the CNS.   
 Lymphoma was chosen as a model because it may occur as either a primary brain tumor 
or as a metastatic (secondary) tumor, and its incidence is markedly increasing.  While lymphoma 
is not a common brain tumor, non-Hodgkin lymphoma accounts for approximately 4% of all 
primary brain tumors (Surawicz et al. 1999), and 4-8% of patients with non-Hodgkin lymphoma 
(Kim and Glantz 2001) are diagnosed with CNS metastases.  Primary CNS lymphoma is more 
frequent than secondary cerebral spread of a systemic lymphoma, and it is being diagnosed with 
increasing frequency in most parts of the world, with a 10-fold increase in incidence rate 
between 1973 and 1992 (Werner, Phuphanich, and Lyman 1995; Corn et al. 1997; Dubuisson et 
al. 2004).  Primary CNS lymphoma is highly aggressive with a prognosis only slightly better 
than that of glioblastoma and a median survival time of only a few months when untreated or 
treated with surgery alone (as reviewed in Commins 2006).  Treating the tumors with radiation 
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and chemotherapy improves survival (13.9-60 months) depending upon the treatment used, but 
some treatment regimens, are associated with a high incidence of neurotoxicity (Dubuisson et al. 
2004; Abrey, Yahalom, and DeAngelis 2000).  Two of the most commonly used treatments, 
whole brain radiation and methotrexate chemotherapy, are neurotoxic and act synergistically 
(Blay et al. 1998).  This neurotoxicity can be progressive and functionally devastating, and 
include symptoms of memory impairment and ataxia (Abrey, Yahalom, and DeAngelis 2000).  
In one study, neurotoxicity developed in more than 80% of patients aged 60 or more (Blay et al. 
1998).  Review of 5 patients who died after combination treatment showed that all had evidence 
of cortical atrophy and leukoencephalopathy and 3 had cerebral infarcts (necrosis) (Abrey, 
DeAngelis, and Yahalom 1998; Lai et al. 2004).  It is clear that novel treatments that are less 
toxic are needed to treat patients with cerebral lymphoma.       
 We choose glioma as our primary brain tumor model because gliomas are the most 
frequently occurring primary brain tumors.  Gliomas are a heterogeneous group of tumors that 
resemble glial cells, which include astrocytes and oligodendrocytes.  The most common types of 
gliomas are:  astrocytomas, oligodendrogliomas, and mixed gliomas.  Astrocytomas are the most 
common, and include low grades (grades I and II) and high grades (III and IV) (Louis et al. 
2007).  Glioblastoma multiforme (GBM) is a grade IV glioma and is one of the most aggressive 
and lethal forms of cancer.  It has a poor median survival rate of 14 months when treated with 
combination chemotherapy and radiation therapy (Stupp, van den Bent, and Hegi 2005), and the 
survival rate has not improved much in the last few decades.  Malignant gliomas do not 
metastasize systemically, but are extremely invasive within the CNS, and widespread early 
migration of tumor cells has typically occurred by the time of clinical diagnosis.  There are no 
curative treatments for malignant glioma at present, and survival has remained essentially the 
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same in the last three decades despite advancements in surgical technology and medical 
treatments.  The overall incidence rate of primary brain tumors of adults in the United States is 
24.55 per 100,000 persons, with 33% of those diagnosed as malignant gliomas (Kohler et al. 
2011).      
 Murine brain tumor models of melanoma, lymphoma, and giloma were treated with 
recombinant myxoma virus (MYXV:Tomato) to determine if viral treatment could increase 
survival.  Tumors were induced by intracranial injection of murine cancer cells into mice.  
GL261 cells were used to model primary glioblastoma, B16-F10 cells modeled metastatic 
melanoma, and EL4 cells modeled lymphoma.  The use of transfected tumor cell lines that could 
be recognized by a specific set of CD8+ T cells was also explored to track the tumor-specific T 
cell response to infected tumors.  In preparation of these experiments, GL261, B16-F10 and EL4 
cell lines were transfected with an SIY peptide (that could be recognized by 2C T cells) and a 
green fluorescent (GFP) marker:  designated GLSIY, B16.SIY, and DP1, respectively.  The 
results of our in vivo experiments utilizing some of these cell lines to model brain cancer are 
described in the following parargraphs. 
Intratumoral MYXV treatment safety 
 Cancer cells expressing tomato red protein (viral infection) could be found up to 8 days 
post-injection with live MYXV:Tomato, but peaked at 48-72 HPI (Thomas et al. 2011).  Tomato 
red expression was not observed in tumors treated with UV-inactivated MYXV (dead MYXV) 
confirming that the virus was inactivated by UV treatment.  Tomato red expression was also not 
observed in untreated contralateral brain tumors (tumors on the opposite side of the brain) 
following IT MYXV:Tomato injection of mice with bilateral tumors.  In order to determine 
MYXV safety if injected outside of the tumor, mice that did not have any brain tumors were 
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injected with MYXV directly into the brain parenchyma.  These mice did not develop any 
adverse clinical signs.  In addition, while a small focus of neutrophils could be observed in the 
brain parenchyma at the site of MYXV injection, necrosis was not observed in the normal brain 
parenchyma (France et al. 2010).  Transient expression of red fluorescent protein was observed 
in some ependymal cells if the virus was injected near/into the ventricle; however, expression 
was not associated with any necrosis (France et al. 2010).  Live virus was not detected in the 
blood, spleen, lymph nodes, liver, kidney, lung, heart, intestine, or reproductive tract from any 
mouse (data not shown).  Mice eventually experienced clinical signs such as weight loss, 
hunched posture, rough haircoat, head tilt, or circling that were attributed to growth of the tumor 
rather than viral infection.  This was due to the observation that the clinical signs did not occur 
directly after injection, but occurred 1 or more weeks later, in addition to the fact that no virus 
was detected in the tissues at the time when the mice showed clinical signs.   
Intratumoral treatment with live or dead MYXV resulted in neutrophilic infiltration and 
necrosis of B16.SIY brain tumors 
 Mice were stereotactically injected on one side of the brain with B16.SIY melanoma cells 
and then, 3-5 days later, tumors were injected with PBS, recombinant MYXV, or UV-inactivated 
MYXV as described in the methods (Table 2.1).  Histopathology revealed that both live and UV-
inactivated MYXV induced a neutrophilic response at the site of injection within B16.SIY 
tumors in mice (Figure 4.1).  The neutrophils were visible at 24 and 48 h after intracranial 
injection of MYXV:Tomato or UV-MYXV, while injection of PBS did not result in any 
inflammatory response.  Tumors injected with PBS also did not have any necrosis (Figure 4.1A), 
while necrosis was minimal in UV-MYXV treated tumors (Figure 4.1B), and was signficiant in 
tumors injected with MYXV:Tomato (Figure 4.1C).  By 1 week after treatment with 
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MYXV:Tomato the neoplastic cells had proliferated to the point where the tumor was very large 
and distorting the brain (Figure 4.2A), and neither neutrophils nor necrosis were observed 
(Figure 4.2B).  While mice treated with MYXV:Tomato were observed to survive slightly longer 
than mice treated with UV-MYXV or PBS (Figure 4.3), the difference was not statistically 
significant.        
Intratumoral treatment with live or dead MYXV resulted in neutrophilic infiltration and 
necrosis of DP1 brain tumors 
 Mice were stereotactically injected on one side of the brain with DP1 lymphoma cells and 
then the tumors were injected with PBS, UV-MYXV, or MYXV:Tomato, 5 days later as 
described in the methods (Table 2.1).  On subgross examination, DP1 tumors (Figure 4.4A) were 
much smaller than the B16.SIY tumors.  Histopathology revealed that both live and UV-
inactivated MYXV induced a neutrophilic response at the site of injection within DP1 tumors in 
mice (Figure 4.4B).  The neutrophils were visible at 24 and 48 HPI after intracranial injection of 
MYXV:Tomato or UV-inactivated MYXV, while injection of PBS did not result in any 
inflammatory response.  Necrosis was minimal in UV-MYXV treated tumors and was not 
observed in PBS treated tumors (data not shown), while tumors injected with live 
MYXV:Tomato had significant necrosis (Figure 4.4B).  Mice treated with MYXV:Tomato 
survived for a slightly shorter time than mice treated with UV-MYXV, but the difference was not 
statistically significant (Figure 4.5).      
Intratumoral treatment with MYXV:Tomato resulted in neutrophilic infiltration and 
necrosis of GL261 brain tumors 
 Mice were stereotactically injected on one or both sides of the brain with GL261 glioma 
cells and then the tumors were injected with PBS or MYXV:Tomato, 11-14 days later as 
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described in the methods (Table 2.1).  Subgross examination showed that these tumors were also 
small (Figure 4.6A, dashed circles), similar to the DP1 tumors.  Histopathology revealed that 
while injection of PBS into GL261 tumors did not result in any inflammatory response (Figure 
4.6B) at 24 HPI, injection with live MYXV:Tomato induced a neutrophilic response at the site of 
injection (Figure 4.6C).  Mild lymphocytic perivascular cuffing of cerebral vessels adjacent to 
MYXV:Tomato treated tumors was observed 24 HPI (Figure 4.6C inset), but was not present in 
PBS treated mice (Figure 4.6B inset).  These observations are consistent with recruitment of an 
immune response to the area of the brain that was treated with MYXV:Tomato.  A single IT 
injection of MYXV:Tomato increased survival in mice with GL261 brain tumors (Figure 4.7A), 
with one mouse surviving to 100 days post tumor inoculation.  An inflammatory infiltrate was 
not visible at the time of death in the GL261 survival mouse, nor was there any trace of 
neoplastic cells, or evidence of necrosis (Figures 4.7B and 4.7C).  However, GL261 cells have 
been classified in the literature as mildly immunogenic, and spontaneous cures of mice injected 
with GL261 cells were observed.  Subsequent studies using GLSIY cells resulted in spontaneous 
rejection of most of the tumors, suggesting that transfection with the SIYRGFP peptide made the 
cells even more immunogenic.  This made evaluation of the statistical significance of survival 
rate in the GL261 and GLSIY tumor models difficult and would have required utilization of very 
large numbers of mice.  This prohibited further use of the GL261 and GLSIY brain tumor 
models for this study.   
Discussion 
 Treatment with MYXV:Tomato by intracranial injection was shown to be safe in all of 
the tumor models, without detection of virus in any other organs, or any evidence of encephalitis, 
or neurological signs after injection.   However, MYXV tomato red fluorescence was transiently 
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detected in ependymal and choroid plexus cells within the brain at early time points (France et al. 
2010).  Tomato red expression was absent by 11 days post-infection and there was no evidence 
of necrosis or disruption of the ependymal lining (France et al. 2010).  Experiments were also 
performed on RAG mice (Thomas et al. 2011), with no evidence of viral replication or pathology 
in other organs, indicating that MYXV treatment is also safe in immunodeficient  hosts, as has 
been documented in other studies (Lun et al. 2005; Kim et al. 2009).    
 Initial experiments using recombinant MYXV to treat intracranial murine tumors 
suggested that treatment of tumors with MYXV:Tomato or UV-inactivated MYXV resulted in a 
focus of neutrophilic inflammation and necrosis in the tumor at the site of injection at 24 and 48 
HPI that was no longer present at 1 week PI or thereafter.  The neutrophilic inflammation was 
observed whether live (MYXV:Tomato) or dead (UV-MYXV) virus was injected into the tumor, 
or into the brain parenchyma itself; however, injection of virus into the brain parenchyma did not 
result is visible necrosis.  A neutrophilic response to oncolytic viral infection has been 
documented in other studies (Best, Collins, and Kerr 2000; Fu et al. 2011; Grote, Cattaneo, and 
Fielding 2003).  Using standard laboratory strains of MYXV to infect European rabbits, one 
study observed a neutrophilic inflammatory response in the deep dermis of infected rabbits, 
whereas the same virus in wild rabbits, or an attenuated strain (Uriarra) in laboratory rabbits, 
produced a more intense mononuclear inflammatory response (Best, Collins, and Kerr 2000).  
That study may indicate that effective viral clearance depends on recruitment of mononuclear 
(likely T lymphocyte) cellular responses.  
 Despite evidence of tumor necrosis and an immune response to the virus, B16.SIY and 
DP1 tumors treated with a single injection of MYXV did not have any statistically significant 
increase in survival.  The lack of a statistically significant increase in survival in mice with 
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B16.SIY tumors treated with MYXV:Tomato was unexpected.  Due to the high viral titers that 
were obtained in B16.SIY cells in vitro, rapid infection and proliferation of the virus within the 
tumor was expected in vivo.  However, trypan blue and CellTiter blue analyses of B16.SIY cells 
after MYXV infection had indicated that despite high rates of cell infection and visibly 
impressive CPE, there are still many tumor cells that survive.  Tumor cells that survive continue 
to proliferate, and since the doubling time of B16.SIY cells in vivo is approximately 20 hours, it 
is likely that the tumor is rapidly able to recover from the necrosis caused by a single injection of 
MYXV:Tomato.   
 Treatment of GL261 tumors with live MYXV did result in increased survival in 2 mice; 
however, rare apparent spontaneous cures were also observed in GL261-bearing untreated mice, 
making these results questionable.  Spontaneous cures of GLSIY tumors were also often 
observed, indicating that this tumor cell line is too immunogenic to use as a tumor model.  The 
GL261 cell line has previously been shown to be mildly immunogenic, possibly due to elevated 
MHC class I expression and the constitutive expression of low levels of B7-1 and B7-2 
(Szatmari et al. 2006).  This may be due to the fact that GL261 is a chemically-induced tumor, 
rather than a spontaneous tumor.  The tumor was originally induced by intracranial injection of 
3-methylcholantrene into C57BL/6 mice, and was propagated by serial intracranial and 
subcutaneous transplantations.  It has mutated p53, K-ras, and c-myc, but does not express glial 
differentiation markers (glial fibrillary acidic protein:  GFAP), which is unexpected if it is truly 
derived from astrocytes.   However, it is similar to human gliomas in that it is an aggressive 
tumor with slightly invasive growth but does not metastasize. 
 The GL261 and GLSIY murine glioma cell lines in our hands were determined to be too 
immunogenic to use as a tumor model.  This was likely at least partially due to the multiple 
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passages that both cell lines underwent in our laboratory, which could have resulted in the 
evolution of more immunogenic cell lines.  Since the glioma cell lines were immunogenic and 
only moderately permissive to MYXV infection, and since the lymphoma cell lines did not 
support MYXV infection, the melanoma model was the only model that was pursued further, and 
experiments utilizing GL261, GLSIY, EL4, and DP1 cells were discontinued.   
 A timely publication reported that multiple injections of MYXV at high titer resulted in 
increased survival times and decreased tumor size in either lung or subcutaneous B16-F10 
tumors in C57BL/6 mice (Stanford et al. 2008).  Since administration of multiple intracranial 
injections of virus was not practical, and experiments using the glioma and lymphoma cell lines 
were no longer being pursued, it was determined that the intracranial model was no longer 
necessary.  Subcutaneous tumor models allow for daily monitoring of tumor volume as well as 
direct and repeatable injection of cancer treatments.  Subcutaneous tumor growth can be 
followed for a longer period of time than intracranial tumor growth, as vital organs are not 
affected by tumor mass effect.  Also, swelling of the tumor due to inflammation and necrosis (a 
potential complication of viral treatment), could have been a limiting factor in the intracranial 
tumor model, but was not an issue with the subcutaneous tumor model.  Additionally, melanoma 
tumors typically originate in the dermis, and can metastasize to many locations, so using a 
subcutaneous site for melanoma tumor initiation was a logical choice.   
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Figure 4.1.  B16.SIY tumors 48 HPI.  IT PBS (A), UV-MYXV (B), or MYXV:Tomato (C).  
Dead or live MYXV results in a focus of neutrophils* at the site of injection.  Necrosis is 
indicated with an arrow.  Images were taken at a magnification of 400x. 
 
Figure 4.2.  Intracranial B16.SIY MYXV-treated survival mouse 7 days post virus injection.  
A. Subgross (12.5x) examination revealed that the melanoma tumor was large and distorting 
the brain, pushing the midline to one side.  B. Neither inflammatory infiltrates nor areas of 
necrosis were noted within or surrounding the tumor, but there were many dilated blood 
vessels and multifocal areas of hemorrhage (400x). 
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Figure 4.4.  Intracranial DP1 tumor 24 HPI with MYXV:Tomato.  A. Subgross (12.5x, 
coronal section) examination revealed that the lymphoma tumor was very small.  B. An 
intense focus of neutrophil infiltration* and necrosis was observed within the 
MYXV:Tomato treated tumor (400x). 
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Figure 4.3.  Intracranial B16.SIY Kaplain-Meier survival curve.  Intratumoral injection 
with live MYXV did not significantly increase survival in B16.SIY intracranial tumor 
models over PBS or dead (UV-inactivated) MYXV treated controls. 
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Figure 4.5.  Intracranial DP1 Kaplain-Meier survival curve.  Intratumoral injection with 
live MYXV did not significantly increase survival in DP1 intracranial tumor models over 
PBS or dead (UV-inactivated) MYXV treated controls.    
Figure 4.6.  Bilateral intracranial GL261 tumors 24 HPI with MYXV:Tomato.  A. Subgross (x, 
coronal section) examination revealed small tumor size (A, dashed circles).  One tumor was 
injected with PBS (B) and the other with MYXV (C).   At 24 HPI the PBS tumor does not 
have a neutrophilic infiltrate and does not have any vascular response (B and B inset), while 
the MYXV tumor has an intense focus of infiltrating neutrophils*, increased glial cells in the 
parenchyma, and mild perivascular cuffing (C and C inset).  
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Figure 4.7.  Intracranial GL261 survival study.  Mice treated with MYXV:Tomato survived 
significantly longer than mice treated with PBS (A).  Examination of the brain from a mouse 
that survived to 100 days (B and C) revealed no detectable tumor, and no focus of necrosis, 
inflammation, scarring, or detectable parenchymal loss.  Subgross images were photographed 
at 12.5 x magnification (cross-section). 
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CHAPTER 5 
TREATMENT OF MURINE SUBCUTANEOUS MELANOMA TUMORS WITH 
RECOMBINANT MYXOMA VIRUSES 
 
 In order to test the effectiveness of MYXV and MYXV:IL15 for the treatment of murine 
melanoma, we injected immunocompetent C57BL/6 mice subcutaneously with B16.F10 cells, 
and then injected the tumors IT with MYXV.  The tumors were injected when they reached 5 
mm in diameter and injections were repeated on a weekly basis, as our previous studies indicated 
that the virus titer decreased between 96 hours and 1 week PI.  UV-MYXV and PBS were also 
injected into the tumors of some mice as controls.  Mice were monitored for survival and for 
viral titer, IL-15 levels, and leukocyte infiltration at 5 different time points.  Our hypothesis was 
that treatment of murine melanomas IT with MYXV:IL15 would result in increased numbers of 
tumor- infiltrating leukocytes and increased survival over treatment with MYXV.      
Introduction 
 Skin cancer is the most common form of cancer in the United States (U.S. Cancer 
Statistics Working Group 2010).  Melanoma is the third most common skin cancer (after basal 
cell carcinoma and squamous cell carcinoma), but is more deadly, and is currently ranked as the 
fifth most common cancer in men, and the seventh most common cancer in women (U.S. Cancer 
Statistics Working Group 2010).  The incidence is statistically significantly increasing every year 
by an average annual percent change of a 2.4% increase in men and a 2.2% increase in women 
(Kohler et al. 2011).  This increase is despite an average annual percent decrease in the overall 
cancer rate of 0.8% in the general population (Kohler et al. 2011).    
 In order to explore new treatments for melanoma, animal models of melanoma are 
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initially utilized.  The original B16 melanoma cell line was derived from a spontaneous 
melanoma in a C57BL/6 mouse.  B16 murine melanoma is an aggressive model in which 
treatment is notoriously difficult, and it is believed by some that if a treatment works in this 
mouse model, it is also likely to work in human melanomas.  Therefore, inoculation of B16 cells 
into C57BL/6 mice is a well-established and widely-used spontaneous mouse tumor model for 
human melanoma.  Melanomas grow rapidly in C57BL/6 mice after injection with B16 murine 
melanoma cells, allowing research to be performed in an immunocompetent animal model.  This 
has benefits over treating a human xenograft tumor model in immunodeficient mice, because the 
immune system can play a large role in cancer development, metastasis, and treatment.   It has 
been observed with many virotherapeutics that while a treatment may have good anti-tumor 
effects in a xenograft model, treatment benefit is often lost or reduced when used in an 
immunocompetent animal model or when used in people with cancer.  This is likely due to a 
combination of factors.  For one, a xenograft is a foreign tumor from a different species, so there 
is an increased likelihood that the host animal will reject those cells, even when the animal is 
immunodeficient.  These foreign cells are coated with foreign antigens, which can act as TAAs 
to the host immune system.  Even in immunodeficient animal models the host immune system 
still possesses functional NK cells, the very cells responsible for monitoring the body for 
abnormal cells.  Another reason xenograft models are not ideal is that the immune system can 
affect the ability of the tumor to establish and spread, as well affect the body's response to the 
cancer treatment.  This is especially relevant in the case of oncolytic viruses, which are an 
infectious agent and have a large effect on the immune system.   
 Our results using recombinant myxoma virus as a treatment for melanoma in 
immunocompetent mice follow.  We assessed treatment safety, characterized the tumor 
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histologically, including necrosis and cellular infiltrates, and evaluated survival in the different 
treatment groups.    
Virus treatment did not cause any deleterious effects in the mice 
The most important consideration for an oncolytic virus is that it is safe.  In these 
experiments, we noted that mice did not have any observable adverse effects after IT injection of 
the any of the viral treatments or control treatments.  Mice continued to eat and drink after 
treatment, maintained their weight without even a transient drop, and continued to act normally.   
 Portions of organs collected at the time of euthanasia were evaluated histologically for 
pathological changes that might be associated with treatment.  Review of the organs did not 
reveal any significant pathological changes that could be attributed to treatment.  In addition, 
portions of multiple organs were homogenized and plated on RK13s to detect the presence of 
virus.  Viral infection of organs was generally absent, but 2-4 viral colonies (106-108 pfu/gram) 
were detected in lung homogenates from 2 mice at 24 HPI, and one viral colony (53 pfu/gram 
tissue) was detected in an eye homogenate at 96 HPI (data not shown).     
Characterization of the subcutaneous B16-F10 melanoma tumor after IT treatment 
 Tumors collected at various time points were examined histologically.  Subgross 
examination (Figure 5.1A) revealed an unencapsulated, moderately well-demarcated, invasive, 
and highly cellular tumor within the dermis that occasionally invaded the deep skeletal muscle 
(Figure 5.1B and 5.2A).  The tumor cells were large round cells with distinct cell margins and 
abundant basophilic cytoplasm that occasionally had a fine to moderate dusting with brown 
melanin granules.  The nuclei were large and round to oval with marginated chromatin and 1-3 
large nucleoli.  Anisocytosis and anisokaryosis were marked.  Mitotic figures averaged 6 per 
400x field.  Individual or small rafts of neoplastic cells could be observed within surrounding 
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lymphatics in some tumors (Figure 5.2B).  The tumors contained multifocal to coalescing areas 
of necrosis (Figure 5.1A) that ranged from 5% to 85% of the tumor, and tended to be located 
centrally.  The multifocal necrosis was due to remaining viable blood vessels, which were 
surrounded by a thick cuff of viable neoplastic cells, while cells further away from the blood 
vessel were necrotic (Figure 5.1C).  When large areas of necrosis were present, the vessels in the 
area were also necrotic (Figure 5.1C, upper right).  Tumors from the 24, 48 and 96 HPI time 
points were often surrounded by mild to marked dermal edema that contained mixed leukocytes, 
including lymphocytes, macrophages, and neutrophils (Figure 5.1D).  The outer edge of the 
tumors was lined by a thin band of necrosis (Figure 5.1E) and was surrounded by a band of 
granulation tissue (Figure 5.1F).  The epidermis overlying the tumors was occasionally absent 
(ulcerated) but was more often hypereosinophilic with loss of cellular detail (necrotic) and 
variably infiltrated by neutrophils (Figure 5.1G).  
B16-F10 melanoma cells tend to metastasize to the draining (renal) lymph node and the 
lungs 
 Mice were examined after euthanasia for grossly apparent metastases, and the organs 
(brain, eye, lung, heart, liver, kidney, adrenal, lymph node, spleen, genital tract, and bladder) 
were examined microscopically for micrometastases.  Metastases were most often located in the 
renal lymph node (Figure 5.2A-B) which is located medial to the kidney, but were also rarely 
found in the axillary lymph nodes (which drain the trunk) consistent with previous studies (Van 
den Broeck, Derore, and Simoens 2006; Tilney 1971).  The draining lymph node in this 
subcutaneous flank model appeared to be the renal lymph node (Figure 5.2A, yellow arrow), 
likely due to the proximity of the tumor to the retroperitoneal space (Figure 5.2A, white arrow).  
The tumors were observed histologically to invade the surrounding lymphatics (Figure 5.2C), the 
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deep muscles (lumbar and gluteal muscles) (Figure 5.2D), and grossly the melanotic tumor could 
be observed through the thin muscle of the abdominal wall (Figure 5.2A, white arrow); however, 
the tumors did not infiltrate all of the way through the wall.  The renal lymph node has been 
documented to drain the lumbar area, as well as the kidney and perirenal area in rats (Tilney 
1971).  The renal lymph node also receives drainage from the iliac and para-aortic lymph nodes, 
both of which drain the gluteal area (Tilney 1971).  In fact, in rats, the renal lymph node 
ultimately receives lymph from all pelvic and retroperitoneal viscera, hind limbs, and the tail 
(Tilney 1971).  Similarly, in humans, injection of dye into the perirenal space has been found to 
track into the posterior pararenal space and the fascial planes of the lumbar and sacral areas 
(Thornton et al. 2001).    
 The second most common area to find metastases was the lungs.  Tumors could be 
observed grossly (Figure 5.2E-F), but sometimes were only detectable by light microscopy 
(Figure 5.2G-H).  Microscopic metastases were most often adjacent to small vessels (Figure 
5.2G) in the lungs or along the pleural surface (Figure 5.2H).  Melanoma cells likely spread to 
the lungs by the hematogenous route since micrometastases were often adjacent to small vessels 
(Figure 5.2G).  Additionally, melanoma cells were also rarely observed in blood vessels within 
the lung (Figure 5.2I).   
 Invasion of the renal lymph node by melanoma cells was observed in 27% of survival 
mice, while metastases were detected in the lungs of 25% of survival mice.  Metastases were 
more common in the renal lymph node and lung of MYXV:IL15 (5/12 and 5/12, respectively) 
and MYXV (5/12 and 3/12, respectively) treated mice than in UV-MYXV (1/12 and 2/12, 
respectively) and PBS (2/12 and 2/12, respectively) mice, possibly due to the longer survival 
times obtained by the mice treated with live virus.  Most metastases were present in mice that 
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survived at least 14 days PI, and the average survival times of PBS and UV-MYXV treated mice 
were only 11 days and 14.5 days, respectively, while MYXV:IL15 treated mice survived an 
average of 17 days PI, and MYXV mice survived an average of 19 days PI.  However, invasion 
of the renal lymph node was detected in one mouse treated with MYXV:IL15 at 4 days PI and 
invasion of the lung was found in one mouse treated with MYXV:IL15 at 7 days PI, and in the 
lung of a mouse treated with MYXV at 8 days PI.  Other organs where metastases were found 
include the spleen (1 mouse) and the diaphragm (1 mouse). 
Repeated injections of MYXV:IL15 or MYXV resulted in significantly increased survival 
compared to controls 
 Injections of virus were repeated weekly in survival mice until the mice exhibited 
criterion of euthanasia, resulting in survival mice receiving between 1 and 4 injections of virus.  
Both groups of mice that were treated with live virus (MYXV:IL15 or MYXV) survived 
statistically significantly longer than did control mice (UV-MYXV or PBS)  
(Figure 5.3, Table 5.1).  This was an encouraging finding, confirming the idea that repeated 
injections of the virus can result in clinically significant improvement, without the need to 
employ immunosuppressants.  However, there was not a significant difference between the 
treated groups, indicating that the expression of IL15 by MYXV did not result in any increased 
survival.  In fact, the average survival of the mice treated with MYXV:IL15 was slightly shorter 
(17 days) than the mice treated with MYXV (19 days).  
Virus remained at high levels within the tumor until 96 HPI, but drastically declined by 1 
week PI  
 In order to determine how long virus persisted in the subcutaneous melanoma tumors, the 
presence of virus within the treated tumors was detected by plaque assay and by detecting 
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Tomato red protein expression by fluorescent microscopy.  Sections of tumors from mice that 
were treated with MYXV:IL15, MYXV:Tomato, UV-MYXV, or PBS were homogenized, 
serially diluted, and plated on RK13 cells to detect and quantitate the amount of virus within the 
treated tumors.  Virus was detected from most of the tumors treated with either MYXV:IL15 or 
MYXV:Tomato that were collected at 24, 48, and 96 HPI (Figure 5.4), but the frequency of 
detection as well as the viral titer significantly decreased by 1 week PI, and was similar in tumors 
collected from survival mice.  By 1 week PI, only 33.3% (2/6) of mice treated with MYXV:IL15 
had virus detectable by plaque assay, and only 42.9% (3/7) of mice treated with MYXV:Tomato 
had detectable virus (Figure 5.4A).  In survival mice, 42.9% (3/7) of MYXV:IL15 mice and 20% 
(1/5) of MYXV:Tomato treated mice had detectable virus by plaque assay.  Tumors from UV-
MYXV and PBS treated mice did not have any detectable virus by plaque assay.  Observation of 
the tumors for viral tomato red expression had similar results, but was not as sensitive (Figure 
5.4B-C).  Tomato red fluorescence was observed in 66% of tumors collected at 24 HPI and in 
100% of tumors collected at 48 HPI in either MYXV:IL15 (2/3 and 3/3, respectively) and 
MYXV:Tomato (2/3 and 4/4, respectively) treated mice (Figure 5.4B).  Only 33% of 
MYXV:IL15 (1/3) and MYXV:Tomato (1/3) treated mice had observable viral fluorescence by 
96 HPI, and while 20% of MYXV:Tomato (1/5) treated mice had viral fluorescence at 1 week 
PI, none of the MYXV:IL15 (0/3) treated mice had detectable virus (Figures 5.4B-C).  None of 
the MYXV:IL15 (0/3) or MYXV (0/3) survival mice had virus observed (Figure 5.4B-C), and no 
viral fluorescence was observed from tumors of UV-MYXV or PBS treated mice (data not 
shown).  These results indicate that while virus can persist for 1 week PI, virus is present in 
higher amounts at earlier (24, 48, and 96 HPI) timepoints.  In addition, plaque assay appears to 
be a more sensitive test for detecting virus in tumors than fluorescent microscopy.    
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Interleukin-15 was detected in tumors collected at 24, 48, and 96 HPI, as well as at survival 
time points, but dropped to very low levels by 1 week PI 
 In order to confirm production of IL-15 and in order to determine how long IL-15 was 
present after treatment, levels of IL-15 were determined by ELISA after in vitro and in vivo 
treatment with MYXV:IL15.  Tumors collected from MYXV:IL15 mice were homogenized.  
Both in vivo and in vitro collected cells were lysed by multiple freeze-thaw cycles and 
sonication.  IL-15 was detected for a shorter period of time in vitro (Figure 5.5A) than in vivo 
(Figure 5.5B).  This is presumed due to the ability of the virus to continue to spread to adjacent 
viable cells in vivo and produce more virus and IL-15, while the amount of virus produced (and 
therefore the amount of IL-15) is limited by the number of cells in the well in vitro.  If most of 
the cells are infected and die with the first round of viral infection, then there are fewer cells left 
for the virus to spread to in order to replicate and produce virus and IL-15.  This may be what 
occurred in vitro, as the IL-15 level was high at 24 hours after infection but then rapidly declined 
to near the detection limit by 48 hours (Figure 5.5A).  Levels of IL-15 present in cells infected 
with MYXV:Tomato were below the minimal detection limit of the ELISA, similar to the study 
by Liu et al 2009.  Similarly, IL-15 levels were below the detection limit for cells mock-infected 
with media without virus, or in wells with only media and no cells.  Positive controls were also 
run and contained samples of MYXV:IL15 treated cells combined with the company standard.       
The degree of tumor necrosis between treatment groups was not significant 
 Tumors were evaluated histologically for the degree of tumor necrosis present in order to 
determine if the degree of necrosis correlated with treatment or survival time.  Tumors from 
various time points and treatment groups were graded according to the degree of necrosis as 
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described in the methods (Table 2.2, Figure 2.1) and the results were statistically compared.  
While the degree of necrosis tended to increase over time in all treatment groups, there was not a 
statistically significant difference in the amount of necrosis between treatment groups and 
control groups (Figure 5.6), and therefore, not a statistically significant correlation between 
necrosis and survival. 
The number of lymphocytes surrounding and within the tumors was significantly different 
between treatment groups 
 In order to determine if MYXV:IL15 recruited more lymphocytes to the tumor than 
MYXV that does not express IL-15, or UV-MYXV or PBS controls, tumors were examined for 
infiltrating lymphocytes.  All collected tumors from each treatment group and time point were 
graded histologically on the number of lymphocytes observed per 400x high powered field as 
described in the methods (Table 2.2, Figure 2.1).  The average lymphocyte grades surrounding 
the tumor or within the tumor were compared between treatment groups and at various time 
points (24h, 48h, 96h, 1w, survival).  Overall, lymphocytes grade was found to be statistically 
significantly different between treatment groups (p<0.0001) and at different time points 
(p=0.0358), with more lymphocytes present in groups treated with live MYXV and at earlier 
time points than at survival (Figure 5.7, Table 5.2).  MYXV:IL15 treated tumors were found to 
have more lymphocytes surrounding and within the tumors than PBS (p=0.0008 and 0.0001, 
respectively)  and UV-MYXV treated control mice (p<0.0001 and 0.0020, respectively) as well 
as MYXV (p=0.0436 and 0.0179, respectively) treated mice.  MYXV treated tumors also had 
more lymphocytes surrounding and within the tumors than PBS treated control mice (p=0.0398 
and 0.0025, respectively) but only had significantly more lymphocytes surrounding the tumors 
(p=0.0001) of UV-MYXV treated mice, not within the tumors (p=0.1716).  UV-MYXV and PBS 
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treated control mice did not significantly differ in the number of lymphocytes surrounding or 
within the tumors (p=0.2937 and 0.2389, respectively).   
 The number of immunohistochemically labeled mononuclear leukocytes was rarely 
significantly different between treatment groups 
 In order to determine which type of leukocytes were infiltrating into the tumors after 
treatment, we used immunohistochemistry for several different cell types.  We anticipated 
increased numbers of cytotoxic lymphocytes and NK cells in tumors treated with MYXV:IL15.  
At least three tumors from each treatment group and time point were evaluated for the number of 
lymphocytes per 400x high powered field that labeled with anti-CD3 (all T cells), CD4 (helper T 
cells), and CD8 (CTLs) antibodies, as well as for cells that labeled with anti-granzyme B (GrB; 
NK cells and CTLs) antibodies and anti-MHCII antibodies (APCs).   
 CD3 (cluster of differentiation 3) is a glycoprotein that is part of the T cell receptor 
complex present on all mature T cells.  Overall, the number of CD3+ lymphocytes present at the 
junction of the tumor and the surrounding tissue was not statistically significantly different 
between treatment groups (p=0.5046), but was found to be more prevalent at early time points 
(24, 48 and 96 HPI) than at later time points (p=0.0285).  The MYXV:IL15 treated tumors were 
found to have more lymphocytes surrounding tumors, at the tumor junction, or within the tumors 
than PBS and UV-MYXV treated control mice as well as MYXV treated mice but none of the 
numbers were statistically significant (Table 5.3).  MYXV treated tumors were found to have 
more lymphocytes surrounding tumors or within the tumors than PBS and UV-MYXV treated 
control mice, but the only statistically significant difference was the number of CD3+ cells 
within the tumor of MYXV treated tumors compared to PBS treated tumors (p=0.0356).  The 
number of CD3+ cells at the tumor junction of MYXV mice was not much different than that 
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present in PBS or UV-MYXV treated mice (Table 5.3).  UV-MYXV and PBS treated control 
mice did not significantly differ in the number of lymphocytes surrounding tumors or at the 
tumor junction (Table 5.3).  More CD3+ lymphocytes were present within UV-MYXV treated 
tumors than in PBS treated tumors but the number was not statistically significant (Table 5.3).  
 CD4 and CD8 are glycoproteins present on the surface of the 2 main subsets of T cells:  
helper and cytotoxic T cells, respectively.  Overall, the number of CD4+ or CD8+ cells present 
was not statistically significantly different between treatment groups (p=0.6743 and 0.1895, 
respectively), or at different time points (p=0.7592 and 0.4874, respectively).  The MYXV:IL15 
treated mice did not have significantly more CD4+ lymphocytes than PBS, UV-MYXV, or 
MYXV treated mice (Table 5.4).  The MYXV:IL15 treated mice were found to have more CD8+ 
lymphocytes than PBS or UV-MYXV treated control mice as well as MYXV treated mice but 
none of the numbers were statistically significant (Table 5.5).  MYXV treated mice did not differ 
significantly in the number of CD4+ or CD8+ lymphocytes from PBS treated mice.  MYXV 
treated mice had more CD4+ and CD8+ cells than UV-MYXV treated mice but not significantly 
more.  UV-MYXV and PBS treated control mice did not significantly differ in the number of 
CD4+ and CD8+ lymphocytes (Table 5.5).   
 Granzyme B is a serine protease present in CTLs and NK cells.  The number of cells that 
were positively labeled with anti-GrB antibodies was observed by fluorescent microscopy (Table 
5.6).  Overall, the number of GrB+ cells present was not statistically significantly different 
between treatment groups (p=0.2121), or at different time points (p=0.3763).  Rare GrB+ cells 
were observed in MYXV:IL15 or MYXV treated mice, but were not observed at all in UV-
MYXV or PBS treated mice.  The MYXV:IL15 treated mice did not have significantly more 
GrB+ cells than PBS (p=0.2209), UV-MYXV (p=0.2209), or MYXV (p=0.2393) treated mice.  
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MYXV treated mice also did not have significantly more GrB+ cells than PBS (p=0.3055) or 
UV-MYXV (p=0.3055) treated mice.  UV-MYXV and PBS treated control mice did not 
significantly differ in the number of GrB+ cells (p=1.0). 
 Cells that express MHCII are APCs, and include dendritic cells, macrophages, and B 
lymphocytes.  Overall, the number of MHCII+ cells present surrounding or within the tumors, or 
in areas of tumor necrosis, were not statistically significantly different between treatment groups 
(p=0.6288, 0.5341, and 0.3376, respectively).  Significantly more MHCII+ cells were present at 
early time points surrounding the tumor (p=0.0347) than at later time points, but the number of 
MHCII+ cells within the tumor or in areas of tumor necrosis (p=0.8449 and 0.0934, respectively) 
were not significantly different between time points (Table 5.7).  The MYXV:IL15 treated 
tumors were found to have more MHCII+ cells surrounding them than tumors treated with PBS 
but the difference was not significant (Table 5.7).  There was also not a significant difference 
between the MYXV:IL15 and PBS treated mice in the number of MHCII positive cells within 
the tumors and in areas of tumor necrosis.  MYXV:IL15 treated mice did not differ significantly 
in the number of MHCII positive cells surrounding the tumor, within the tumor, or in areas of 
tumor necrosis than UV-MYXV or MYXV treated mice (Table 5.7).  The MYXV treated tumors 
were found to have more MHCII+ cells within areas of tumor necrosis than tumors treated with 
PBS but the difference was not significant (Table 5.7).  There was also not a significant 
difference between the MYXV and PBS treated mice in the number of MHCII positive cells 
surrounding the tumors or within the tumors (Table 5.7).  However, if the number of MHCII+ 
cells were assessed in all areas, there was a statistically significant difference between the 
MYXV treated mice and PBS treated mice (p=0.0470).  MYXV treated mice did not differ 
significantly from UV-MYXV treated mice in the number of MHCII positive cells in any area of 
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the tumor (Table 5.7).   UV-MYXV and PBS treated control mice did not significantly differ in 
the number of MHCII+ cells in any area, although there were generally more in the UV-treated 
mice than the PBS treated mice (Table 5.7).   
The number of neutrophils surrounding and within the tumors was significantly different 
between MYXV treated tumors and PBS treated control tumors 
 Tumors were observed histologically to determine if neutrophils significantly varied 
between treatment groups.  Tumors were graded histologically on the number of neutrophils 
observed per 400x high powered field as described in the methods (Table 2.2, Figure 2.1).  The 
average neutrophil grade surrounding the tumor, within viable areas of the tumor, and within 
areas of tumor necrosis were compared between treatment groups and at various time points 
(24h, 48h, 96h, 1w, survival).  Overall, neutrophil grade was found to be statistically 
significantly different surrounding the tumor, within viable areas of the tumor, and within areas 
of tumor necrosis, between treatment groups (p=0.0280, 0.0016, and <0.0001, respectively).  
Neutrophil grade was also found to be statistically significantly different surrounding the tumor 
(p<0.0001), and within viable areas of the tumor (p=0.0015) at different time points, but not 
within areas of tumor necrosis (p=0.4422).  Overall, neutrophils were more prevalent in areas of 
tumor necrosis and surrounding the tumor than in viable areas of the tumors, which only had 
neutrophils during early time points (Figure 5.8, Table 5.8). 
 MYXV:IL15 treated tumors were found to have statistically more neutrophils 
surrounding, within the tumors, and within areas of necrosis than PBS control mice (p=0.0448, 
0.0050,  and 0.0040, respectively), which tended to have few neutrophils, but not statistically 
more than UV-MYXV or MYXV treated mice (Table 5.8).  MYXV treated tumors, however, 
had significantly more neutrophils surrounding, within tumors, and within areas of necrosis than 
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PBS control mice (p=0.0049, 0.0001, and <0.001, respectively) and UV-MYXV treated mice 
(p=0.0500, 0.0291, and 0.0017, respectively).  UV-MYXV and PBS treated control mice 
significantly differed in the number of neutrophils present in viable areas of the tumors 
(p=0.0083), with UV-MYXV mice having more neutrophils present than PBS treated mice.  UV-
MYXV treated mice also had more neutrophils histologically than PBS treated mice had 
surrounding the tumors or in area of necrosis, but the numbers were not statistically significant 
(Table 5.8).       
 In summary, while MYXV:IL15 and MYXV treated tumors were both observed to have 
more neutrophils in all areas than PBS treated tumors, and MYXV treated tumors also had more 
neutrophils in all areas than UV-MYXV treated tumors; MYXV:IL15 treated tumor did not have 
significantly more neutrophils than MYXV treated tumors, indicating that the IL-15 expressed 
by the virus did not significantly affect neutrophil infiltration.   
The number of immunohistochemically labeled neutrophils (Gr-1 positive cells) was not 
significantly different between most treatment groups  
 Since neutrophils were observed histologically, we used immunohistochemistry to further 
evaluate the numbers of neutrophils present in different areas of the tumor to determine if 
neutrophils significantly varied between treatment groups.  At least three tumors from each 
treatment group and time point were evaluated for the number of neutrophils per 400x high 
powered field that labeled with anti-Gr-1 antibodies.  Overall, the number of Gr-1+ cells present 
surrounding tumors, within tumors and within areas of tumor necrosis did not statistically 
significantly differ between treatment groups (p=0.4763, 0.2370, and 0.1023, respectively), or 
between different time points (p=0.7776, 0.05089, and 0.5902). 
 The MYXV:IL15 treated tumors were found to have more Gr-1 positive cells in areas of 
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tumor necrosis (0.0781) than PBS treated cells, but not surrounding or within the tumors (Table 
5.9).  MYXV:IL15 treated tumors did not differ significantly in the number of Gr-1 positive cells 
in any area than UV-MYXV or MYXV treated mice (Table 5.9).  The MYXV treated tumors 
were found to have significantly more Gr-1 positive cells in areas of tumor necrosis (0.0305) 
than PBS treated cells, but not surrounding or within the tumors (Table 5.9).  MYXV treated 
tumors did not significantly differ from UV-treated tumors in the number of Gr-1 positive cells 
present in any areas (Table 5.9).  UV-MYXV and PBS treated control mice did not significantly 
differ in the number of neutrophils in any area (Table 5.9).  In summary, our IHC evaluation of 
neutrophils only found significant differences between MYXV:IL15 or MYXV treated tumors 
and PBS treated tumors in areas of tumor necrosis.     
Antibody response to the virus was present in some treated mice 
 In order to evaluate the humoral antibody response to viral treatment, blood was collected 
at the time of euthanasia of all mice and the ability of the serum to neutralize the virus was 
evaluated.  An antibody response capable of reducing the formation of MYXV:Tomato plaques 
by more than 50% (when compared to serum from control mice inoculated with PBS) was 
observed in some survival mice treated with MYXV:Tomato (4/5), MYXV:IL15 (4/5), and UV-
MYXV (1/4).  Since some of the treated mice did not develop an antibody response detectable 
by plaque reduction neutralization titer (PRNT) 50 (as described in materials and methods), the 
results were not statistically significant between groups (Figure 5.9).  However, variability in the 
formation of a detectable antibody response to vaccination with vaccinia virus has been 
documented (Harrop et al. 2006); therefore, these results are not unexpected with IT treatment 
with MYXV. 
Discussion 
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 A statistically significant increase in survival was achieved in the B16 aggressive murine 
melanoma model by repeating intratumoral injections of MYXV or MYXV:IL15 every week.  
This is similar to other studies with oncolytic viruses, including MYXV, which have shown that 
while a single injection with an oncolytic virus often does not have beneficial results, multiple 
injections with the same virus can have positive results (Stanford et al. 2008).  For this 
experiment, weekly injections were chosen because previous experiments had demonstrated that 
MYXV was usually no longer detectable at 1 week PI.  This experiment further confirmed that 
virus titer markedly decreased in tumors at one week PI, but was still high at 96 HPI.  
Visualization of virus tomato red expression within the tumor by fluorescent microscopy was 
similarly absent at 1 week PI in all mice, but was visualized in some mice at 96 HPI.  These 
findings support that MYXV should be administered at least weekly, but also indicates that 
boostering the injections every 5-6 days may be beneficial.  Some studies with oncolytic viruses 
have utilized daily boostering of virus in an attempt to infect and kill as many cancer cells as 
possible (Stanford et al. 2008).   This approach is feasible due to the fact that oncolytic viruses 
have a very wide safety margin, with most only causing mild flu-like symptoms, and with 
clinical trials generally unable to find a maximum tolerated dose (MTD).  Due to the rapid 
course of disease with B16-F10 melanomas in mice, survival mice in this study only received 
between 1 and 4 injections before they met criteria of euthanasia.  The use of multiple treatment 
doses is common when treating cancer, especially with chemotherapy and radiation therapy, so it 
should be no surprise that multiple treatments may also be necessary for oncolytic virotherapy.  
Additional studies may find that daily injections or a short series of daily injections that are 
repeated periodically (e.g. every 1-2 weeks) may provide even better results than those seen in 
this study.        
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 The average survival of the mice treated with MYXV:IL15 was shorter (17 days) than the 
mice treated with MYXV (19 days).  However, the difference was not statistically significant.  
This is also an important observation, as there is always a concern that any treatment that will 
increase the immune response during treatment with an oncolytic virus will result in faster 
clearance of the virus, with subsequent decreased tumor cell lysis and shorter survival times.  In 
addition, there is also concern when using cytokines that the patient may experience adverse 
events, as has been observed in some people treated with IL-2 (Eisner, Husain, and Clark 2004).  
Treatment with cytokines can result in adverse events that could decrease survival, up to and 
including rapid death due to a cytokine storm.  However, the mice that were injected with 
MYXV:IL15 did not have any observable adverse effects, with no evidence of weight loss or 
decreased appetite, and it does not seem likely that the slight decrease in survival time is due to 
IL-15 treatment, since the mice appeared normal and the difference is not statistically significant.  
 One of the goals of this study was to characterize the response of the immune system to 
IT injection of the virus as well as to IL-15.  Histological analysis of the tumors revealed that the 
initial response at the site of tumor injections was an infiltration of neutrophils and an area of 
necrosis.  Overall, neutrophils were more prevalent in areas of tumor necrosis and surrounding 
the tumor than in viable areas of the tumors, which only had neutrophils during early time points 
(Table 5.7, Figure 5.8).  Large areas of necrosis were often associated with necrotic blood 
vessels, whereas tumor cells remaining in areas of multifocal necrosis were surrounding viable 
vessels.  Neutrophils have been shown to inhibit blood flow in some pathological conditions, and 
this has been documented to occur following oncolytic virotherapy with VACV (Breitbach et al. 
2007).  Depletion of neutrophils in that study, resulted in improved blood flow with subsequent 
decreased tumor cell apoptosis in uninfected cells, as well as improved viral replication, spread, 
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and persistence, over mice whose neutrophils were not depleted (Breitbach et al. 2007).  This 
suggests that treatments that target the vasculature may or may not be of benefit if given in 
combination with MYXV oncolytic therapy, since they may increase tumor cell death but may 
limit the spread of the virus.    
 Macrophages were also present in the areas of necrosis, but not lymphocytes.  This is 
expected as neutrophils and macrophages are commonly found in areas of necrosis, but 
lymphocytes are not.  Lymphocytes were most prevalent at the junction of the tumor and the 
dermis, with some present at the outer edge of the mass, and many in the dermis surrounding the 
tumor.  Lymphocytes were also rarely surrounding vessels in tumors treated with virus.  A rim of 
necrosis and granulation tissue surrounded the tumors at early time points, and the surrounding 
dermis was edematous and contained increased numbers of lymphocytes in all tumors.  This was 
present at early time points regardless of treatment, and was most likely a response to growth of 
the tumor.         
 The statistically significant increase in the number of lymphocytes in mice treated with 
live MYXV indicates that MYXV results in an influx of lymphocytes to the tumor bed and to the 
dermis surrounding the tumor that would be minimally present in control mice that are not 
treated with the virus.  Additionally, treatment with MYXV:IL15 resulted in a greater influx of 
lymphocytes than MYXV without IL-15, suggesting that IL-15 induced increased infiltration of 
the tumor bed and surrounding area by lymphocytes.  While dead MYXV resulted in a mild 
increase in lymphocytes over PBS treated control mice, the mere presence of these virus particles 
was not enough to result in more than a minimal increase in lymphocytes.   
 Intratumoral treatment with virus was found to be safe, with no adverse effects noted, and 
rare viral spread.  When compared to the viral titers detected in the treated tumors, which 
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averaged over 1,000,000 pfu/gram between 24 and 96 HPI, the titers detected in the lung (106-
108 pfu/gram) from 2 mice at 24 HPI and eye (53 pfu/gram tissue) of 1 mouse at 96 HPI, are 
miniscule.  It is likely that the virus detected in the lung was due to hematogenous spread that 
occurred right after injection, since the 2 positive mice were collected at 24 HPI.  Due to the 
increased blood supply that is commonly found in tumors, it is possible that the IT injection 
resulted in some virus being injected into a vessel.  Alternatively, the virus may have gained 
access to the circulation through leaky vessels in the tumor or by infecting cells that entered the 
blood stream and circulated to the lung.  Indeed, detection of virus in the blood after IT injection 
has been documented with adenovirus and vaccinia virus, with one study showing viral DNA in 
the blood of 18/21 patients treated with adenovirus (Nokisalmi et al. 2010) and in 14/14 patients 
treated with vaccinia virus (Park et al. 2008).  In the vaccinia study, all patients had viral 
genomes detected in the blood immediately after IT injection, but concentrations decreased by 
90% within the first 4-6 hours (Park et al. 2008).  However, there was also delayed re-emergence 
of circulating viral DNA consistent with viral replication (Park et al. 2008).  In this experiment, 
we were able to detect higher levels of MYXV than the original injected dose, also consistent 
with viral replication.  The fact that virus was not detected in the lungs of mice at later time 
points in our experiments indicates that the virus was not able to productively infect the normal 
cells in the lung.  The one viral colony from the eye was likely on the exterior of the eye, and 
was possibly secondary due to autoinoculation or contact with another mouse with an ulcerated 
mass.   
 Some of the treated survival mice in each treatment group that received virus developed 
an antibody response, whether they were treated with live or dead virus.  Meanwhile, some mice 
that received the same treatment did not develop an antibody response detectable by PRNT.  This 
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is common with poxviruses, and has been documented in patients receiving vaccinia treatments.  
In one study, only 82% (14/17) of patients developed a neutralizing antibody response to VACV 
(modified vaccinia Ankara), despite multiple intratumoral injections (Harrop et al. 2006).  This is 
in contrast to some other virotherapeutics, such as adenovirus, in which most if not all patients 
treated with the virus develop a strong antibody response (Kimball et al. 2010).  The 
development of an antibody response in the mice in this study did not correlate with any 
significant difference in the length of survival or in the number of infiltrating leukocytes.  A lack 
of significant correlation between an antiviral antibody response and clinical responses is not 
uncommon, and has been documented in several studies (Park et al. 2008; Harrop et al. 2006; 
Dummer et al. 2010).  Antibodies can be produced as early as 3-5 days post-infection with some 
viruses (Park et al. 2008; Liang et al. 1999), and levels rise over time and may or may not be 
detected depending on the virus and the method of antibody detection.  In addition, titers rise 
significantly after repeated exposure, which is why vaccine regimens against most viruses 
typically require booster inoculations.  The fact that an antiviral antibody response is not 
necessary in order to achieve a treatment benefit with oncolytic virotherapy lends support to the 
theory that it is the development of cell-mediated immune responses that may be important in 
tumor regression.   
 Intratumoral treatment with MYXV:IL15 was found to be safe, with no discernable 
deleterious effects to the mice and no statistically signficant decrease in survival time compared 
to mice treated with MYXV.  MYXV:IL15 treatment did result in a statistically significant 
increase in survival when compared to control mice, but not when compared to mice treated with 
MYXV that does not express IL-15.  Additionally, MYXV:IL15 treatment did not result in a 
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decreased rate of metastases compared to MYXV treated mice, nor was there a difference in the 
rate of formation of a humoral immune response to the virus.  
  Infection with MYXV:IL15 resulted in the production of IL-15 within the melanoma 
tumors as well as in cell culture, and IL-15 was able to be detected for a longer period of time in 
vivo (96 h, Figure 5.5B) than in vitro (24 h, Figure 5.5A).  This is presumed due to the ability of 
MYXV:IL15 to spread and infect adjacent cells within the tumor, while infection of cells in vitro 
is limited by the number of cells within the well, many of which were dead by 48 h (Figure 3.1 
and 3.7C).  Treatment with MYXV:IL15 resulted in a statistically significant increase in 
infiltrating lymphocytes in all areas of the tumors versus treatment with MYXV that does not 
express IL-15, as well as controls, which was one of the goals of this study.  However, 
expression of IL-15 and increased numbers of lymphocytes did not correlate with an increase in 
survival as was expected.  It may be that the level of IL-15 expressed was not sufficient to 
overcome tolerance to the tumor.  The presence of higher numbers of lymphocytes at earlier time 
points (48-96 HPI), with fewer present at 1 week PI and at survival time points suggests that the 
immune response was dampened over time.   
 Treatment with MYXV:IL15 did not result in statistically significant increases in CTL 
lymphocytes or NK cells in this model.  Similarly, there was not a significant increase in the 
numbers of helper T cells.  In fact, when the numbers of CD4+, CD8+, and GrB+ cells detected 
by IHC was compared to the number of CD3+ cells, there were much fewer CD4+, CD8+ and 
GrB+ cell than CD3+ cells.  This is likely due to the increased sensitivity of the CD3+ IHC, 
compared to the other IHC’s, which displayed much weaker fluorescence even when using much 
higher amounts of primary antibody.  It is possible that some CD4+ Tcells, CD8+ T cells, and 
NK cells that labeled weakly were not able to be differentiated.  MHCII labeled cells very well 
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but was detected in all tumors treated with either virus or control, with no statisitically significant 
differences.  While there was an increase in infiltrating neutrophils in mice treated with 
MYXV:IL15 over PBS treated tumors, the number of neutrophils was not increased over MYXV 
treated tumors, indicating that IL-15 expression does not recruit neutrophils, as expected.    
 In summary, multiple IT treatments with MYXV or MYXV:IL15 were able to provide a 
small but statistically significant increase in survival over control treated mice without the 
necessity of using immunosuppressants.  While IL-15 did not provide a survival advantage 
compared to MYXV treatment alone, it did result in a statistically significant increase in 
lymphocytes within the tumor and in the dermis surrounding the tumor.  Additional modification 
of treatment (e.g. co-expression of IL-15 receptor alpha, IL-12, or a tumor antigen) or of the 
tumor model (e.g. different tumor, daily injections) may provide a survival benefit.      
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Chapter 5 Tables and Figures 
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Figure 5.1.  Diagram of a B16-F10 subcutaneous tumor. Tumors occasionally infiltrated the 
deep muscle (B).  Tumors had a large central area of necrosis or multifocal to coalescing 
areas of necrosis (C).  When necrosis was multifocal, thick bands of viable neoplastic cells 
were typically remaining surrounding vessels (C).  Most tumors at the early stages were 
covered by dermis that was markedly thickened by edema (D), multifocally had a necrotic 
edge (E), and were surrounded by a rim of granulation tissue (F).  Some tumors were 
covered by an area of ulceration or an area of necrotic epithelium (G).     
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Figure 5.2.  Metastases and invasion.  Metastases were most commonly found in the 
renal lymph node (A, yellow arrow, and B). Adjacent skeletal muscle was commonly 
invaded with B16-F10 neoplastic cells (D), which could also be found in the 
surrounding lymphatic vessels (C).  Metastases in the lung ranged from grossly visible 
masses (E-F) to small micrometastases that were only visible with a light microscope 
(G-H).   Metastases in the lung most often surrounded a small vessel (G) or were along 
the pleural surface (F and H).  Neoplastic cells were also observed in the blood vessels 
(I).   
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Figure 5.3.  Subcutaneous B16-F10 Kaplan-Meier survival curves.  Mice were inoculated 
intratumorally with MYXV:Tomato, MYXV-IL15:Tomato, UV-MYXV, or PBS once their 
B16-F10 tumors reached ≥ 5 mm in diameter.  The day of virus inoculation was designated 
day 0, and mice were monitored daily until they reached a criterion of euthanasia.  A 
statistically significant increase in survival was present between the treated and control 
mice, but not between the MYXV:Tomato and MYXV-IL15:Tomato treated mice, or 
between the UV-MYXV or PBS treated mice.  
A 
B 
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Treatment Groups Log-rank P-value Gehan-Breslow-Wilcoxon P-value 
MYXV:IL15 vs. MYXV 0.6102 0.6826 
MYXV:IL15 vs. UV-MYXV 0.0382* 0.1136 
MYXV:IL15 vs. PBS 0.1209 0.0314* 
MYXV vs. UV-MYXV 0.0011* 0.0046* 
MYXV vs. PBS 0.0124* 0.0041* 
UV-MYXV vs. PBS 0.5396 0.2480 
Treated vs. Control 0.0028* 0.0008* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1.  Survival statistics.  Treatment groups were compared by log-rank and 
Gehan-Breslow-Wilcoxon tests.  * significant p-values less than 0.05 
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Figure 5.4.  Myxoma virus in tumors.  A) Sections of tumors were collected at 
various time points, homogenized, serially diluted, and plated on RK13s to 
determine pfu’s of virus per gram of tissue.  B and C) Tumors were analyzed by 
fluorescent microscopy for the presence of red fluorescence, which was 
considered indicative of the presence of MYXV:Tomato (or MYXV:IL15).  Red 
fluorescence was not observed in any UV-MYXV or PBS treated tumors.    
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Figure 5.4.  Myxoma virus in tumors, continued. 
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Figure 5.5.  IL-15 levels in B16-F10 cells and tumors.  B16-F10 cells (A) were 
infected with MYXV:IL15 and collected at 24, 48, and 96 HPI.  Tumors (B) 
inoculated IT with MYXV:IL15 were collected at euthanasia (24h, 48h, 96h, or 
1 w after inoculation or at survival).  IL-15 levels were detected by ELISA.  
Positive control consisted of adding 62.5 pg of IL-15 standard to lysates from a 
1 week PI treated tumor. 
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Figure 5.6.  Average grade of subcutaneous tumor necrosis.  The amount of 
tumor necrosis as graded histologically did not differ significantly between 
treatment groups.   
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Figure 5.7.  Lymphocytes surrounding and within subcutaneous melanoma tumors.  A few 
scattered lymphocytes surrounded most tumors regardless of treatment, but were more 
prevalent in virally treated tumors and at early time points.  Lymphocytes often surrounded 
vessels, and were more prevalent in MYXV:IL15 treated tumors and at early time points. 
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Lymphocyte MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum Surr Tum Surr Tum Surr Tum 
24 hours 0.50 
±0.34 
0.17 
±0.17 
0.33 
±0.33 
0.00 
±0.00 
0.00 
±0.00 
0.50 
±0.50 
0.14 
±0.14 
0.00 
±0.00 
48 hours 1.67 
±0.49 
0.83 
±0.65 
0.17 
±0.17 
0.17 
±0.17 
0.14 
±0.14 
0.00 
±0.00 
0.71 
±0.57 
0.00 
±0.00 
96 hours 1.67 
±0.49 
2.00 
±0.68 
0.83 
±0.17 
0.17 
±0.17 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
1 week 0.67 
±0.49 
0.83 
±0.54 
1.14 
±0.40 
1.00 
±0.38 
0.17 
±0.17 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
Survival 0.50 
±0.34 
0.00 
±0.00 
0.18 
±0.12 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.08 
±0.08 
0.00 
±0.00 
 
 
 
 
 
 
 
CD3 MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum TDJ Surr Tum TDJ Surr Tum TDJ Surr Tum TDJ 
24 hours 5.33 
±2.91 
7.00 
±4.36 
16.00 
±13.58 
4.00 
±4.00 
1.33 
±1.33 
3.00 
±3.00 
1.67 
±0.67 
7.67 
±5.36 
12.33 
±12.33 
2.67 
±2.67 
8.33 
±4.41 
7.00 
±7.00 
48 hours 71.33 
±64.34 
32.67 
±24.91 
66.67 
±66.67 
3.33 
±1.76 
14.33 
±6.53 
37.00 
±17.20 
0.00 
±0.00 
5.33 
±5.33 
22.67 
±13.92 
0.00 
±0.00 
0.00 
±0.00 
22.33 
±12.85 
96 hours 38.67 
±21.98 
12.33 
±7.84 
23.33 
±6.01 
10.00 
±6.43 
6.00 
±3.46 
6.00 
±6.00 
1.67 
±0.67 
3.33 
±2.40 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
1 week 0.00 
±0.00 
4.00 
±4.00 
1.33 
±1.33 
0.00 
±0.00 
38.20 
±14.45 
0.00 
±0.00 
0.00 
±0.00 
14.00 
±7.81 
1.33 
±1.33 
0.00 
±0.00 
0.00 
±0.00 
16.00 
±16.00 
Survival 0.00 
±0.00 
2.00 
±2.00 
1.67 
±1.67 
0.00 
±0.00 
16.33 
±16.33 
0.00 
±0.00 
0.00 
±0.00 
0.67 
±0.67 
0.33 
±0.33 
1.00 
±1.00 
0.00 
±0.00 
0.00 
±0.00 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2.  Average lymphocyte grades.   
Table 5.3.  Average numbers of CD3 positive cells.   
 
Surr = tissue surrounding the tumor, Tum = tumor.  ± standard error of the mean 
Surr = tissue surrounding the tumor, Tum = tumor, TDJ = tumor dermis junction.  ± 
standard error of the mean 
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CD8 MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum Surr Tum Surr Tum Surr Tum 
24 hours 0.00 
±0.00 
4.33 
±2.60 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
48 hours 0.00 
±0.00 
4.67 
±4.67 
0.00 
±0.00 
0.00 
±0.00 
1.33 
±1.33 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
96 hours 0.00 
±0.00 
6.67 
±6.67 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
1 week 0.00 
±0.00 
17.33 
±17.33 
0.00 
±0.00 
3.40 
±2.14 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
5.00 
±5.00 
Survival 0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
9.00 
±9.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.67 
±0.67 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4 MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum Surr Tum Surr Tum Surr Tum 
24 hours 0.00 
±0.00 
7.00 
±7.00 
0.00 
±0.00 
0.00 
±0.00 
1.33 
±1.33 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
48 hours 1.33 
±1.33 
0.00 
±0.00 
0.00 
±0.00 
13.25 
±10.75 
0.00 
±0.00 
2.67 
±2.67 
0.00 
±0.00 
0.00 
±0.00 
96 hours 0.00 
±0.00 
1.33 
±1.33 
4.00 
±4.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
1 week 0.00 
±0.00 
4.67 
±4.67 
0.00 
±0.00 
0.80 
±0.80 
1.33 
±1.33 
0.00 
±0.00 
0.00 
±0.00 
2.00 
±2.00 
Survival 0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
14.00 
±14.00 
Table 5.4.  Average numbers of CD4 positive cells.   
 
Table 5.5.  Average numbers of CD8 positive cells.   
 
 
 
 
Surr = tissue surrounding the tumor, Tum = tumor.  ± standard error of the mean 
 
Surr = tissue surrounding the tumor, Tum = tumor.  ± standard error of the mean 
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CD8 MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum/n Surr Tum/n Surr Tum/n Surr Tum/n 
24 hours 4.67 
±2.40 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
48 hours 2.00 
±2.00 
0.00 
±0.00 
0.00 
±0.00 
2.50 
±2.50 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
96 hours 0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
1 week 0.00 
±0.00 
24.33 
±24.33 
0.00 
±0.00 
1.40 
±1.17 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
Survival 0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
 
 
 
 
 
 
MHCII MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum Tnec Surr Tum Tnec Surr Tum Tnec Surr Tum Tnec 
24 h 30.33 
±2.96 
3.33 
±3.33 
138.00 
±62.00 
12.33 
±6.49 
11.00 
±9.54 
133.33 
±66.67 
29.00 
±3.79 
0.67 
±0.67 
81.67 
±59.23 
21.67 
±7.22 
16.67 
±8.17 
70.67 
±64.76 
48 h 17.00 
±5.00 
0.00 
±0.00 
76.33 
±62.40 
13.50 
±9.43 
100.00 
±57.74 
5.00 
±2.20 
15.00 
±11.68 
18.33 
±4.48 
31.33 
±31.33 
5.67 
±2.96 
2.00 
±2.00 
49.00 
±15.78 
96 h 15.33 
±8.19 
66.67 
±66.67 
4.00 
±2.00 
24.33 
±7.54 
0.00 
±0.00 
98.67 
±55.21 
22.33 
±4.98 
12.33 
±11.35 
79.67 
±37.30 
5.67 
±4.25 
0.00 
±0.00 
9.00 
±4.58 
1 w 2.67 
±2.67 
10.00 
±10.00 
18.33 
±14.08 
19.00 
±16.61 
45.20 
±39.03 
81.40 
±48.43 
12.67 
±2.19 
16.00 
±16.00 
67.33 
±24.88 
11.67 
±11.67 
7.00 
±7.00 
16.67 
±0.88 
Surv 7.67 
±7.67 
31.33 
±15.33 
4.33 
±4.33 
1.33 
±1.33 
0.00 
±0.00 
67.67 
±17.37 
1.00 
±1.00 
7.33 
±4.67 
38.33 
±22.84 
0.00 
±0.00 
17.00 
±11.15 
18.00 
±10.12 
 
 
 
 
 
 
 
 
 
 
Table 5.7.  Average numbers of MHCII positive cells.   
Surr = tissue surrounding the tumor, Tum = tumor, TDJ = tumor dermis junction.  ± 
standard error of the mean 
 
 
Surr = tissue surrounding the tumor, Tum/n = tumor including areas 
of necrosis.  ± standard error of the mean 
 
Table 5.6.  Average numbers of GrB positive cells.   
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MYXV:IL15 MYXV UV-MYXV PBS 
24 hours 
48 hours 
96 hours 
1 week 
Survival 
Figure 5.8.  Neutrophils surrounding and within subcutaneous melanoma tumors. 
Neutrophils were most numerous in areas of necrosis in tumors treated with MYXV.  
Neutrophils were most typically associated with ulceration and crusts in PBS mice.  Small 
numbers of neutrophils were surrounding tumors or in areas of necrosis in most mice.   
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Neuts MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum Tnec Ulc Surr Tum Tnec Ulc Surr Tum Tnec Ulc Surr Tum Tnec Ulc 
24 h 2.33 
±0.21 
0.83 
±0.54 
2.33 
±0.80 
1.33 
±0.84 
1.67 
±0.21 
0.67 
±0.49 
2.67 
±0.72 
0.50 
±0.50 
2.50 
±0.50 
0.50 
±0.34 
1.83 
±0.70 
0.00 
±0.00 
1.71 
±0.42 
0.14 
±0.14 
0.00 
±0.00 
0.00 
±0.00 
48 h 2.17 
±0.31 
0.67 
±0.49 
2.50 
±0.81 
0.67 
±0.67 
3.17 
±0.17 
1.83 
±0.60 
3.50 
±0.22 
0.00 
±0.00 
1.71 
±0.36 
0.29 
±0.18 
0.71 
±0.56 
1.14 
±0.74 
1.57 
±0.53 
0.00 
±0.00 
0.71 
±0.42 
1.00 
±0.65 
96 h 1.17 
±0.48 
0.67 
±0.49 
2.00 
±0.89 
0.00 
±0.00 
2.17 
±0.40 
0.17 
±0.17 
2.50 
±0.62 
0.67 
±0.67 
1.33 
±0.33 
0.17 
±0.17 
1.00 
±0.63 
0.50 
±0.50 
1.20 
±0.73 
0.00 
±0.00 
0.00 
±0.00 
3.20 
±0.80 
1 w 2.33 
±0.49 
0.50 
±0.50 
0.67 
±0.49 
0.67 
±0.67 
3.00 
±0.31 
0.86 
±0.46 
1.57 
±0.53 
0.00 
±0.00 
3.00 
±0.45 
0.50 
±0.34 
1.33 
±0.71 
0.00 
±0.00 
1.67 
±0.61 
0.00 
±0.00 
1.83 
±0.83 
0.00 
±0.00 
Surv 1.83 
±0.37 
0.00 
±0.00 
2.17 
±0.51 
0.58 
±0.40 
0.82 
±0.35 
0.00 
±0.00 
1.64 
±0.59 
1.09 
±0.56 
1.17 
±0.42 
0.00 
±0.00 
0.83 
±0.37 
1.00 
±0.52 
0.67 
±0.33 
0.00 
±0.00 
0.25 
±0.25 
1.67 
±0.59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.8.  Average neutrophil grades.   
Surr = tissue surrounding the tumor, Tum = tumor, Tnec = areas of necrosis within the 
tumor, Ulc = ulcerated area.  ± standard error of the mean 
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Gr-1 MYXV:IL15 MYXV UV-MYXV PBS 
 Surr Tum Tnec Surr Tum Tnec Surr Tum Tnec Surr Tum Tnec 
24 h 13.67 
±10.81 
0.00 
±0.00 
71.67 
±64.20 
4.33 
±4.33 
0.00 
±0.00 
133.33 
±66.67 
1.67 
±1.67 
0.00 
±0.00 
6.33 
±4.48 
11.00 
±6.08 
0.00 
±0.00 
0.00 
±0.00 
48 h 0.00 
±0.00 
0.00 
±0.00 
66.67 
±66.67 
35.00 
±35.00 
50.00 
±50.00 
53.75 
±48.88 
1.67 
±1.67 
1.33 
±1.33 
6.33 
±6.33 
0.00 
±0.00 
0.00 
±0.00 
16.67 
±8.96 
96 h 2.00 
±2.00 
4.00 
±4.00 
133.33 
±66.67 
8.67 
±4.33 
0.00 
±0.00 
133.33 
±66.67 
6.67 
±2.67 
5.00 
±5.00 
80.00 
±60.80 
0.00 
±0.00 
0.00 
±0.00 
0.00 
±0.00 
1 w 0.00 
±0.00 
0.00 
±0.00 
4.67 
±2.40 
3.20 
±3.20 
1.00 
±0.80 
133.33 
±39.34 
11.00 
±4.16 
3.67 
±3.67   
85.00 
±57.82 
0.00 
±0.00 
0.00 
±0.00 
66.67 
±66.67 
Surv 12.00 
±12.00 
0.00 
±0.00 
78.33 
±61.67 
0.00 
±0.00 
24.33 
±24.33 
66.67 
±66.67 
2.67 
±2.67 
1.33 
±1.33 
3.67 
±1.86 
0.00 
±0.00 
12.00 
±12.00 
0.00 
±0.00 
 
 
 
 
 
Table 5.9.  Average numbers of Gr-1 positive cells.  
 
Surr = tissue surrounding the tumor, Tum = tumor, Tnec = areas of necrosis within the 
tumor.  ± standard error of the mean 
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Figure 5.9.  Plaque reduction neutralization titer 50%.  Some mice treated 
with either live MYXV (MYXV, MYXV:IL15) or dead MYXV (UV-
MYXV) developed a neutralizing antibody response to MYXV.   
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CHAPTER 6 
CONCLUSIONS 
 
 Oncolytic viruses are multi-modal therapeutics that cause tumor-specific necrosis and a 
local immune response, which ideally may target the neoplastic cells in addition to the virus.  
They can also be armed to act as vehicles to deliver any number of targeted combinations to the 
tumor by inserting one or more genes that encode inflammatory cytokines, antiangiogenic 
factors, proteases, costimulatory molecules, tumor antigens, or prodrugs.  We evaluated MYXV 
for its ability to infect murine tumor cell lines, and for safety and effectiveness in a brain tumor 
model and a subcutaneous tumor model.  In addition, we evaluated MYXV that expressed the 
gene for murine IL-15 in order to determine if the cellular immune response could be enhanced 
and survival subsequently increased.  We chose MYXV for the oncolytic virus in this series of 
experiments for its many beneficial attributes, which include safety, rapid replication, and a large 
maniputable genome.  Immunocompetant mice were utilized, as was a murine tumor cell line and 
murine IL-15, in order to best evaluate the immune response without potential complications 
from xenobiotics.  Notably, we performed a detailed histological analysis of the tumor during 
treatment and documented the immune cell response, which to our knowledge is the first time 
this has been reported following MYXV oncolytic treatment.   
 Susceptibility of tumor cell lines to viral replication and necrosis after infection with 
MYXV in vitro was initially evaluated in order to determine which cell lines would be most 
successful when used in an in vivo model.  We then evaluated histology and survival in mice 
with glioma, lymphoma, or melanoma brain tumors that were treated with MYXV versus control 
treatment (UV-MYXV or PBS).  However, the brain tumor model revealed a problem with 
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increased immunogenicity in the glioma cell lines.  Additionally, the rapid growth of the 
melanoma cells resulted in rapid death due to neurological compromise, which made evaluation 
of survival time difficult.  Also, the rapid growth of the melanoma cells results in rapid 
repopulation of the tumor cells after MYXV treatment.  This made switching to a subcutaneous 
model that could be treated repeatedly imperative when using this tumor model.  Additional 
attributes of tumor cell lines, may also affect the success of an in vivo model include the presence 
of TAAs, the ability of the cells to express cytokines after viral infection, predilection to invade 
and metastasize early, ability to suppress immune responses, and ability to initiate angiogenesis.
 In both the brain tumor model and the subcutaneous tumor model, neutrophils were 
observed to infiltrate the tumors the tumors and surrounding area in the first 48 hours after IT 
injection of MYXV.  In the brain tumor model, initial experiments indicated that both live and 
UV-inactivated MYXV induced a neutrophilic response at the site of injection within B16.SIY 
tumors in mice (Figure 4.1).  Neutrophil infiltration is not unexpected, since neutrophils are one 
of the first cell types recruited to sites of infection (Nathan 2006).  In our experiment, infiltration 
was likely due to an initial innate immune response against the physical virus.  Histological 
analysis of the number of infiltrating neutrophils in the subcutaneous model revealed a 
statistically significant increase in mice treated with MYXV or MYXV:IL15 vs. PBS control 
mice in all areas, but not a difference in the number of neutrophils between MYXV and 
MYXV:IL15.  This suggests that neutrophils infiltrate as a response to the presence of virus and 
that the expression of IL-15 does not play a significant role in the recruitment of neutrophils.  
Indeed, it is IL-8, IL-17, and GMCSF, rather than IL-15 that have been found to be associated 
with neutrophil responses.  At higher doses of IL-15, it may be possible for IL-15 to indirectly 
affect neutrophils through the release of GM-CSF from stimulated NK cells.      
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 An influx of neutrophils has been documented in other studies using oncolytic viruses 
(Best, Collins, and Kerr 2000; Fu et al. 2011; Grote, Cattaneo, and Fielding 2003; Breitbach et 
al. 2007).  In rabbits, a neutrophilic response to virus has been documented to occur in rabbits 
susceptible to MYXV infection, while rabbits that are resistant to infection respond with a 
monocytic infiltrate (Best, Collins, and Kerr 2000).  This suggests that the inability to adequately 
respond to a virus can result in a neutrophilic rather than a monocytic inflammatory response.  
Since interferons and other cytokines are often not induced in these situations, T lymphocytes 
and NK cells are not recruited to the area.  Production of IL-15 in vitro and in vivo after 
MYXV:IL15 infection was confirmed; and as expected, there was not a significant difference in 
the number of neutrophils observed histologically in MYXV:IL15 treated tumors compared to 
MYXV treated tumors, but there was an increased number of lymphocytes suggesting that IL-15 
is associated with increased infiltration of lymphocytes, but not of neutrophils, as would be 
expected.         
 Most of the survival mice treated with MYXV developed an antiviral antibody response; 
however, there was not see a correlation between an antiviral antibody response and survival.  
This has been documented in other cases.  In a study using VACV that encoded a tumor antigen 
(5T4), antibody response to the tumor antigen correlated with an increase in survival, but an 
antibody response to VACV did not correlate with increased survival (Harrop et al. 2006).  
While an antiviral cellular and antibody response typically developed after the first treatment, a 
5T4-specific (tumor targeting) immune response usually only occurred following 2-3 treatments 
(Harrop et al. 2006).  This suggests that repeated exposure is required to overcome the tolerance 
to this tumor (self) antigen.  In addition, immune responses were relatively short-lived, indicating 
that repeated boosters are likely needed for a successful antitumor treatment.  For future 
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experiments using MYXV, increasing the number of boosters by giving injections more 
frequently, combined with engineering MYXV to express a tumor antigen, would likely produce 
a significant increase in treatment efficacy by promoting an antitumor response.   
 The absence of “danger signals”, such as inflammatory cytokines, and the lack of cellular 
and molecular T cell activation have been considered the main causes of poor tumor immunity 
(Matzinger 2002; Fuchs and Matzinger 1996).  Immunotherapy, which stimulates the immune 
system in an attempt to overcome tolerance to tumor cells, has already become a state of the art 
treatment for some cancers.  Superficial bladder cancer is currently treated with BCG (bacillus 
Calmette-Guerin), which creates an acute local inflammatory response (Herr and Morales 2008).  
Similarly, interleukin-2 (which stimulates T cells) is approved for the treatment of renal 
carcinoma and melanoma, (Eklund and Kuzel 2004; Dillman 2011) despite its serious side 
effects at high doses (Eklund and Kuzel 2004; Eisner, Husain, and Clark 2004).  Oncolytic 
viruses have the potential to act as immunotherapeutics by causing a severe acute inflammatory 
response (danger signals) in the tumor microenvironment.  Combined with lysis of the cells, 
which should result in the release of tumor antigens, oncolytic viruses have the potential to 
stimulate the immune system to mount an immune response to the tumor itself, through cross-
presentation of antigens.  This can be greatly enhanced if the virus has been engineered to 
express the tumor antigen, as has been shown in other studies (Harrop et al. 2006).  In addition, 
viruses can be engineered to express genes that enhance immunity, such as IL-2 or IL-15.  For 
example, a herpesvirus which contains the coding sequence for GM-CSF resulted in regression 
not only of injected tumors but also of distant metastases, consistent with an antitumor immune 
response (Senzer et al. 2009).  Analysis revealed a significant decrease in immunosuppressive 
cell types (Park et al. 2008).  Similarly, an adenovirus encoding IFN-γ had regression of 
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noninjected lesions in 27% of patients (Dummer et al. 2010).   
 The results of our study indicate that oncolytic viral expression of IL-15 delivered 
intratumorally is safe and is effective at increasing the number of lymphocytes infiltrating the 
tumor.  Delivery of the gene for IL-15 directly into the tumor via a virus has the benefit of 
providing continuous production of IL-15 every time the virus replicates, which is important for 
effective treatment since cytokines have a short half-life.  However, while viral production of IL-
15 results in higher levels of IL-15 within the tumor for a longer period of time, boostering of the 
virus is necessary since viral titer eventually decreases (between 4 and 7 days post-infection in 
our experiment, Figure 5.4).  Boostering the tumors with virus more often, perhaps every 2 days, 
or with higher concentration of virus, would result in even higher levels of IL-15 within the 
tumor, which could result in a more dramatic infiltration of leukocytes.  Additionally, the IL-15 
could be placed under a stronger promoter which could result in higher levels of secretion of IL-
15.  This has been done in another study that used vesicular stomatitis virus, and IL-15 levels 
were detected that were many times the levels detected in this experiment (Stephenson, et al. 
2012).   
 Our finding that expression of IL-15 by MYXV correlated with increased infiltrating 
lymphocytes histologically is important as increased numbers of infiltrating leukocytes has been 
correlated with improved clinical outcome in some tumors (Pagès et al. 2009).  While increased 
survival was not observed in mice treated with MYXV:IL15 over mice treated with MYXV 
alone, treatment of a less aggressive tumor, or combination with another therapeutic 
(chemotherapy), or adding another gene to MYXV:IL15 (such as IL-15Rα, IL-12, or GM-CSF) 
could potentially result in improved efficacy and increased survival.  
 In tumors injected with either MYXV or MYXV:IL15, levels of virus were detected that 
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were higher than the initial input dose (1 × 106 pfu), indicating viral replication.  This was 
especially evident in tumors during the 96 hours after injection, with lower levels detected 
thereafter.  Detection of viral titer within the tumor that is higher than the input dose has been 
documented in several studies using oncolytic virues and is considered to be evidence of 
productive viral infection of the cancer cells (Harrington et al. 2010a; Nemunaitis et al. 2010).  
While the viral dose is not always correlated with improved therapeutic results, in general, the 
more virus within the tumor, whether due to initial dose, viral replication, or repeated dosing, the 
better the clinical results.  For example, in a study with HSV, 100% of patients treated with the 
lowest dose (3 x 10^6) showed steady progression of their cancer, while those treated at higher 
doses (3 x 10^7 and 1 x 10^8) showed disease stabilization (75% and 100%, respectively) 
(Geevarghese et al. 2010).  In our experiment, replication of the virus was also important for the 
continued production of IL-15 that could act locally within the tumor.  In future experiments, it 
would likely be beneficial to give injections that contain a much higher concentration of virus, 
and to booster the injections more often.      
 While there are many oncolytic viruses currently or recently in clinical trials (Appendix 
B), virotherapy is typically used as an experimental last resort treatment in patients that have 
received multiple rounds of treatment and have become refractory (Park et al. 2008; Geevarghese 
et al. 2010; Nokisalmi et al. 2010; Galanis et al. 2010; Pecora et al. 2002).  Therefore, any 
improvement in the clinical course that occurs after oncolytic virotherapy is significant, but is 
also much less likely to occur.  Due to the limited responses obtained thus far, oncolytic viruses 
are increasingly being tested as a component of combination therapy.  Oncolytic viral treatment 
has been repeatedly shown to be safe, with minimal side effects, and can be combined with other 
commonly used cancer treatments without decreasing their efficacy.  In cases where oncolytic 
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virotherapy has been used in previously untreated cancers, better responses are typically 
observed, especially if given with concurrent chemotherapy and radiotherapy (Harrington et al. 
2010a).  Due to the complexities of tumor biology and the heterogeneity of tumors, it is unlikely 
that one kind of virus or one targeting strategy will be sufficient to treat tumor types.  Similar to 
chemotherapy, there is a wide range of oncolytic viruses (Appendix B) that can be utilized for 
treatment of different types of cancer, and each may deliver one or more cytokines, chemokines, 
costimulatory molecules, tumor antigens, or prodrugs to the tumor.  Analyzing patients for 
clinical biomarkers and their tumors for mutations could help select the most appropriate 
treatment regimen for each individual patient.   Even if these therapies do not provide a cure for 
cancer, in advanced terminal cancers, treatments that result in modest increases in survival (1-2 
months) are considered useful as long as they do not significantly decrease quality of life.   
 These experiments demonstrated that MYXV and MYXV:IL15 are safe and result in 
significantly increased survival, and are therefore suitable for further study as oncolytic viruses.  
MYXV:IL15 also resulted in the local production of IL-15, which resulted in increased numbers 
of leukocytes within and surrounding the tumor.  Despite the lack of improved survival with 
MYXV:IL15 over MYXV without IL-15, there was also not a significant decrease in survival, 
which is essential to consider, since immunotherapy combined with virotherapy always has the 
potential to target the virus and clear it early, negating the virus’ oncolytic effects.  Additional 
manipulation of the virus to express other cytokines or tumor antigens, use in a different model, 
or administration of higher levels of virus and/or more frequent dosing may greatly improve 
results with this viral therapy.      
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APPENDIX A: 
 
ABBREVIATIONS AND ACRONYMS 
 
 
Ab:  antibody 
Ad:  Adenovirus 
Ag:  antigen 
Akt:  a serine/threonine protein kinase also called protein kinase B 
APC:  antigen-presenting cells 
B16-F10:  murine melanoma cell line 
B16.SIY:  B16-F10 cell line that expresses the SIY peptide and GFP protein 
C57BL/6:  immunocompetent strain of mice 
CEA:  carcinoembryonic antigen  
CEV:  cell-associated enveloped virus 
CNS:  central nervous system 
COX2:  cyclooxygenase-2 
CPE:  cytopathic effect 
CR:  complete response 
CRAd:  conditionally-replicative adenovirus 
CRC:  colorectal carcinoma 
CTL:  cytotoxic T lymphocytes 
d:  day 
DC:  dendritic cells 
DLT:  dose-limiting toxicity 
DNA:  deoxyribonucleic acid 
DP1:  EL4 cell line that expresses the SIY peptide and GFP protein 
EEV:  extracellular enveloped virus 
EL4:  murine thymic lymphoma cell line 
ELISA:  enzyme-linked immunosorbent assay 
EM:  electron microscopy 
ERK1/2:  extracellular signal-regulated kinase 
FITC:  fluorescein isothiocyanate 
FBS:  fetal bovine serum 
GBM:  glioblastoma multiforme 
GFP:  green fluorescent protein 
GL261:  murine glioma cell line 
GLSIY:  GL261 cell line that expresses the SIY peptide and GFP protein 
GM-CSF:  granulocyte macrophage colony stimulating factor 
Gy:  Gray, the international unit of absorbed radiation dose (1 joule of ionizing radiation 
absorbed by 1 kilogram of matter) 
h:  hour 
HBSS:  Hanks balanced salt solution 
HNC:  head and neck cancer 
HPI:  hours post-infection 
HSV:  Herpesvirus 
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ID:  intradermal 
IFN:  interferon 
IHC:  immunohistochemistry 
IL-12:  interleukin 12 
IL-15:  interleukin 15 
IM:  intramuscular 
IMV:  intracellular mature virus 
Inj:  injection 
IP:  intraperitoneal 
ISG:  interferon-stimulated genes 
IT:  intratumoral 
IV:  intravenous 
kb:  kilobases 
MEM:  Eagle’s minimum essential medium  
ml:  milliliter  
min:  minute 
MIP-1α:  macrophage inflammatory protein-1α  
MIP-1β:  macrophage inflammatory protein-1β 
MOI:  multiplicity of infection 
MTD:  maximum tolerated dose 
mTOR:  mammalian target of rapamycin 
MV:  Measles virus 
MYXV:  Myxoma virus, a rabbit poxvirus 
MYXV:GFP:  recombinant MYXV expressing green fluorescent protein 
MYXV:IL15:  recombinant MYXV expressing red tomato fluorescent protein and IL-15 
MYXV:RFP:  recombinant MYXV expressing red fluorescent protein 
MYXV:Tomato:  recombinant MYXV expressing red tomato fluorescent protein 
MV:  Measles virus, a paramyxovirus 
NDV:  Newcastle disease virus, a paramyxovirus 
NK:  natural killer cells 
nm:  nanometer 
ORR:  objective response rate 
PAMPs:  pathogen-associated molecular patterns 
PBS:  phosphate buffered saline 
PFU:  plaque-forming units 
PGE2:  prostaglandin E2 
PI:  post-infection 
PMV:  Paramyxovirus 
PR:  partial response 
PRNT:  plaque-reduction neutralization test 
PTI:  post-tumor inoculation 
PV:  Picornavirus 
q:  every (typically used in dosing) 
RANTES:  regulated upon activation, normal T cell-expressed and secreted 
RCC:  renal cell carcinoma 
RNA:  ribonucleic acid 
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RT:  room temperature 
RT3D:  Reovirus type 3 Dearing (also Reolysin) 
SCC:  squamous cell carcinoma 
SCCHN:  squamous cell carcinoma of the head and neck 
SD:  stable disease 
SQ:  subcutaneous (also SC) 
SVV:  Seneca valley virus, a picornavirus 
sx:  surgery 
TAAs:  tumor-associated antigens 
TBS/T:  1× Tris Buffered Saline with 0.1% Tween-20 
TGF-β:  transforming growth factor-β 
TNF:  tumor necrosis factor 
TNTC: too numerous to count 
tx:  treatment 
µl:  microliter 
UV-MYXV:  Myxoma virus (MYXV:Tomato) that has been UV-inactivated 
VACV:  Vaccinia virus, the virus used to vaccinate against smallpox 
VARV:  Variola virus, the causative agent of smallpox 
VEGF:  vascular endothelial growth factor 
w:  week 
XRT:  radiation therapy  
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APPENDIX B: 
 
RECENT ONCOLYTIC VIRUS CLINICAL TRIALS IN HUMAN CANCER PATIENTS 
 
Viral Agent Tumor Ph-
ase 
Injection Additional 
treatments 
Response Comments 
ADVEXIN 
(replication-
deficient Ad 
containing p53 
cDNA  (Wolf et 
al. 2004) 
Epithelial 
ovarian 
cancer 
 
Refractory 
I IP daily × 
5d, q 3w 
None 0% CR 
0% PR 
55% SD 
No DLT 
Ad5-∆24-RGD 
(CRAd)  
(Kimball et al. 
2010) 
Malignant 
gynecologic 
cancer 
I IP, daily × 
3 
None 0% CR 
0% PR 
71% SD 
No DLT, 100% 
developed antiviral 
Abs 
H101 (CRAd)  
(Xia et al. 2004) 
SCCHN III IT daily × 
5d, q 3w 
Cisplatin + 
5-FU (PF) 
or 
Adriamycin 
+ 5-FU (AF) 
PF + H101= 
78% ORR, 
PF alone = 
40% ORR, 
AF +/- 
H101 = 
50% ORR 
 
ICOVIR-7 (Ad) 
(Nokisalmi et al. 
2010) 
Solid 
tumors 
Refractory 
I IT Cyclophos-
phamide 
0% CR 
6% PR 
24% SD 
No DLT 
Virus detected in 
blood (86%) 
KH901 (CRAd + 
GM-CSF) 
(Chang et al. 
2009) 
HNC I IT None Not 
evaluated 
No DLT  
GM-CSF in blood 
12 HPI, increased 
Ab titer 
ONYX-015 
(CRAd)  (Vasey 
et al. 2002) 
Epithelial 
ovarian 
cancer 
I IP, daily × 
5d 
None 0% CR 
0% PR 
0% SD 
Dose-limiting 
toxicity, viral DNA 
in blood 
ONYX-015 
(CRAd)  
(Mulvihill et al. 
2001) 
Pancreatic 
cancer 
I IT q 4w None 0% CR 
0% PR 
0% SD 
No DLT, no viral 
replication 
ONYX-015 
(CRAd)  (Ganly 
et al. 2000) 
HNC 
recurrent 
I IT None 0% CR 
0% PR 
0% SD 
No DLT 
ONYX-015 
(CRAd)  
(Nemunaitis et 
al. 2007) 
Advanced 
solid tumors 
I IV weekly 
up to 4 
doses 
Enbrel 0% CR 
0% PR 
44% SD 
No DLT, no adverse 
effects with drug 
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ONYX-015 
(CRAd)  
(Galanis et al. 
2005) 
Advanced 
sarcomas 
I/II IT daily × 
5d, q 
month 
Mitomycin-
C, 
doxorubicin, 
cisplatin 
17% CR 
0% PR 
67% SD 
No DLT, viral 
replication 
ONYX-015 
(CRAd)  (Khuri 
et al. 2000) 
SCCHN II IT daily × 
5d, q 3w 
Cis-
platinum,  
5-FU 
27% CR 
36% PR 
Grade 3 and 4 
toxicities. No 
correlation between 
Ab’s and tx results 
Telomelysin 
(Ad-TERT) 
(Nemunaitis et 
al. 2010)  
 
Solid 
tumors 
I IT None 0% CR 
6% PR 
25% SD 
No DLT 
Viral replication 
           TG1042 (Ad-
IFNγ) (Dummer 
et al. 2010) 
Cutaneous 
Lymphoma 
II IT None Local:   
20% CR 
33% PR 
27% SD 
Global:  
20% CR 
7% PR 
53% SD 
Tumor and antiviral 
Abs produced, not 
correlated with 
response 
G207 (HSV)  
(Markert et al. 
2000) 
Malignant 
glioma 
I IT 1-5 
doses 
Reccurence 
post-sx and 
post-XRT 
None 0% CR 
0% PR 
40% SD 
No DLT 
Not all patients 
seroconverted 
G207 (HSV)  
(Markert et al. 
2009) 
GBM 
Recurrent 
Ib IT pre-sx 
IC post-sx 
None 0% CR 
0% PR 
No DLT 
HF10 (HSV) 
(Nakao et al. 
2011) 
Pancreatic 
cancer  
Un-
resectable 
I IT at sx, IT 
by catheter 
daily × 2d 
None 0% CR 
17% PR 
50% SD 
No DLT 
Blood NK cells 
increased after 
injection 
OncoVEXGM-CSF 
(HSV+GM-CSF) 
(Hu et al. 2006) 
Various 
cancers 
I IT, 1-3 tx None 0% CR 
0% PR 
12% SD 
Local reaction was 
dose-limiting in 
sero-negative 
patients 
OncoVEXGM-CSF 
 (HSV+GM-
CSF)  
(Harrington et al. 
2010a)  
Stage III/IV 
SCCHN 
Untreated 
I/II IT  on days 
1, 22, 43 
and 64 
XRT and 
cisplatin 
24% CR 
59% PR 
No DLT, Viral 
replication 
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OncoVEXGM-CSF 
 (HSV-GMCSF) 
(Senzer et al. 
2009) 
Melanoma 
Un-
resectable 
II IT, 
repeated in 
3w, then q 
2w up to 
24 tx 
None 16% CR 
10% PR 
20% SD 
No DLT 
Regression of 
injected and distant 
lesions 
Doubled 1 year 
survival rate 
NV1020 
(attenuated 
HSV)  
(Geevarghese et 
al. 2010) 
CRC 
metastatic 
to liver 
Refractory 
I/II In hepatic 
artery, 
weekly × 4 
Chemo-
therapy after 
tx  
50% SD 
after virus 
tx 
5% PR and 
64% SD 
after chemo 
Mild toxicity, no 
DLT, 
No viral shedding 
PV701 (PMV)  
(Pecora et al. 
2002) 
Advanced 
solid 
cancers 
Refractory 
I IV, various 
tx 
regimens 
None 
Heavily pre-
tx 
2% CR 
2% PR 
19% SD 
Grade 1-4 toxicities, 
viral shedding  
MV-CEA 
(PMV)  (Galanis 
et al. 2010) 
Recurrent 
ovarian 
cancer 
(refractory) 
I IP q 4w up 
to 6 tx 
None 
Pre-tx 
0% CR 
0%PR 
67% SD 
No DLT, no 
increased antiviral 
Ab’s 
SVV-001 (PV)  
(Rudin et al. 
2011) 
Advanced 
solid tumor  
with Neuro-
endocrine 
features 
I IV one 
dose 
None 0% CR 
0% PR 
3% SD 
No DLT, viral 
clearance correlated 
with antiviral Ab’s 
RT3D=Reolysin 
(Reovirus)  
(Harrington et al. 
2010b) 
Advanced  
solid 
cancers 
I 2 IT inj  
then  2-6 
IT inj 
Concurrent 
XRT 
Low-dose 
XRT:  29% 
PR 71% SD 
High-dose 
XRT: 71% 
PR 29% SD 
No DLT, no viral 
shedding, no 
exacerbation of 
radiation reaction 
Trovax 
(VACV+5T4)  
(Harrop et al. 
2006) 
CRC I/II IM or ID  
at 0,4, 8w, 
+/- 14, 20 
w 
None 29% CR Increased survival 
with Ab response to 
TAA but not virus 
Trovax (VACV 
+ 5T4)  
(Kaufman et al. 
2009) 
RCC II IM q 3w × 
3 
IL-2 0% CR 
0% PR 
48% SD 
Significant increase 
in CD8+ T cells in 
patients with SD  
Trovax (VACV 
+ 5T4)  (Amato 
et al. 2010) 
RCC III IM at 
weeks 
1,3,6,9,13, 
17 21, 25, 
33, 41, 49, 
57, 65 
With or 
without IL-2, 
or INFα, or 
sunitinib 
No 
significant 
difference 
No significant 
increase in toxicities 
over controls 
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JX-594 (VACV+ 
GMCSF)  (Park 
et al. 2008) 
Primary and 
metastatic 
liver cancer 
Refractory 
I IT q 3w × 
4 tx 
None 
Heavily pre-
tx 
0% CR 
21% PR 
43% SD 
DLT due to 
hyperbilirubinemia.  
Viral DNA in blood. 
Response in tx and 
untreated tumors 
 
 
 
 
 
 
Ab= antibody, Ad= adenovirus, Ag= antigen, CR= complete response, CRAd= conditionally 
replicative adenovirus, CRC= colorectal carcinoma, d= day, DLT= dose-limiting toxicity, GBM= 
glioblastoma multiforme, GM-CSF= granulocyte macrophage coloncy sitmulating factor, HNC= 
head and neck cancer, HSV= herpes simplex virus, IC= intracranial, IM= intramuscular, 
IP=intraperitoneal, IT= intratumoral, MV= measles virus, NDV= Newcastle disease virus, NK= 
natural killer cells, ORR= objective response rate, PMV= paramyxovirus, PR= partial response, 
PV= picornavirus, q= every, RCC= renal cell carcinoma, RT3D= reovirus type 3 Dearing, 
SCCHN= squamous cell carcinoma of the head and neck, SD= stable disease, SVV= Seneca 
valley virus, sx= surgery, tx= treatment, VACV= vaccinia virus, w= week, XRT= radiation 
therapy, 5T4= a tumor antigen 
 
 
